text
string | url
string | crawl_date
timestamp[ms] | label
int64 | id
string |
|---|---|---|---|---|
EVERYONE DESERVES a second chance, and that includes Carl Connor.
His first attempt at one of hardest jobs in the world, fatherhood, ended badly.
He is the father of Jaden Connor, who was shot and killed two years ago during a home invasion on Central Street in Manchester. Jaden died at 17.
Connor now works with dozens of teenagers at Project Connect, a teen center that opened last December in Manchester. Its explicit goal is reducing gun violence in Manchester.
Connor meets, connects with and helps kids much like Jaden. Kids from lousy families. Kids who live in poverty. Kids at a risk for violence, either as victims or perpetrators.
“I act like they’re Jaden, like my children, no different,” he said when I visited Project Connect last week. “It’s ironic. I lost a son and gained 20, 30, 40 more children.”
Project Connect occupies a storefront at the Granite Square complex at the corner of Granite and Main streets. It is operated by My Turn, a nonprofit, youth-improvement organization that also runs an alternative high school, adult education and job training center at the same location.
Kids who show up at the teen center can play video games. They can produce hip hop tracks in a music studio. They can get help with their homework. They take field trips to destinations such as a Celtics game. They can eat all sorts of food (Dominos pizza the night I visited).
“It’s a chill spot. We joke around, get in the mood and put down a song real quick,” said Mickey Caterson, 19, who was in the sound studio with two middle school students recently.
Some 120 youth have visited Project Connect since it opened. It has a core group of 20 to 30, and another 20 to 30 who are frequent visitors.
Connor and his fellow workers don’t ask much of the kids. For example, they don’t ask them to clean up.
They can’t get kicked out, even for fighting, although warring guests will come and leave at different times, what Director Allison Joseph calls air-traffic control.
“These kids can’t get kicked out, because if they get kicked out there’s nowhere else for them to go,” Joseph said.
And if they’re kicked out they end up on the street, where temptation will find them.
“To be honest,” Caterson said, “anybody who wants to be a gangbanger in Manchester, it’s not too hard.”
Police Chief Allen Aldenberg mentioned My Turn in his 2021 annual report, and the police department has funneled $30,000 in federal Project Safe Neighborhoods to Project Connect.
In the annual report, Aldenberg notes the program uses “specialists with lived-experience to connect with” the youth.
Connor, who is 40, pulls out his phone and shows a photo of him and nine friends, taken in their late teens. Two have been shot and killed; one committed suicide; six, including Connor, have been to prison.
By the time people end up in the custody of the Department of Corrections, he said, it’s too late. “The correction starts here, instead of incorrection,” Connor said.
Connor has a burly physique. He wears his hair short. His face is stoic, with a hint of sadness.
Once, he said, he was driving home a youth who was railing on about life. They passed the spot where Jaden died.
“I know you’ve got a lot going on,” he told the teen. “You’re alive for a reason.”
Although he works an afternoon-evening shift Monday through Saturday, if a kid is in a crisis on a Sunday, he’ll open up the center. His work can be as simple as listening to a teen’s problems and then asking about it two days later.
“I just father them. No one else does that,” he said. Some of the people at My Turn know about Jaden.
Branhon Winslow, who is 13, said Connor once asked him about Jaden; Winslow knew him through others, he said. The father told Winslow that he missed his dead son.
“I don’t ask about that,” said the normally talkative Caterson, who grew uneasy when I asked. “That’s none of my business.”
Joseph said she knew Connor growing up. Both their families participated in Pop Warner football. They reconnected by chance when he delivered a DoorDash order to a My Turn meeting.
Jaden had just died. Originally, she asked his advice about structuring Project Connect.
Eventually, she hired Connor, along with Travis Turcotte, who, like Connor, has a troubled background. Sure, the program also has its social workers, who do the intake, assessments and report writing that are de rigueur in this line of work.
As for the next Jadens, they’ll leave that to Connor and Turcotte.
“The buzzword in this work is credible messenger,” Joseph said. “That’s what they are.”
|
https://www.unionleader.com/voices/city_matters/city-matters-father-who-lost-son-to-guns-tries-to-rescue-others/article_962b5dbb-b278-50f5-8aac-058eb1d895f7.html
| 2022-04-04T01:55:06
| 0
|
https://www.unionleader.com/voices/city_matters/city-matters-father-who-lost-son-to-guns-tries-to-rescue-others/article_962b5dbb-b278-50f5-8aac-058eb1d895f7.html
|
In 1818, Seth Wyman Jr. was brought to the Massachusetts state prison in Charlestown to begin serving a three-year sentence. He had been convicted in Augusta, Maine, for crimes related to his role in a three-man theft operation which had plagued towns in central Maine. At this time, Maine was part of Massachusetts, so its convicts were incarcerated at the Charlestown penal facility.
At the end of his first year in the jail, Wyman wrote to his wife, Wealthy Wyman, in Goffstown, asking her to come to Charlestown and petition the Massachusetts government to pardon him. She complied, and succeeded in her efforts. Wyman wrote in his memoir that, while Wealthy was in town, their son Franklin, “…fell from the fourth story of a house, striking his head on a door-step with such force that the brain ran out on the ground.” The unfortunate 4-year-old was buried in Charlestown.
After being pardoned by the Massachusetts governor and Council, Wyman was released from the Charlestown prison. He returned with Wealthy to Goffstown, where he was reunited with the couple’s remaining four children who ranged in age from 2 to 13. Wyman was either 34 or 35 years old at the time.
Wyman had indulged in what he referred to as his “passion for thieving” since he was a small boy. As an adult he had occasionally been inspired to pursue an honest life, but these experiments had always failed. As Wyman recalled in his book, about a month after his homecoming, “I then took an unsuccessful trip up the Connecticut river to buy me a farm, and on my way back, saw a fulling mill in Bow, which I resolved to visit.” A fulling mill is a water-powered mill where woolen cloth is cleaned and felted (thickened). This was one of his favorite types of establishments to rob.
His account continued, “I went up to it about a week after in a dark night, and…I took as much cloth as I could carry, and arrived at home about sunrise the next morning.” He put the stolen cloth in a box which he concealed in a cove on the Piscataquog River in Goffstown.
Wyman was immediately suspected of the theft, but there was no proof. After a few weeks had passed, he felt confident enough to sell some of the cloth to a store in Goffstown. This was a bad move, as someone recognized the cloth and identified it as coming from a lot that had been processed at the fulling mill. Wyman was arrested, tried, and convicted of stealing. He was sentenced to three years confinement in the New Hampshire state prison in Concord.
The prison was located on North State Street between Beacon and Tremont streets, close to the center of town. It was a solid building, constructed in 1812 out of granite quarried in Concord. (It would be replaced in 1878 by the current state men’s prison, located about 1½ miles north on the same street.) Wyman entered the facility on April 22, 1820. His listing in the prison record book indicates that he was 5 feet, 11 inches tall, and had dark blue eyes, dark hair, and a dark complexion.
Inmates at the state prison were required to do hard labor. According to Wyman, “I was taken to Concord, where they asked me if I could cut stone, and I answered that I was blind, and could not. They set me to turning a tremendous heavy grind-stone, heavy enough for a yoke of oxen. I found this harder than cutting stone, and my eyesight soon returned. I was taken sick in reality, and recovered after a close run with fever.” These were the last words that Wyman wrote in his memoir.
After he was released on April 22, 1823, Wyman lived another 20 years. However, while he was in the process of completing his book, he died, so was not able to tell the rest of his story. His publisher, J. Hamilton Cate, sketched out the basics of the remainder of Wyman’s life in a short addendum to the text of “The Life and Adventures of Seth Wyman.” The book was published in Manchester in 1843, the year of Wyman’s death.
Next week: The last years of Seth Wyman Jr.’s troubled life and some family notes.
|
https://www.unionleader.com/voices/looking_back/looking-back-nh-state-prison-is-destination-for-seth-wyman-jr/article_a9888600-e135-5d30-94dd-0a3c1081ea8d.html
| 2022-04-04T01:55:12
| 1
|
https://www.unionleader.com/voices/looking_back/looking-back-nh-state-prison-is-destination-for-seth-wyman-jr/article_a9888600-e135-5d30-94dd-0a3c1081ea8d.html
|
INDIANAPOLIS (AP) — Saddiq Bey scored 31 points and Fred Jackson had 19 to lead the sharpshooting Detroit Pistons past the Indiana Pacers 121-117 on Sunday.
Bey hit 11 of 18 shots, including shooting 7 of 9 on 3-pointers, in 23 minutes. The Pistons, who have won three games in a row, sank 21 of 41 3-pointers and set a team record for 3s in a half with 13 in the opening two quarters.
“My team did a great job of playing together,” Bey said. “I just tried to take what the defense was giving me. We were playing together, sharing the ball and the coaching staff did a good job putting us in the right position.”
Pistons coach Dwane Casey thought Bey could go for 50 points, but the Pistons needed to play some young players.
“When he gets going, he gets it going,” Casey said. “When he started in the first quarter, the basket looked like the ocean. He has that knack. He’s more than just a shooter. He’s putting it on the floor, he’s posting up, he’s really expanding his game. He has to take a lot of things he’s doing well now and keep improving over the summer.”
Oshae Brissett scored 20 points and had nine rebounds to lead the Pacers, who have lost seven straight.
Tyrese Haliburton flirted with a triple-double with 19 points, a career high-tying 17 assists and a season-high nine rebounds. He became the first player in Pacers history to record at least 17 assists without a turnover and first to do it in the NBA since LeBron James on March 21, 2018.
“I pride myself on taking care of the ball and getting guys involved,” Haliburton said. “I think that’s my best asset as a point guard.”
Buddy Hield and Isiah Jackson also scored 19 each for the Pacers. Hield had a season-high nine rebounds and Jackson had seven as the Pacers held a 58-38 rebounding edge.
Detroit, which shot 43.4% overall from the field, erased a 66-62 halftime by outscoring the Pacers by 11 in the third quarter to take a 98-91 lead.
Bey scored 15 of Detroit’s first 17 points, finishing with 20 points in the first quarter as the Pistons led 38-34 lead after the first quarter.
The Pistons hit their first eight 3-point shots and 10 off their first 11 3-pointers.
“We just didn’t play well at all,” Pacers coach Rick Carlisle said. “Our level of consistent hard play just wasn’t there from start to finish. They played hard from start to finish.”
Haliburton said poor starts have plagued the Pacers.
“We need to have more of a sense of urgency starting games,” he said. “This is our fourth or fifth game in a row where we start bad and then get it going. We have to open games like that.”
TIP-INS
Pistons: Cade Cunningham missed the game with right hip soreness. … Carsen Edwards, who averaged 26.7 points with the Salt Lake City Stars of the NBA G League, signed a two-year deal Sunday. The former Purdue standout scored 13 points on 5-of-15 shooting off the bench and had nine assists. “He had no clue what we were doing, he just walked in off the streets,” Casey said. “He came in played hard, played the right way. He’s a little sparkplug.”. … Braxton Key signed a two-way deal with the Pistons and scored 12 points. … Detroit released Chris Smith, who recently had ACL surgery.
Pacers: Chris Duarte remained sidelined with a sore left big toe. The rookie hasn’t played since March 15 and Carlisle said it’s likely Duarte will miss the last three games. … Reggie Miller was a surprise guest to help celebrate media relations director David Benner’s retirement after 28 years.
UP NEXT
Pistons: Hosts Dallas on Wednesday night.
Pacers: Hosts Philadelphia on Tuesday night.
|
https://fox59.com/sports/pacers/bey-jackson-lead-pistons-past-pacers-121-117/
| 2022-04-04T01:55:21
| 1
|
https://fox59.com/sports/pacers/bey-jackson-lead-pistons-past-pacers-121-117/
|
KOB Web Staff
Updated: April 03, 2022 05:24 PM
Created: April 03, 2022 04:17 PM
ALBUQUERQUE, N.M. – The Bernalillo County Sheriff's Office has identified 37-year-old, Taylor John Crabb, as the man who was shot and killed after a chase and shootout.
Deputies say Crabb had an extensive criminal history that includes drug trafficking and battery on an officer.
It started in the South Valley Friday morning, as deputies say they responded to a call of someone stripping a car, and then Crabb led them on a chase. He started a shootout with deputies and then shot at SWAT team members -- before at least one of them shot and killed him.
"Where our deputies got into an exchange of gunfire with the suspect. Several of our deputies did fire their weapons," said Bernalillo County Sheriff Manny Gonzales.
Deputies say Crabb got a 14-year sentence in 2012, and they're still looking into the details of his release.
This incident was the second time Bernalillo County Sheriff's deputies were shot at in one week. No officers were hurt during this shooting.
Copyright 2022 - KOB-TV LLC, A Hubbard Broadcasting Company
|
https://www.kob.com/albuquerque-news/bcso-idrsquos-suspect-killed-in-shootout-with-deputies/6436316/?cat=500
| 2022-04-04T02:34:23
| 0
|
https://www.kob.com/albuquerque-news/bcso-idrsquos-suspect-killed-in-shootout-with-deputies/6436316/?cat=500
|
LAS VEGAS -- A list of winners Sunday in the top categories at the 64th annual Grammy Awards:
- Best new artist: Olivia Rodrigo
- Song of the year (songwriter's award): "Leave the Door Open," Silk Sonic (Brandon Anderson, Christopher Brody Brown, Dernst Emile II and Bruno Mars)
- Best country album: "Starting Over," Chris Stapleton.
- Best pop solo performance: "Drivers License," Olivia Rodrigo
- Best rock album: "Medicine at Midnight," Foo Fighters
- Best rock song: "Waiting On a War," Foo Fighters
- Best rock performance: "Making a Fire," Foo Fighters
- Best rap song: "Jail," Kanye West featuring Jay-Z
- Best rap album: "Call Me If You Get Lost," Tyler, the Creator
- Best alternative music album: "Daddy's Home," St. Vincent
- Best traditional pop vocal album: "Love for Sale," Tony Bennett and Lady Gaga
- Best music video: "Freedom," Jon Batiste
- Producer of the year, non-classical: Jack Antonoff
- Best R&B song: "Leave the Door Open," Silk Sonic
- Best R&B performance: (tie) "Leave the Door Open," Silk Sonic, and "Pick Up Your Feelings," Jazmine Sullivan
- Best music film: "Summer of Soul"
- Best country song: "Cold," Chris Stapleton
- Best country solo performance: "You Should Probably Leave," Chris Stapleton
- Best country do/group performance: "Younger Me," Brothers Osborne
- Best comedy album: "Sincerely Louis CK," Louis C.K.
- Best roots gospel album: "My Savior," Carrie Underwood
- Best gospel album: "Believe For It," CeCe Winans
- Best American roots performance: "Cry," Jon Batiste
- Best American roots song: "Cry," Jon Batiste
- Best música urbana album: "El Último Tour Del Mundo," Bad Bunny
- Best Latin rock or alternative album: "Origen," Juanes
- Best improvised jazz solo: "Humpty Dumpty (Set 2)," Chick Corea
- Best Latin jazz album: "Mirror Mirror," Eliane Elias with Chick Corea and Chucho Valdés
- Best musical theater album: "The Unofficial Bridgerton Musical"
- Best compilation soundtrack for visual media: "The United States vs. Billie Holliday"
- Best score soundtrack for visual media: (tie) "Soul," Jon Batiste, Trent Reznor and Atticus Ross, and "The Queen's Gambit," Carlos Rafael Rivera
- Best dance/electronic album: "Subconsciously," Black Coffee
- Best global music: "Mohabbat," Arooj Aftab
- Best global music album: "Mother Nature," Angélique Kidjo
- Best traditional blues album: "I Be Trying," Cedric Burnside
- Best contemporary blues album: "662," Christone "Kingfish" Ingram
- Best folk album: "They're Calling Me Home," Rhiannon Giddens with Francesco Turrisi
- Best historical album: "Joni Mitchell Archives, Vol. 1: The Early Years (1963-1967)"
------
Olivia Rodrigo has won the best new artist crown at the Grammy Awards, joining esteemed previous company including Carly Simon, Crosby, Stills & Nash, Tom Jones, the Beatles and Billie Eilish.
A veteran of the "High School Musical" series, Rodrigo became the breakout music star of 2021, leading with her massive viral hit "Drivers License" and following with the aching album "Sour" and the single "Good 4 U."
So far Sunday, "Drivers License" has earned her the trophy for best pop solo performance, and it is up for record of the year, while "Sour" is up for album of the year. Rodrigo came into the night nominated for the night's top four awards - best new artist, album, record and song of the year - but lost the best song trophy to Silk Sonic.
"This is my biggest dream come true," she said. Earlier in the show, she performed her heartbreak song "Drivers License" in a white ruffled dress and black boots.
Silk Sonic - the all-star union of Bruno Mars and Anderson .Paak - opened the Grammys in Las Vegas with their high-energy, infectious fix of retro soul and funk by performing their "777." They returned to the stage a short time later to collect the song of the year trophy for "Leave the Door Open."
The win helps Mars tie the record for most song of the year wins. He had previously won for "24K Magic."
Both Mars and .Paak jumped out their seat, threw up their hands and dance to their song.
"I couldn't be more proud to be doing this with than anyone other than you," Mars said to .Paak. "We'll be singing this song together for the rest of our lives."
Host Trevor Noah introduced the duo's opening performance by saying they were singlehandedly bringing back the 1970s, "which might explain the inflation."
By the time the show started on CBS, Jon Batiste has already taken home four Grammy Awards, including his first ever. During the show's pre-telecast ceremony, Batiste won for best American roots performance, best American roots song, best music video and tied with Carlos Rafael Rivera for best score soundtrack for visual media. His song "Freedom" in the music video category beat out several other tough competitors, including Rodrigo, Lil Nas X and Eilish.
"I am so grateful for the gifts that God has given me and the ability to share that for the love of humankind," Batiste said. "We just wanted everyone to see it. Any depression, any bondage or any darkness that was over your life is completely removed by just the love and the joy of the video."
It's the first tie since 2019 when Kendrick Lamar, Jay Rock, Future and James Blake tied with Anderson .Paak to win best rap performance.
Batiste entered the Grammys as the leading nominee with 11 nominations. The losses halted the multi-talented performer from making history for most wins in one night.
It was a family affair from cousins Baby Keem and Kendrick Lamar, who won best rap performance for their song "Family Ties." Lamar won his 14th Grammy and the first for Keem, who said "nothing could have prepared me for this moment" after stepping out onstage to claim his trophy.
Chris Stapleton won his third Grammy for best country solo performance for "You Should Probably Leave." He extended his record for the most wins.
Dressed in all black, BTS took the stage with a flirty moment between V and Rodrigo before the group performed their hit single "Butter." The made an appearance after one of the members tested positive for COVID-19. All seven of the members - Jin, Jimin, V, RM, J-Hope, Suga and Jungkook - acted as if they were secret agents with neon-blue lasers, dancing with smooth choreography before going into a brief rap portion of the song.
Foo Fighters won three awards Sunday, but were not in attendance to pick up their trophies following the recent death of its drummer Taylor Hawkins. The rock band did extend their record for most best rock album wins with five for "Medicine at Midnight." The group's song "Making a Fire" won best rock performance and "Waiting on a War" bested other nominees for best rock song.
During Eilish's performance, she paid homage to the late Foo Fighters drummer Taylor Hawkins by sporting a black T-shirt with his image. She stepped onstage in an upside-down house along with her brother Finneas before stepping into the rain to perform the title track from her "Happier Than Ever."
TJ Osborne, who came out as gay last year, fought back tears as he and his brother accepted a Grammy for the Brothers Osborn song "Younger Me." He noted the song was inspired by his coming out.
"I never thought that I would be able to do music professionally because of my sexuality. And I certainly never thought I would be here on the stage accepting a Grammy after having done something I felt like was going to be life changing and potentially in a very negative way," Osborne said.
"And here I am tonight, not only accepting this Grammy Award with my brother, which I love so much, but I'm here with a man that I love and he loves me back. ... I don't know what I did be so lucky."
Ahmir "Questlove" Thompson won his sixth Grammy for best music film through "Summer of Soul (... Or, When the Revolution Could Not Be Televised.") His documentary also won an Oscar for best documentary feature last weekend.
Chick Corea and Vicente Fernandez each won posthumous Grammys. Joni Mitchell won best historical album for "Joni Mitchell Archives - Vol. 1: The Early Years (1963-1967)."
"Thanks to the academy for this nomination and this win, I didn't expect this," she said.
Eilish could become the first artist ever to win record of the year three times in a row, and the only artist along with Paul Simon to take home the award three times. She's in position to join Adele as the only artists to ever win three major categories - record, song and album of the year - twice. She previously won for "Bad Guy" and "Everything I Wanted."
The ceremony shifted from Los Angeles to Las Vegas because of rising COVID-19 cases and the omicron variant in January, with organizers citing "too many risks" to hosting the performance-filled show at the time.
Artists competing with Eilish for album of the year include Rodrigo, Batiste, Tony Bennett and Lady Gaga, Justin Bieber, Doja Cat, H.E.R., Taylor Swift, Lil Nas X and Kanye West.
Bennett extended his record as the artist with the most traditional pop vocal album with 14 wins with "Love for Sale," a duet album with Lady Gaga.
___
AP Entertainment Writer Mark Kennedy contributed to this story.
Grammy Awards 2022: List of Grammy winners in top categories
By Jonathan Landrum Jr., AP
Copyright © 2022 by The Associated Press. All Rights Reserved.
|
https://abc11.com/grammy-awards-2022-grammys-red-carpet-winners/11706926/
| 2022-04-04T02:57:57
| 1
|
https://abc11.com/grammy-awards-2022-grammys-red-carpet-winners/11706926/
|
Panthers beat Sabres 5-3 to clinch playoff berth
Published: Apr. 3, 2022 at 10:03 PM EDT|Updated: 1 hour ago
Jonathan Huberdeau set Florida's single-season points record, and the Panthers clinched a playoff berth with a 5-3 win Sunday over the Buffalo Sabres.
Huberdeau scored his 24th goal to extend his point streak to eight games and raise his season total to 97, one more than teammate Aleksander Barkov's record set in 2019.
Anthony Duclair scored twice as the Panthers (48-15-6) established a franchise record for victories.
Jeff Skinner had a goal and an assist for the Sabres, who are on the cusp of of missing the playoffs for an NHL-record 11th consecutive season.
Scripps Only Content 2022
|
https://www.wflx.com/2022/04/04/panthers-beat-sabres-5-3-clinch-playoff-berth/
| 2022-04-04T03:06:39
| 0
|
https://www.wflx.com/2022/04/04/panthers-beat-sabres-5-3-clinch-playoff-berth/
|
Staley leads South Carolina over UConn for second NCAA title
MINNEAPOLIS (AP) — Dawn Staley hoisted the championship trophy high, strutted around the court and stopped only for a brief victory dance. She handed over the hardware to South Carolina’s student band, then headed back to midcourt for more merriment.
After hitting all the right notes this season, it’s time for the Gamecocks to celebrate.
Staley’s team buttoned up on defense and dominated on the glass, beating UConn 64-49 on Sunday night to end the Huskies’ undefeated streak in title games. Destanni Henderson scored a career-high 26 points, Aliyah Boston added 11 points and 16 rebounds, and the Gamecocks handed Geno Auriemma’s Huskies their first loss in 12 NCAA title games.
“We played every possession like it was our last possession,” Staley said. “They were determined to be champions today.”
A year ago, South Carolina lost in the Final Four when Boston missed a layup before the buzzer.
“Obviously, I’ve been thinking about this since last season. Everyone had a picture of me crying,” said Boston, who was the Most Outstanding Player of the Final Four. “Today, we’re national champions and I’m in tears.”
With Staley calling the shots in a Louis Vuitton letterman jacket, South Carolina took UConn to school on the boards and capped a wire-to-wire run as the No. 1 team in the country in The Associated Press poll. The Gamecocks also won the championship in 2017 with A’ja Wilson leading the way.
This time it was Boston — the AP Player of the Year — and her fellow South Carolina post players who dominated on the game’s biggest stage. The Gamecocks outrebounded UConn by 49-24, including a 21-6 advantage on offensive boards. They also clamped down on star Paige Bueckers and the Huskies on defense, just like they did all season long.
“They deserved it 100%,” Auriemma said. “They were the best team all year. The first five minutes, I thought they came out and set the tone then and there for how the game was going to be played.”
It was South Carolina’s night from the start. The Gamecocks (35-2) jumped to an 11-2 lead, grabbing nearly every rebound on both ends of the floor. They led to 22-8 after one quarter much to the delight of their fans, who made the trip to Minneapolis to be part of the sellout crowd.
UConn (30-6) trailed by 16 in the second quarter before Bueckers, a Minnesota native, got going. After having just one shot in the first quarter, she scored nine points in the second to get the Huskies within 35-27 at the half. She finished with 14.
An 8-2 run to start the third quarter put South Carolina up 43-29 before the Huskies finally started connecting from behind the arc. UConn missed its first eight 3-point attempts until Caroline Ducharme made one from the wing and Evina Westbrook followed with another to get the Huskies within 43-37.
That’s as close as they could get because of Henderson.
The senior guard had a three-point play to close the third quarter and then had the team’s first four points in the fourth to restore the double-digit lead. The Huskies couldn’t recover.
“My teammates believed in me once again. We’ve been working so hard since Day 1, and it finally paid off, all my hard work, all my focus,” Henderson said. “Me trusting the process. Me trusting God. She just put me in a position just to be great, and today, we national champions.”
This was UConn’s first trip to the championship game since 2016, when the Huskies won the last of four straight titles. Since then, the team has suffered heartbreaking defeats in the national semifinals, losing twice in overtime, before holding off Stanford on Friday night. The Huskies were trying to win their 12th title in the same city they won their first one in 1995.
Auriemma said Saturday that when his team had won each of its 11 titles, the Huskies entered the game as the better team. They certainly weren’t on Sunday.
“We just didn’t have enough,” he said. “They were just too good for us.”
It had been one of the most challenging seasons of Auriemma’s Hall of Fame career. UConn overcame losing eight players for at least two games with injury or illness, including Bueckers, who missed nearly three months with a left knee injury suffered in early December. She came back in late February but wasn’t at the same level that earned her AP Player of the Year as a freshman last season.
DEFENSE WINS CHAMPIONSHIPS
The Gamecocks have been stalwarts on defense all season long, ranking third nationally with 50.5 points allowed per game. They were even sharper in the NCAA Tournament, holding opponents to 44.8 points entering Sunday’s finale.
Henderson had three steals, Boston blocked two shots and South Carolina forced 15 turnovers. The Gamecocks’ plus-25 rebounding margin was the second biggest ever in a title game.
BIG PICTURE
UConn: The Huskies lose three seniors in Christyn Williams, Westbrook and Olivia Nelson-Ododa but still have a solid group back led by Bueckers and freshman Azzi Fudd. If the Huskies stay healthy, they’ll have a good shot to contend for next year’s title.
South Carolina: The Gamecocks lose Henderson and Victaria Saxton but have all the talent to repeat as champions.
___
More AP coverage of March Madness: https://apnews.com/hub/march-madness and https://apnews.com/hub/womens-college-basketball and https://twitter.com/AP_Top25
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wflx.com/2022/04/04/staley-leads-south-carolina-over-uconn-second-ncaa-title/
| 2022-04-04T03:06:45
| 1
|
https://www.wflx.com/2022/04/04/staley-leads-south-carolina-over-uconn-second-ncaa-title/
|
RALEIGH, N.C. (WTVD) -- Many shared their condolences to the family of Millbrook High School's principal Dana King Sunday. King passed away Saturday morning, a month before her planned retirement.
"Our deepest thoughts and prayers and sympathies are with her husband Rick and her family. We're thinking about them first and foremost and making sure that they feel loved and supported," Northern Area Superintendent, Chris McCabe said. "She poured her heart and soul into this community. And the best way to honor that is to continue to make sure that the number of communities stay strong, healthy and does what is right for every kid each day."
The announcement was sent Saturday to all principals in the Wake County Public School System described King as " a leader whose unwavering dedication left a long-lasting impact on students, staff and the community."
"We had the opportunity to celebrate her this past Monday. I knew she was coming when we were in the gym. Even though there were a couple hundred people in the gym chatting, you could hear her laugh coming down the hall. It's a beautiful laugh and it also just shows her vibrance for life," said McCabe
School leaders say they do not want cameras on campus Monday when teachers and staff return to work. They would like to give those who knew King the opportunity to mourn her privately.
|
https://abc11.com/11707063/
| 2022-04-04T03:24:01
| 1
|
https://abc11.com/11707063/
|
Fund for West Palm Beach Police Awards ceremony honors department
The inaugural Fund for Police Awards ceremony took place Sunday at the Kravis Center for the Performing Arts.
"Our funds support wholeheartedly the West Palm Beach police, chief of police, the mayor. Our job is to help them keep our city the safest, best city you can make it. You can't do that without a great police force," said Al Adelson, the chairman of the board of the Fund for West Palm Beach Police non-for-profit 501c3. "All the people we're honoring today represent the best of the West Palm Beach police."
The event started with a champagne brunch at the Kravis Center's Cohen Pavilion.
Later, the ceremony presented awards for civilian, investigator, supervisor and officer of the year.
Fourteen officers were also celebrated, all of whom saved someone's life last year.
"If you ask any of these honorees, they'll say they did their job," said West Palm Beach Police Chief Frank Adderley. "But to be recognized, it's showing that we support them, because they put their lives on the line every day here to keep our city safe. I think that means a lot to them and it definitely means a lot to our agency. We all have one thing in common. We want a safe city."
The Fund for West Palm Beach Police is comprised and funded entirely by generous people and businesses in the community who want to help fund the police department.
"That's what's so inspiring, because you hear so much from others say 'defund the police,' and I don't agree with that at all, but to show that the community supports the job that the police are doing and under the leadership of our very fine Chief Frank Adderley, who was brought in very early in my administration, is very gratifying and it's an honor to be here," said West Palm Beach Mayor Keith James.
The event brought in nearly 400 guests. Every officer honored at the event received a $1,000 award.
"The fact that we're showing them we appreciate their service, hopefully, will inspire them to continue to serve this community in a way they have been serving in years," said James.
Scripps Only Content 2022
|
https://www.wflx.com/2022/04/04/fund-west-palm-beach-police-awards-ceremony-honors-department/
| 2022-04-04T04:40:52
| 1
|
https://www.wflx.com/2022/04/04/fund-west-palm-beach-police-awards-ceremony-honors-department/
|
NEW YORK — Bright pink and all-over metallics were the fashion stories of the Grammys red carpet led by Saweetie in fuchsia Valentino and Tiffany Haddish in sparkling one-shoulder Prada as the music crowd did Las Vegas proud with a show of wild, whimsical and meaningful looks.
Saweetie's full skirt and bra top were paired with long matching gloves. Billy Porter, always a fashion standout, also went with fuchsia in a trouser look that had a sheer button-down shirt and long ruffled cape from Valentino.
Justin Bieber, in a baggy, gray suit a few sizes too big, wore a fuchsia beanie on his head as walked with his wife, Hailey, in white Saint Laurent. Count Chrissy Teigen in the pink camp as well.
“The color of the season I hear is fuchsia,” Porter told E! His look was straight off the runway.
Saweetie was a twofer on the carpet, changing into an Oscar de la Renta black gown with a silver piece covering one breast.
Lady Gaga chose classic Hollywood in black-and-white velvet Armani Prive. She dripped in Tiffany & Co. diamonds that included a short statement necklace as she hit the carpet just before the televised awards. Her hair was swept into an updo.
Haddish stunned in a fitted one-shoulder gown, and Carrie Underwood went full ballgown with sparkle in the top with sash and a full skirt of sunset orange. Mickey Guyton rocked an ombre long-sleeve silver and gold fringe flapper sparkle dress by Ashish, shimmying for the cameras.
Brandi Carlile toted about 40 pounds of hand-cut crystals on a multicolored Huge Boss tuxedo jacket with stripes of the same crystals on the trousers and waist.
“I’m finally morphing into Elton John, which is my dream,” she said.
Olivia Rodrigo waved and smiled in a black sheath gown from Vivienne Westwood, who included purple sparkle trim with rocker chokers. She was joined in black by Billie Eilish in a Rick Owens trench coat turned cape, lug soul boots on her feet.
“Olivia Rodrigo in her black opera gloves and black sheath floor length was giving me Morticia Addams in a totally hip way. Very mature and lady like for her,” said Holly Katz, a stylist and host of the Fashion Crimes podcast. “A similar Pressiat corset dress was worn by Halsey that had the same vibe. This is a trend for the long and lean but will always be a classic dress style for decades to come.”
Katz was not a fan of Eilish's look.
“As far as the ‘unfashion’ trends go, let's all hope that Billie Eilish doesn’t get her curtain dress trend to trickle down. We would have one too many fashion blobs on the streets.”
All seven members of the sensation BTS, meanwhile, wore custom Louis Vuitton suits with sneakers in a range of colors from bright white to muted blue.
Multiple nominee H.E.R. paid homage to Aretha Franklin in an embellished orange and yellow ombre look, and fashion favorite Cynthia Erivo was in sparkling silver and gray from Louis Vuitton. H.E.R. wore a custom winged kaftan jumpsuit from Dundas. It was chiffon and embellished with a golden beaded and sequin phoenix motif.
Sofia Carson wore an elegant Grecian gown from Valentino with a long sheer cape that swept over the carpet as she walked. And Lil Nas X didn't disappoint in embellished white Balmain with butterflies at the chest and on the sleeves, sky high platforms on his feet.
Jon Batiste went full sparkle in a Dolce & Gabbana suit with yellow and black touches honoring his hometown, New Orleans.
“These are New Orleans Saints colors. I wanted to bring home with me on the carpet,” he said.
Megan Thee Stallion went in another direction in an animal print dress with an oh-so-high slit. The lining was a contrast animal strip, an unusual touch. Dua Lipa was a study in straps sporting long blonde hair. Her Versace gown was adorned with straps and gold hardware.
Lady Gaga was high on the fashion list for Katz.
“Unexpected, old Hollywood glam that shows her more feminine, traditional side. Vey different from her edgy persona we are all used to. Don’t be surprised to see this dress trickle down in many knockoffs soon to come,” she said.
Among early walkers was Li Saumet from Colombia's Bomba Estéreo, who covered her face with a helmet-like mask. Cherry Moon of the 1 Tribe Collective children's group went all out in full gold, complete with a huge architectural collar. Victoria Evigan smooched her husband, Jason, in a peach and yellow dress with “Love is the Weapon” at the back.
Alisha Gaddis, with comedy on her resume, paired her shiny, minty gown with a head piece of high, golden branches. Elle King was resplendent in a red bell-bottom trouser suit with swinging bell sleeves and an ultra-wide brim hat to match. Black Coffee, the DJ from South Africa, paid homage to his friend Virgil Abloh, wearing a pair of the late designer's sneakers before his win for dance/electronic music album.
King, a new mom, was thrilled to be wearing Christian Siriano.
“I just trusted him. He knows how to dress all types of bodies and I really celebrate that in him,” she told The Associated Press. "I just wanted to feel powerful.”
Japanese Breakfast smiled for cameras in a mini dress of bright yellow ruffles from Valentino, while Doja Cat, her hair accentuated in spikes, wore an ice blue Atelier Versace crystal embellished sheer look.
As for the men, there was plenty of ornate, brocade jackets and suits in the early bunch.
“It's the sort of thing that can look genuinely fantastic when executed carefully,” said Jonathan Evans, Esquire's style director.
Leon Bridges lent a nod to his native Texas in a cream tuxedo look embellished with embroidery and a touch of blue bonnets.
“I just like to look good, you know,” he told the AP.
Among Evans' early standouts was something on the other end of that spectrum, Cory Henry in a double-breasted suit and turtleneck combo.
“Rich, offbeat colors like purple can prove tricky when it comes to tailoring, but he nails the modernized ’70s vibe,” he said.
___
Associated Press writers Gary Hamilton and Marcela Isaza in Las Vegas contributed to this story.
___
Associated Press writers Gary Hamilton and Marcela Isaza in Las Vegas contributed to this story.
|
https://www.kgw.com/article/entertainment/music/grammys/gammys-red-carpet-does-las-vegas-proud/507-96b20ae5-e31c-4513-896f-67f2d90433f3
| 2022-04-04T04:47:20
| 1
|
https://www.kgw.com/article/entertainment/music/grammys/gammys-red-carpet-does-las-vegas-proud/507-96b20ae5-e31c-4513-896f-67f2d90433f3
|
LAS VEGAS — Jon Batiste won album of the year honors for “We Are” at the Grammy Awards on Sunday, giving him five trophies on a night that saw the ’70s funk of Silk Sonic take record of the year and song of the year and newcomer Olivia Rodrigo take three awards.
Batiste honored the artists he beat. “The creative arts are subjective,” he said. “Be you.”
The multi-genre performer also won for his song “Cry,” the video for “Freedom” and his work with Trent Reznor and Atticus Ross on the soundtrack for “Soul.”
“I just put my head down and I work on the craft every day. I love music,” he said.
The R&B supergroup Silk Sonic took home four awards, including record of the year. Olivia Rodrigo collected three trophies, including the coveted best new artist honor.
Bruno Mars and Anderson .Paak were exuberant as they accepted the honor toward the end of the ceremony. The win puts Mars in historic company again: He becomes the only artist along with Paul Simon to take home the award three times.
“We are really trying our hardest to remain humble at this point,” .Paak said. “But in the industry, they call that a clean sweep!” later adding “drinks is on Silk Sonic tonight!”
PHOTOS: Grammy Awards 2022
The win came after the night's festivities grew grim when Ukrainian President Volodymyr Zelenskyy addressed the gathering with an update on the war and his numbers included children injured and killed. “Our musicians wear body armor instead of tuxedos,” he said. “We are fighting Russia, which brings horrible silence with its bombs. The dead silence. Fill the silence with your music.”
He ended by saying: "Tell the truth about the war on your social networks, on TV. Support us in any way you can any, but not silence. And then peace will come to all our cities.”
John Legend then performed “Free” with Ukrainian exiles including singer-actress Mika Newton and poet Lyuba Yakimchuk.
Rodrigo’s win for best new artist putting her in esteemed company including Carly Simon, Crosby, Stills & Nash, Tom Jones, the Beatles and Billie Eilish.
A veteran of the “High School Musical” series, Rodrigo became the breakout music star of 2021, leading with her massive viral hit “Drivers License” and following with the single “Good 4 U” and the aching album “Sour,” which took best pop vocal album.
“This is my biggest dream come true,” she said after her best new artist win. She thanked her parents for supporting her dreams, which at one point involved being an Olympic gymnast and quickly veered toward music.
“I want to thank my mom for being so supportive for all of my dreams, no matter how crazy. I want to thank my mom and dad for being equally as proud of me for winning a Grammy as they were when I learned how to do a back walk.”
Silk Sonic — the all-star union of Bruno Mars and Anderson .Paak — opened the Grammys in Las Vegas with their high-energy, infectious fix of retro soul and funk by performing their “777.” They returned to the stage a short time later to collect the song of the year trophy for “Leave the Door Open.”
The win helps Mars tie the record for most song of the year wins. He had previously won for “24K Magic.”
Both Mars and .Paak jumped out their seat, threw up their hands and dance to their song.
“I couldn’t be more proud to be doing this with than anyone other than you,” Mars said to .Paak. “We’ll be singing this song together for the rest of our lives.”
Host Trevor Noah introduced the duo’s opening performance by saying they were singlehandedly bringing back the 1970s, “which might explain the inflation.”
Both Mars and .Paak jumped out their seat, threw up their hands and dance to their song.
“I couldn’t be more proud to be doing this with than anyone other than you,” Mars said to .Paak. “We’ll be singing this song together for the rest of our lives.”
Host Trevor Noah introduced the duo’s opening performance by saying they were singlehandedly bringing back the 1970s, “which might explain the inflation.”
By the time the show started on CBS, Jon Batiste has already taken home four Grammy Awards, including his first ever. Batiste won for best American roots performance, best American roots song, best music video and tied with Carlos Rafael Rivera for best score soundtrack for visual media. His song “Freedom” in the music video category beat out several other tough competitors, including Rodrigo, Lil Nas X and Eilish. All the honors were handed out during a pre-telecast ceremony.
“I am so grateful for the gifts that God has given me and the ability to share that for the love of humankind,” Batiste said. “We just wanted everyone to see it. Any depression, any bondage or any darkness that was over your life is completely removed by just the love and the joy of the video."
It's the first tie since 2019 when Kendrick Lamar, Jay Rock, Future and James Blake tied with Anderson .Paak to win best rap performance.
Batiste entered the Grammys as the leading nominee with 11 nominations. The losses halted the multi-talented performer from making history for most wins in one night.
It was a family affair from cousins Baby Keem and Kendrick Lamar, who won best rap performance for their song “Family Ties.” Lamar won his 14th Grammy and the first for Keem, who said “nothing could have prepared me for this moment” after stepping out onstage to claim his trophy.
Chris Stapleton won his third Grammy for best country solo performance for “You Should Probably Leave.” He extended his record for the most wins.
Dressed in all black, BTS took the stage with a flirty moment between V and Rodrigo before the group performed their hit single “Butter.” The made an appearance after one of the members tested positive for COVID-19. All seven of the members – Jin, Jimin, V, RM, J-Hope, Suga and Jungkook – acted as if they were secret agents with neon-blue lasers, dancing with smooth choreography before going into a brief rap portion of the song.
Foo Fighters won three awards Sunday, but were not in attendance to pick up their trophies following the recent death of its drummer Taylor Hawkins. An extended tribute to Hawkins played before the show's In Memorium segment honoring artists and music industry figures who've died.
Eilish paid homage to Hawkins during her performance by sporting a black T-shirt with his image. She stepped onstage in an upside-down house along with her brother Finneas before stepping into the rain to perform the title track from her “Happier Than Ever.”
TJ Osborne, who came out as gay last year, fought back tears as he and his brother accepted a Grammy for the Brothers Osborn song “Younger Me.” He noted the song was inspired by his coming out.
“I never thought that I would be able to do music professionally because of my sexuality. And I certainly never thought I would be here on the stage accepting a Grammy after having done something I felt like was going to be life changing and potentially in a very negative way,” Osborne said.
“And here I am tonight, not only accepting this Grammy Award with my brother, which I love so much, but I’m here with a man that I love and he loves me back. ... I don’t know what I did be so lucky.”
Eilish could become the first artist ever to win record of the year three times in a row, and the only artist along with Paul Simon to take home the award three times. She’s in position to join Adele as the only artists to ever win three major categories — record, song and album of the year — twice. She previously won for “Bad Guy” and “Everything I Wanted.”
The ceremony shifted from Los Angeles to Las Vegas because of rising COVID-19 cases and the omicron variant in January, with organizers citing “too many risks” to hosting the performance-filled show at the time.
Artists competing with Eilish for album of the year include Rodrigo, Batiste, Tony Bennett and Lady Gaga, Justin Bieber, Doja Cat, H.E.R., Taylor Swift, Lil Nas X and Kanye West.
Bennett extended his record as the artist with the most traditional pop vocal album with 14 wins with “Love for Sale,” a duet album with Lady Gaga.
___
AP Entertainment Writer Mark Kennedy contributed to this story.
|
https://www.kgw.com/article/entertainment/music/grammys/silk-sonic-kicks-off-grammys/507-696d72f9-a3eb-4b02-aafa-a9ad48a530cd
| 2022-04-04T04:47:26
| 1
|
https://www.kgw.com/article/entertainment/music/grammys/silk-sonic-kicks-off-grammys/507-696d72f9-a3eb-4b02-aafa-a9ad48a530cd
|
WASHINGTON — Ukrainian president Volodymyr Zelenskyy appeared in a video message at the Grammy Awards to ask for support in telling the story of Ukraine's invasion by Russia.
During the message that aired on the show Sunday, he likened the invasion to a deadly silence threatening to extinguish the dreams and lives of the Ukrainian people, including children.
“Our musicians wear body armor instead of tuxedos. They sing to the wounded in hospitals, even to those who can’t hear them,” he said. “But the music will break through anyway.”
The Recording Academy, with its partner Global Citizen, prior to the ceremony highlighted a social media campaign called “Stand Up For Ukraine” to raise money and support during the humanitarian crisis.
“Fill the silence with your music. Fill it today to tell our story. Tell the truth about the war on your social networks, on TV, support us in any way you can any, but not silence. And then peace will come to all our cities,” Zelenskyy said.
Following Zelenskyy’s message, John Legend performed his song “Free” with Ukrainian musicians Siuzanna Iglidan and Mika Newton, and poet Lyuba Yakimchuk, as images from the war were shown on screens behind them.
The war in Ukraine had taken a particularly gruesome turn Sunday when Ukrainian forces entering the town of Bucha, recently held by Russian soldiers, found bodies of people who had been shot, some after being bound and tortured. Ukrainian authorities accused the Russians of war crimes, and European leaders called for tougher sanctions against Moscow. Russia said the atrocities had been committed by Ukrainians.
|
https://www.kgw.com/article/entertainment/music/grammys/zelenskyy-speaks-at-grammys/507-8cb4f20d-efba-4a0f-b274-8c0605201b79
| 2022-04-04T04:47:32
| 1
|
https://www.kgw.com/article/entertainment/music/grammys/zelenskyy-speaks-at-grammys/507-8cb4f20d-efba-4a0f-b274-8c0605201b79
|
GOVERNMENT CAMP, Ore. — The U.S. Forest Service has reviewed and accepted Timberline's master development plan. Although nothing has been officially approved, Timberline hopes the plan guides improvements over the next decade.
Mount Hood has gotten busier and busier over the years. Timberline Lodge and Ski Area are prime destinations. But Highway 26 and the road up to Timberline are now regularly choked with traffic.
Enter the concept of the master development plan, as laid out in a new Timberline presentation. Over conceptual renderings, Jeff Kohnstamm, president and area operator of the Timberline owner R.L.K. and Company, said the cornerstone is, “essentially a gondola that would go from Summit Pass Lodge to Timberline, great for getting to Timberline for skiing, to Timberline for sightseeing, but especially beneficial as an alternative form of transportation.”
The gondola is the star of this new presentation, but it is an idea that's been around for a long time.
Just a few years ago, Timberline had some rougher renderings to share.
Now timberline owns Summit Pass Ski in Government Camp, the natural place to park and ride up the mountain.
“The current concept right now is a 10-person gondola to be about 2.5 miles long and it will originate down at summit pass base area,” said Timberline Director of PR and marketing John Burton.
Burton said a gondola system could move from 1,800 to 2,400 people an hour up and down the mountain, whatever the season.
That would do a lot to ease traffic and the parking problem at Timberline that currently can be so frustrating.
Down below, Timberline said it will keep Summit Pass geared toward more economical family and beginner skiing, but the plan envisions developing an expanded Summit Pass Lodge, with parking and much more to offer.
“There will be skier services, ski patrol, retail, food and beverage, there will be a circulation plan for shuttles,” said Burton.
Again, nothing is set in stone. This is forest service-controlled land and respecting the mountain and Timberline's 85-year history means things don't happen quickly.
“This plan has simply been accepted and it's guiding Timberline's vision for the next 10 years and we're really excited about it,” said Burton.
And the vision is becoming clear.
|
https://www.kgw.com/article/news/local/timberline-master-development-plan/283-276db216-cb34-46e4-adf3-24c7ae012cd7
| 2022-04-04T04:47:39
| 0
|
https://www.kgw.com/article/news/local/timberline-master-development-plan/283-276db216-cb34-46e4-adf3-24c7ae012cd7
|
Just say no to using more provisional ballots here
To the Editor: It is hard for me to understand why we have to fight so hard for American citizens to exercise their constitutional right to vote. Free and fair elections are the hallmark of the democracy America is supposed to represent.
But bad actors in the State House are working hard to create needless barriers to voting. Why? The Big Lie of election fraud. They admit it.
Senate Bill 418 says that a provisional ballot with a tracking number must be given to anyone who registers on election day or to registered voters who forget their photo ID. Those voters are required to make another trip to town hall within 10 days to confirm their identity or their ballot will be discarded.
SB 418 overburdens voters exercising their constitutional right to cast a secret ballot. The complicated paperwork (and extra time) will deter some Granite Staters from voting altogether.
Currently, voters sign an affidavit swearing to their identity (under penalty of law) before voting. The New Hampshire Secretary of State follows up with them. For much of my life, picture IDs were never even required. Even Governor Chris Sununu brags that our elections are fair, accessible, and well-run.
Anyone who believes in free and fair elections should find SB 418 a threat to those very ideals and a backdoor way to discard legally-cast ballots. Please join me in emailing or calling the Senate Election Law and Municipal Affairs Committee to oppose SB 418.
|
https://www.unionleader.com/opinion/letters_to_editor/letter-just-say-no-to-provisional-ballots/article_6f153f02-060b-5362-9751-99e605e4e1db.html
| 2022-04-04T05:04:42
| 1
|
https://www.unionleader.com/opinion/letters_to_editor/letter-just-say-no-to-provisional-ballots/article_6f153f02-060b-5362-9751-99e605e4e1db.html
|
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe
|
https://www.unionleader.com/opinion/letters_to_editor/letter-think-twice-before-voting/article_151604f3-f896-5087-b2d9-de58358004a6.html
| 2022-04-04T05:04:48
| 0
|
https://www.unionleader.com/opinion/letters_to_editor/letter-think-twice-before-voting/article_151604f3-f896-5087-b2d9-de58358004a6.html
|
To the Editor: I had the opportunity to witness a State House Session last Thursday in Concord. I’m not going to lie, it is a pretty interesting event. I proceeded to find a seat in the visitor’s gallery where you get a powerful panoramic view of the Speaker’s pulpit and the members of the leadership for both parties.
Suddenly, I decided to look down and a wave of white hair from older state representatives hit me, it was noticeable. I tried to find young representatives that look like me — by young I mean less than 35 years old. I counted four and to be honest they might be older than that. Then I thought, why are college students or Granite Staters younger than 35 years old not running for office. The answer is clear. The system is not designed for young people to run for office. $200 a term? Who is paying for my rent? My gas? College expenses? It is hard. Young Granite Staters need representation urgently. We have retirees walking all over our education. We have seniors, most likely not having more children, passing legislation telling young women what to do with an unborn child.
Those halls in Concord are full of titles but empty of purpose. If you are young, ignore my feelings and run for office. It will be a sacrifice, believe me, but worth your efforts. We need urgent representation, otherwise nothing will be left to fight for.
|
https://www.unionleader.com/opinion/letters_to_editor/letter-young-leaders-must-buck-the-states-gerontocracy/article_c0bbd5da-10c8-5265-a7c7-ae3e6083ffe7.html
| 2022-04-04T05:04:54
| 0
|
https://www.unionleader.com/opinion/letters_to_editor/letter-young-leaders-must-buck-the-states-gerontocracy/article_c0bbd5da-10c8-5265-a7c7-ae3e6083ffe7.html
|
I AM CONCERNED that the Veterans Centers have lost their way. Vet Centers were created as nontraditional places where combat veterans meet, access services and develop a support/peer group. In the past 8 to 10 years, the centers began to operate more like a traditional mental health center.
One of the changes was for a “readjustment counselor” to have clinical credentials. The original intent for that was to allow veterans without clinical credentials to work with veterans. The focus was on getting the veteran settled and secure in the civilian world. The Vet Centers all had clinical positions to complement this role.
The most harmful change has been a lack of hiring veterans to staff the centers. The final straw were protocols put in place for COVID-19.
The loss of the centers has been damaging for veterans; first trust was lost, and the response made the Vet Centers appear afraid to help.
The switch to remote access is worse than a Band-Aid. It allows the centers to claim hours of service with no real measure of veteran satisfaction or long-term success. Personally, I liken it to a continual dose of half an antibiotic. In the end, the disease becomes untreatable.
Now, I know that someone will give a counter argument with lots of talk of evidence-based practices. Well, my questions are what is the evidence? Yes, numbers can show a gain in treatment, but for how long? Have the results been replicated by others not affiliated with the VA? I have yet to see any review of a patient’s mental health 1 to 5 years later.
Given my experiences with evidence-based practices, they look good on the spreadsheet but are often replaced with new practices.
I have seen many long-term reviews in the medical field focusing on disease outcomes and view the mental health field as riding on the success of the medical field.
So what works? Building trust is the first and most important measure. This is difficult for veterans, especially combat veterans. Getting to a mental health appointment was the most difficult thing I had to do when I returned from Iraq in 2005. It meant a loss of work and income.
This caused a huge stress on my family and I. Getting treatment threatened my ability to feel safe at work because I was disrupting the workplace with my personal mental health needs. I had some local VFW members who guided me through this period and without their support and trust I would now be divorced and maybe homeless.
Several months ago, USAToday had a front page article on the death of four Wisconsin Army National Guard members. As I read this article, I realized how lucky I was when I came back. I had people who would support me face to face when I needed it. This allowed me to regain a sense of stability. I was then able to start moving on to more health, both physical and mental. None of the four Wisconsin service members had this.
I would draw your attention to Nov-Dec 2021 DAV Magazine. On pages 14 and 15 is an article titled “Anybody Can Do It” detailing how a rural DAV post successfully lowered the number of veteran suicides over a five-year period. Everyone at the Vet Centers should read it as it is a model that they should be pursuing!
Let’s ask the remaining Vietnam veterans what was the most help for them. After all, it was due to a total lack of trust in the VA that the Vet Centers were created.
Please also refer to both the DAV, VFW, and American Legion’s past resolutions. You will find that peer outreach is viewed as an underfunded tool the VA is not utilizing. In rural areas, outreach must be the first priority. You have to find the veterans to help them. Then help them find a way to be safe and secure.
No real treatment can start before those needs are met. No 50-minute session in an office or over a computer can accomplish this. If you never leave the office, there is no way to accomplish treating veterans.
This cannot go on without a culture change. Ask any combat veteran to think about whom they would have trusted more, a fellow veteran or a clinical mental health professional?
Every Vet Center, no matter the size, needs an outreach worker focused on being out in the world 36 hours a week working with veterans. This role needs a case management component and should be valued on the level of a patient advocate at a VA Hospital.
|
https://www.unionleader.com/opinion/op-eds/charles-lockhart-vet-centers-are-failing-veterans/article_78f2f1d4-e3f0-5fe0-ba15-25e8d5d2425a.html
| 2022-04-04T05:05:00
| 1
|
https://www.unionleader.com/opinion/op-eds/charles-lockhart-vet-centers-are-failing-veterans/article_78f2f1d4-e3f0-5fe0-ba15-25e8d5d2425a.html
|
LAST MONTH, Joe Biden delivered his State of the Union address with a nation and the world in crisis.
After months of being weak on Russia and appeasing Vladimir Putin, Biden tried to fool the American people with tough talk. Let me be clear: Biden has been weak on Russia his entire career and has been even worse in the months leading up to the invasion of Ukraine.
Last month, Republicans in the U.S. Senate worked to put sanctions on Putin’s Nord Stream 2 pipeline, which is a massive economic boon to Putin and the entire Russian economy. Not only did Joe Biden oppose the sanctions, he actively lobbied against them on Capitol Hill, leveraging massive amounts of political capital to ensure Putin got exactly what he wanted.
Green energy policies driven by Joe Biden have forced the decline of oil and natural gas production. This administration has taken us from energy independence and low fuel prices, to energy dependence and sky-rocketing prices, all to the financial benefit of Russia. Then, as Putin’s army sat on the doorstep of Kyiv, funded by our own tax dollars, Biden finally reinstated sanctions on the pipeline. Too little, too late, Joe.
This is not the first time Putin has invaded Ukraine under Biden’s watch — the first being the annexation of Crimea in 2013 when he was vice president.
Being weak on Russia is a failure Biden shares with his Democrat colleagues, including New Hampshire’s congressional delegation. This year, Democrat Jeanne Shaheen, a self-described “Russia Hawk,” joined Senate Democrats in filibustering and voting against sanctions on Putin’s pipeline. It’s ironic that at the very same time Senate Democrats were calling the filibuster a racist relic of the Jim Crow era, they were leveraging the filibuster to empower Putin to dominate the energy sector.
Fast forward mere days and Shaheen takes to Twitter to praise the very sanctions that she voted against.
New Hampshire’s junior senator, Maggie Hassan, isn’t free of blame in this crisis either. While she did make the election-year calculation to join Republicans and vote to sanction Nord Stream 2, like Biden she has opposed American energy independence her whole career. Hassan is notoriously weak on not only Russia, but their biggest ally, communist China. Her ties to our enemies run far deeper than any constituent would hope. Hassan has been taking money from a lobbyist for ZTE, “A Chinese technology company that’s been fined for exporting U.S. technology to Iran and North Korea and has been designated a national-security threat by the Federal Communications Commission.” Hassan also took a maxed-out contribution from one of the top lobbyists for Putin’s pipeline, a lobbyist whose firm “has been paid $8.5 million for its Nord Stream 2 lobbying work.”
Both Shaheen and Hassan opposed the Keystone XL pipeline in the United States, which would have helped in securing American energy independence for decades. Ultimately, Shaheen tried to block sanctions on Putin’s pipeline and Hassan took campaign cash from lobbyists who defend it, both showing their true colors in efforts to destroy American energy independence and embolden our enemies. Instead of unleashing American energy, they want Putin to have pipelines in Russia.
With skyrocketing inflation, gas prices through the roof, and now a Ukraine invasion by Russia, all brought on by Joe Biden’s weak leadership, our country is in crisis. No matter how Democrats try to paint it, things only continue to get worse — not better. This November you need to head to the polls and vote Republican up and down the ticket to send a clear message to Joe Biden and Democrats nationwide: Americans have had enough.
|
https://www.unionleader.com/opinion/op-eds/stephen-stepanek-send-a-clear-message-by-electing-republicans/article_4d3cdfff-f767-5c59-a4a8-68feec402967.html
| 2022-04-04T05:05:07
| 1
|
https://www.unionleader.com/opinion/op-eds/stephen-stepanek-send-a-clear-message-by-electing-republicans/article_4d3cdfff-f767-5c59-a4a8-68feec402967.html
|
WASHINGTON — Ukrainian president Volodymyr Zelenskyy appeared in a video message at the Grammy Awards to ask for support in telling the story of Ukraine's invasion by Russia.
During the message that aired on the show Sunday, he likened the invasion to a deadly silence threatening to extinguish the dreams and lives of the Ukrainian people, including children.
“Our musicians wear body armor instead of tuxedos. They sing to the wounded in hospitals, even to those who can’t hear them,” he said. “But the music will break through anyway.”
The Recording Academy, with its partner Global Citizen, prior to the ceremony highlighted a social media campaign called “Stand Up For Ukraine” to raise money and support during the humanitarian crisis.
“Fill the silence with your music. Fill it today to tell our story. Tell the truth about the war on your social networks, on TV, support us in any way you can any, but not silence. And then peace will come to all our cities,” Zelenskyy said.
Following Zelenskyy’s message, John Legend performed his song “Free” with Ukrainian musicians Siuzanna Iglidan and Mika Newton, and poet Lyuba Yakimchuk, as images from the war were shown on screens behind them.
The war in Ukraine had taken a particularly gruesome turn Sunday when Ukrainian forces entering the town of Bucha, recently held by Russian soldiers, found bodies of people who had been shot, some after being bound and tortured. Ukrainian authorities accused the Russians of war crimes, and European leaders called for tougher sanctions against Moscow. Russia said the atrocities had been committed by Ukrainians.
|
https://www.5newsonline.com/article/entertainment/music/grammys/zelenskyy-speaks-at-grammys/507-8cb4f20d-efba-4a0f-b274-8c0605201b79
| 2022-04-04T06:11:29
| 1
|
https://www.5newsonline.com/article/entertainment/music/grammys/zelenskyy-speaks-at-grammys/507-8cb4f20d-efba-4a0f-b274-8c0605201b79
|
LITTLE ROCK, Ark. — According to the Little Rock Police Department, officers are investigating an overnight homicide that occurred on Indiana Avenue.
Police say a little after midnight on Sunday, April 3, a man was found on Indiana Avenue suffering from a gunshot wound.
That man was identified as Donnie Hood. He was transferred to a local hospital where he died due to his injuries.
The pickup truck found at the crime scene, belonging to Hood, was taken to the crime scene bay for processing.
The suspect was identified as Joey Doss, and police say he is now in custody.
This investigation is ongoing.
We will update this article with more information as it becomes available.
|
https://www.5newsonline.com/article/news/crime/man-dead-overnight-homicide-indiana-avenue-little-rock/91-e687e7fb-8a91-4577-a63c-e488acfa9442
| 2022-04-04T06:11:35
| 0
|
https://www.5newsonline.com/article/news/crime/man-dead-overnight-homicide-indiana-avenue-little-rock/91-e687e7fb-8a91-4577-a63c-e488acfa9442
|
LITTLE ROCK, Ark. — According to the Little Rock Police Department, officers are investigating a shooting on Markham Street, located on the east portion of the parking lot at Park Plaza mall.
Police say an 18-year-old man was injured in result of the shooting and is currently receiving medical attention.
There is no suspect information at this time.
This investigation is ongoing and we will update this article with more information as it becomes available.
|
https://www.5newsonline.com/article/news/crime/shooting-parking-lot-park-plaza-mall-little-rock/91-5e243a29-98e5-47a6-8886-aa6548ea0ba1
| 2022-04-04T06:11:41
| 0
|
https://www.5newsonline.com/article/news/crime/shooting-parking-lot-park-plaza-mall-little-rock/91-5e243a29-98e5-47a6-8886-aa6548ea0ba1
|
Jury selection to begin in Parkland shooter's sentencing
Jury selection is scheduled to begin Monday in the penalty phase of Parkland school shooter Nikolas Cruz's murder trial.
Cruz previously pleaded guilty to all 17 counts of first-degree murder and 17 counts of attempted murder, but a jury still must be selected to determine his fate.
Jurors will be asked to decide whether the 23-year-old should spend the rest of his life in prison, without the possibility of parole, or be put to death for his crimes on Feb. 14, 2018, at Marjory Stoneman Douglas High School.
Broward County Judge Elizabeth Scherer, prosecutors and Cruz's defense team will spend the next few weeks trying to seat an impartial jury of 12 people, along with six to eight alternates.
Among the challenges they'll face are finding potential jurors who haven't already formulated an opinion on Cruz that could sway their decision and who can commit to seeing it through, possibly into September.
Once a jury is seated, prosecutors will present their case as to why Cruz deserves to die for his crimes, while defense attorneys will attempt to explain how mitigating factors led to Cruz's actions in the hopes that jurors will spare his life.
Whatever the decision, it must be reached unanimously.
Scripps Only Content 2022
|
https://www.wflx.com/2022/04/04/jury-selection-begin-parkland-shooters-sentencing/
| 2022-04-04T06:11:45
| 1
|
https://www.wflx.com/2022/04/04/jury-selection-begin-parkland-shooters-sentencing/
|
VAN BUREN, Ark. — Two pedestrians were hit by a train in Van Buren Sunday, April 3, 2022.
According to the Van Buren Police Department (VBPD), at approximately 7 p.m., the two pedestrians were struck by a train on the bridge crossing Lee Creek just north of Lee Creek Park.
One of the pedestrians died and the other is in critical condition.
Sergeant Jonathan Wear with the VBPD says both pedestrians were adults, but there is no further information on their identities.
No further details have been released at this time.
Stay with 5NEWS for updates on this developing story.
|
https://www.5newsonline.com/article/news/local/2-pedestrians-struck-by-train-in-van-buren/527-f3440ff1-2ba8-406e-be38-f87253ece467
| 2022-04-04T06:11:47
| 0
|
https://www.5newsonline.com/article/news/local/2-pedestrians-struck-by-train-in-van-buren/527-f3440ff1-2ba8-406e-be38-f87253ece467
|
Woman robbed after thief intentionally rear-ended her on highway
SACRAMENTO, Calif. (KCRA) - Police in California’s capital are investigating recent fender bender robberies where thieves purposefully rear-end victims with the intent to rob them.
Rindy Merrifield, a victim of one of these crimes, is sharing her story in hopes it helps others avoid being a target of the thieves. She was headed home on the highway March 10 after running some errands in Sacramento when a driver bumped her car from behind.
She didn’t think much of it, not worried the bump did any damage to her SUV. She says the same car bumped her again about a mile later, but still not too concerned, Merrifield kept driving.
“He pulled beside me, told me to pull over,” Merrifield said. “So, I thought, ‘OK, maybe he did do some damage, and that’s why he wants me to pull over.’”
She found a place to stop off the exit near Cal Expo and got out of her car to speak with the other driver.
“I just came around, looked and said, ‘You know what? No damage. Just go on your way,’” Merrifield said. “That’s when he said, ‘Well, I really think we should exchange insurances because that’s the right thing to do.’”
Merrifield went to the passenger side door and opened it. She says the other driver then pushed her away, grabbed her purse and swatted away her arm, preventing her from retrieving it.
“It was just, ‘How dare you… take my purse.’ And I was bound and determined to get it back or hurt him enough that I could get it,” Merrifield said.
She followed after the other driver as he returned to his own car. She says she slammed his own car door on his legs five times as he was getting away. Merrifield’s efforts didn’t stop the thief, who escaped with her purse and its contents, including her credit cards, cash, car keys and cell phone.
Police say a similar fender bender-type robbery happened the next day, involving a different victim. Detectives arrested Phung Nguyen and Hau Nguyen and charged them for that crime.
Police received an arrest warrant April 1 for Phung Nguyen for charges related to Merrifield’s case. His whereabouts are not currently known, and he is considered wanted by law enforcement.
California law indicates drivers are required to stop and exchange information after a crash.
Merrifield is determined to warn others, using her own experience as an example. She organized a personal safety seminar with law enforcement and safety experts about how to handle situations just like the fender bender robbery she endured.
“Knowing that I was so naïve and trustworthy and not watching my surroundings, I didn’t want anybody else to go through that,” Merrifield said. “It may never happen again… but I’ll be ready.”
She also plans to organize other safety sessions in the near future.
Copyright 2022 KCRA via CNN Newsource. All rights reserved.
|
https://www.wflx.com/2022/04/04/woman-robbed-after-thief-intentionally-rear-ended-her-highway/
| 2022-04-04T06:11:51
| 0
|
https://www.wflx.com/2022/04/04/woman-robbed-after-thief-intentionally-rear-ended-her-highway/
|
Giuli Frendak
Updated: April 03, 2022 11:25 PM
Created: April 03, 2022 08:17 PM
ALBUQUERQUE, N.M. – Albuquerque police are looking for another violent suspect who cut off his GPS ankle monitor on Friday. The department put out a plea to the public on social media, asking for people to keep an eye out for Myzel Hayes.
Hayes is accused of shooting a man eight times last June, and police say he broke free of his monitor Friday.
KOB 4 looked into Hayes' history, and he's the fourth suspect in the past eight months in Albuquerque who has cut off his monitor. Now, we’re taking a closer look at how GPS monitoring, used for keeping track of suspected criminals before trial, continues to face criticism from police and other leaders.
Myzel Hayes' criminal history dates back to 2010. His charges range from DWI, to misdemeanor assault on a police officer and to his most recent crime last June-- aggravated battery.
A criminal complaint says he shot a man eight times outside a northwest Albuquerque apartment complex. That man survived the shooting, and a judge let Hayes out on an ankle monitor in August.
Last week, he cut it off, making him the fourth suspect in Albuquerque in the past eight months to do so.
In August, police say murder suspect Trey Bausby cut his off. He was back in jail within days, but leaders aired frustration with the system.
"I can't stress enough how frustrated the police are, how frustrated my prosecutors are with this system, and we need to get it right. It's just long past time for us to address this issue," said Bernalillo County District Attorney Raúl Torrez.
A month later, Nathanael Neal cut off his monitor. Documents show Neal had violated other conditions of release in a 2019 stolen vehicle case before a judge put him on house arrest. Court records show he still hasn't been arrested.
In December, Daniel Drake cut off his monitor just eight days after he got it. He's been charged with multiple felonies, and spent time on Albuquerque's Metro 15 offenders list.
APD Chief Harold Medina brought up new concerns at that time about the amount of time and effort it takes for police to get the GPS monitor data.
"The frustrating part is he cuts the ankle bracelet off and we are once again having to go through the loops of producing paperwork and getting subpoenas to get the historical data of where this person was on a GPS monitor over the past few days," said Medina. "We really need people to have a sense of urgency in upgrading their processes and programs to fall more in line with the community needs."
Medina shared concerns again about two weeks ago when police arrested an 18-year-old, on an ankle monitor, accused of selling drugs and guns out of his apartment. They found about 4,000 fentanyl pills and six guns.
"This is exactly why I have been critical of the courts for relying on GPS ankle monitors to keep the public safe from violent suspects," Medina said.
An APD representative says the department is working out details of a new GPS data reporting process, and are thankful for the changes. But there is no timeline on when those changes could be in place.
Copyright 2022 - KOB-TV LLC, A Hubbard Broadcasting Company
|
https://www.kob.com/albuquerque-news/a-closer-look-at-murder-suspects-on-gps-monitors/6436372/?cat=500
| 2022-04-04T06:30:09
| 0
|
https://www.kob.com/albuquerque-news/a-closer-look-at-murder-suspects-on-gps-monitors/6436372/?cat=500
|
Kai Porter
Updated: April 03, 2022 10:22 PM
Created: April 03, 2022 09:02 PM
ALBUQUERQUE, N.M. – Albuquerque city councilors are planning to address Mayor Tim Keller’s two vetoes this week. Keller vetoed a potential vaccine mandate for city workers, and the repeal of Albuquerque's plastic bag ban.
Some city councilors want to end Albuquerque's plastic bag ban but it will take six councilors to override a veto. Now, KOB 4 explains why it's only one vote away from staying in the trash for good.
A debate is dividing the Albuquerque city council and Mayor Tim Keller, one that could once again play out during Monday's city council meeting.
"We need to have a middle ground, so we can't be extreme and say ‘no plastics,’ we can't be extreme and say only one thing or another," said Brook Bassan, Albuquerque city councilor.
Bassan is one of the councilors opposing the ban.
"We should allow people the choice for their priority, and what they need to do that best serves their needs, rather than us mandating and telling them what to do," she said.
But last week, Keller vetoed city council's repeal of the ban, writing in his veto message to councilors:
"I write to you not taking lightly the Executive Veto power and also with the acknowledgement that this action may not ultimately stand."
That's because the city council needs just six votes to override the mayor's veto – the same number of councilors who voted to repeal the ban. In his letter, Keller asked city council to hold off.
"To allow proper study of its impact, research alternatives that may better help our city achieve our sustainability goals and keep our city clean."
That study is currently being done by the city's Solid Waste Department, but there hasn't been too much time to study the plastic bag ban. The ban started in January 2020 but was suspended a few months later when COVID hit and was only reinstated last August.
The next city council meeting is on April 4 at 5:00 p.m.
Copyright 2022 - KOB-TV LLC, A Hubbard Broadcasting Company
|
https://www.kob.com/albuquerque-news/city-council-to-address-mayor-kellers-2-vetoes-in-upcoming-meeting/6436403/?cat=500
| 2022-04-04T06:30:15
| 0
|
https://www.kob.com/albuquerque-news/city-council-to-address-mayor-kellers-2-vetoes-in-upcoming-meeting/6436403/?cat=500
|
agate Daily Journal high school baseball rankings, April 4 Brad Locke Brad Locke Senior sports reporter Author twitter Author email Apr 4, 2022 1 hr ago Comments Facebook Twitter WhatsApp SMS Email Evan McCarthy's Saltillo Tigers are No. 6 in this week's rankings. By BRAD LOCKE Daily Journal Facebook Twitter WhatsApp SMS Email Print Save DAILY JOURNAL BASEBALL RANKINGSTeam (Class) | W-L | Pvs1. East Union (2A) | 17-3 | 12. Oxford (6A) | 14-5 | 33. Amory (3A) | 15-3 | 24. Nettleton (3A) | 16-4 | 65. Mooreville (4A) | 13-5 | 56. Saltillo (5A) | 16-4 | 47. Tupelo (6A) | 10-8 | 78. Pontotoc (4A) | 18-4 | 99. Lafayette (5A) | 14-5 | NR10. Tupelo Christian (1A) | 9-6 | 10 brad.locke@journalinc.com Facebook Twitter WhatsApp SMS Email Print Save Tags High School Baseball Rankings Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today Recommended for you Please enable JavaScript to view the comments powered by Disqus. comments powered by Disqus Newsletters Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. The Daily You'll receive our top headlines each morning, seven days a week, as well as each weekday afternoon. News Alerts & Top Stories Get news sent to your inbox as it happens, as well as our top stories each week. The Session Get weekly recaps during Mississippi's annual legislative session, plus breaking alerts, from our state politics team. You must select at least one email list. Please enter a valid email address. Sign up All Newsletters
Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today
|
https://www.djournal.com/sports/high-school/daily-journal-high-school-baseball-rankings-april-4/article_be841d07-1dc4-5cac-88bd-96362536fbd2.html
| 2022-04-04T06:41:56
| 0
|
https://www.djournal.com/sports/high-school/daily-journal-high-school-baseball-rankings-april-4/article_be841d07-1dc4-5cac-88bd-96362536fbd2.html
|
agate Daily Journal high school softball rankings, April 4 Brad Locke Brad Locke Senior sports reporter Author twitter Author email Apr 4, 2022 1 hr ago Comments Facebook Twitter WhatsApp SMS Email Amelia Nelson's Booneville team remains No. 1 in the Daily Journal rankings. Adam Robison | DAILY JOURNAL Facebook Twitter WhatsApp SMS Email Print Save DAILY JOURNAL SOFTBALL RANKINGSTeam (Class) | W-L | Pvs1. Booneville (3A) | 12-4 | 12. Kossuth (3A) | 12-3 | 33. Tishomingo Co. (4A) | 16-3 | 24. Saltillo (5A) | 12-2-1 | 45. Mantachie (3A) | 15-4 | 56. East Webster (2A) | 14-4 | 67. Pontotoc (4A) | 15-3 | 78. Corinth (4A) | 13-3-1 | NR9. Pine Grove (2A) | 17-2 | 910. Hatley (3A) | 15-2 | NR brad.locke@journalinc.com Facebook Twitter WhatsApp SMS Email Print Save Tags High School Softball Rankings Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today Recommended for you Please enable JavaScript to view the comments powered by Disqus. comments powered by Disqus Newsletters Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. The Daily You'll receive our top headlines each morning, seven days a week, as well as each weekday afternoon. News Alerts & Top Stories Get news sent to your inbox as it happens, as well as our top stories each week. The Session Get weekly recaps during Mississippi's annual legislative session, plus breaking alerts, from our state politics team. You must select at least one email list. Please enter a valid email address. Sign up All Newsletters
Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today
|
https://www.djournal.com/sports/high-school/daily-journal-high-school-softball-rankings-april-4/article_a59986b5-9281-5c85-a5f4-e95710bfffe4.html
| 2022-04-04T06:42:02
| 1
|
https://www.djournal.com/sports/high-school/daily-journal-high-school-softball-rankings-april-4/article_a59986b5-9281-5c85-a5f4-e95710bfffe4.html
|
- Streem brand, platform, and local service continue in Australia and New Zealand (ANZ) market
- Management team retained with long-term growth mandate
- Streem joins PR Newswire, Brandwatch, and Falcon.io brands to activate full-service offering for Cision across ANZ
SYDNEY and CHICAGO, April 3, 2022 /PRNewswire/ -- Global communications intelligence company Cision announced today that it has completed the acquisition of realtime media monitoring company Streem.
Since announcing the deal in December 2021, Streem has continued its high-growth trajectory, winning major new customers, including Amazon, HSBC, Crown Resorts, and several government departments.
Cision's Chief Revenue Officer Stephen Boyes noted, "Streem has established itself as the customer-preferred media intelligence platform in the ANZ market. We are excited that they are now part of the Cision family and that our ANZ customers can benefit from a full suite of monitoring, distribution, insights, and social media solutions."
Streem customers will benefit from the global reach of Cision, while continuing to receive the same local support and expertise they have relied on since the company's launch in 2017. Streem's customers will also continue to access the company's existing media monitoring and insights platform, supported by its local product and engineering teams.
"The closing of this deal gives us the opportunity to create the ANZ region's leading media intelligence offering. Streem is best positioned to deliver on every customer's need through a single platform and local team," Elgar Welch, CEO of Streem said.
The completion of the acquisition follows approval by Australia's Foreign Investment Review Board (FIRB) and the United States' Department of Justice (DoJ), and results in a sale of 100% of Streem shares to Cision. Streem will continue to operate as an independent brand, with operations and people, including key management and founders Elgar Welch (CEO) and Antoine Sabourin (CTO), to remain in place.
Cision is a portfolio company of Platinum Equity, which acquired the business in 2020. The Streem transaction marks the second add-on acquisition Cision has completed this year.
"We are delivering on our promise to invest in Cision's growth, expand its product offering and extend its geographic reach," said Platinum Equity Partner Jacob Kotzubei and Platinum Equity Managing Director Matthew Louie in a joint statement. "We will continue working with the team to pursue more opportunities to drive growth organically and through acquisitions."
Streem is one of the ANZ market's fastest growing media intelligence companies, delivering comprehensive and realtime Print, Online, TV, Radio, & Social media monitoring, insights, and reporting to leading corporate and government organisations including Telstra, Amazon, Qantas, Commonwealth Bank, and the Department of Prime Minister & Cabinet. Through Desktop, Tablet and Mobile, Streem's customers can see, stream and analyse millions of news items in realtime, helping PR and Corporate Affairs teams to do their jobs.
As a global leader in PR, IR, marketing and social media management technology and intelligence, Cision helps brands and organisations to identify, connect and engage with customers and stakeholders to drive business results. Through a suite of IR services, PR Newswire helps companies meet their communications and disclosure needs. A network of over 1.1 billion influencers, in-depth monitoring, analytics and its Brandwatch and Falcon.io social media platforms headline a premier suite of solutions. Cision has offices in 24 countries throughout the Americas, EMEA and APAC. For more information about Cision's award-winning solutions, including its next-gen Cision Communications Cloud®, visit www.cision.com and follow @Cision on Twitter.
Media Contacts:
Streem
Jack McLintock
Media Relations Manager
Streem
jack.mclintock@streem.com.au
Cision
cisionpr@cision.com
View original content to download multimedia:
SOURCE Cision Ltd.
|
https://www.wflx.com/prnewswire/2022/04/03/cision-completes-acquisition-streem/
| 2022-04-04T07:27:08
| 1
|
https://www.wflx.com/prnewswire/2022/04/03/cision-completes-acquisition-streem/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grab Holdings Limited ("Grab" or the "Company") (NASDAQ: GRAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Grab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
In December 2021, Grab went public through a special-purpose acquisition company ("SPAC") merger, emphasizing the Company's dramatic growth in the food delivery, digital payments, ride-hailing and financial services areas through its "super app." The Company highlighted a purportedly significant opportunity for further growth in the firm's core businesses in Southeast Asia and other regions. Then, on March 3, 2022, Grab announced its first quarterly earnings report as a public company. Among other items, the Company reported a 44% revenue decline from the same period in the prior year, along with a loss of $3.6 billion for the year. Grab's management blamed the results on the Company's need to increase spending in order to offer higher commissions to attract drivers and greater incentives to users and partners.
On this news, Grab's stock price fell $1.95 per share, or 37.28%, to close at $3.28 per share on March 3, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-grab-holdings-limited-grab/
| 2022-04-04T07:27:18
| 1
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-grab-holdings-limited-grab/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or the "Company") (NASDAQ: RIVN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Rivian and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On or around November 10, 2021, Rivian conducted its initial public offering ("IPO") of 153 million shares priced at $78.00 per share. Unbeknownst to investors, the Registration Statement failed to disclose, among other things, that the Company's electric vehicles were underpriced to such a degree that Rivian would have to raise prices shortly after the IPO and that these price increases would tarnish Rivian's reputation as a trustworthy and transparent company and would put a significant number of the existing backlog of 55,400 preorders along with future preorders in jeopardy of cancellation. Since the IPO, Rivian's stock price has closed as low as $42.21 per share, down nearly 46% from the $78.00 offering price.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-rivian-automotive-inc-rivn/
| 2022-04-04T07:27:26
| 1
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-rivian-automotive-inc-rivn/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 22-cv-00388, is on behalf of a class consisting of all purchasers of Acutus common stock between May 13, 2021 and November 11, 2021, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").
If you are a shareholder who purchased or otherwise acquired Acutus common stock during the Class Period, you have until April 18, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Acutus designs and manufactures a range of tools for catheter-based ablation procedures and markets and sells its products to hospitals and electrophysiologists that treat patients with arrhythmias. The Company's primary product is its AcQMap imaging and mapping system, which consists of a console, workstation, proprietary software algorithms, and a single-use catheter that contains ultrasound transducers and electrodes which collect the data required to create a comprehensive map of a patient's cardiac anatomy and electrical propagation pathways and patterns.
To gain a market foothold, Acutus initially lent its first-generation AcQMap console and workstation to users free of charge to facilitate the sale of its disposable products. In late 2019, Acutus began to install its second generation AcQMap console and workstation products with potential purchasers under evaluation arrangements. Pursuant to these agreements, Acutus places the AcQMap console and workstation with potential customers free of charge for a specified period. The Company then attempted to sell the console and workstation to the potential customers in exchange for a cash payment, or a contractual commitment to purchase a minimum amount of its disposable products.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a material percentage of the AcQMap systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, the Company's products; (ii) a material percentage of the AcQMap systems under evaluation had been installed in locations where the Company did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system's operations; (iii) as a result of (i) and (ii) above, Defendants were in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (iv) the Company's management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on the Company's 2021 financial results; (v) the Company's risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing the Company; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
On November 11, 2021, Acutus announced that it had slashed its 2021 revenue guidance due, in part, to a strategic decision by Defendants during the third quarter of 2021 to relocate approximately 20% of AcQMap systems installations under then-existing evaluation arrangements to address meaningfully lower-than-expected product adoption. Further, contrary to Defendants' representations during the Class Period, Defendants revealed that Acutus needed to relocate AcQMap systems that had been placed in improper locations, thereby negatively impacting customer uptake.
On this news, the Company's stock price fell $3.02 per share, or 45.35%, to close at $3.64 per share on November 12, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-acutus-medical-inc-class-action-lawsuit-upcoming-deadline-afib/
| 2022-04-04T07:27:33
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-acutus-medical-inc-class-action-lawsuit-upcoming-deadline-afib/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired Akebia securities during the Class Period, you have until May 13, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The Company's lead investigational product candidate is vadadustat, an oral therapy, which is in Phase 3 development for the treatment of anemia due to chronic kidney disease ("CKD") in dialysis-dependent and non-dialysis dependent ("NDD") adult patients.
Akebia's Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the "PRO2TECT Program"). The PRO2TECT Program's primary safety endpoint was defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events ("MACE").
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Program's clinical prospects; (iii) accordingly, Defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On September 3, 2020, Akebia issued a press release announcing "top-line results" from the PRO2TECT Program, disclosing that "[v]adadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of [MACE.]"
On this news, Akebia's common stock price fell $7.35 per share, or 73.5%, to close at $2.65 per share on September 3, 2020.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-akebia-therapeutics-inc-class-action-lawsuit-upcoming-deadline-akba/
| 2022-04-04T07:27:40
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-akebia-therapeutics-inc-class-action-lawsuit-upcoming-deadline-akba/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Astra Space Inc. ("Astra" or the "Company") f/k/a Holicity Inc. ("Holicity") (NASDAQ: ASTR; HOL) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01591, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired the publicly traded securities of the Company between February 2, 2021 and December 29, 2021, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.
If you are a shareholder who purchased or otherwise acquired Astra securities during the Class Period, you have until April 11, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Astra purportedly operates as an operational space launch company. On June 30, 2021 Astra Space Inc. and Holicity Inc., a special purpose acquisition company, merged.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Astra cannot launch "anywhere"; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
On December 29, 2021, during market hours, market researcher Kerrisdale Capital released a report entitled "Astra Space, Inc (ASTR): Headed for Dis-Astra" which alleged myriad issues with the Company.
On this news, Astra's shares fell $1.10 per share, or approximately 14%, to close at $6.61 per share on December 29, 2021, on unusually heavy trading damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-astra-space-inc-fka-holicity-inc-class-action-lawsuit-upcoming-deadline-astr-hol/
| 2022-04-04T07:27:47
| 1
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-astra-space-inc-fka-holicity-inc-class-action-lawsuit-upcoming-deadline-astr-hol/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against C3.ai, Inc. ("C3.ai" or the "Company") (NYSE: AI) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 22-cv-01413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) C3.ai Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about December 9, 2020 (the "IPO" or "Offering"); and/or (b) C3.ai securities between December 9, 2020 and February 15, 2022, both dates inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act").
If you are a shareholder who purchased or otherwise acquired C3.ai Class A common stock pursuant and/or traceable to the IPO; and/or securities during the class period, you have until May 3, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
C3.ai operates as an enterprise artificial intelligence ("AI") software company. The Company offers a variety of software-as-a-service applications for enterprises and software solutions and integrated turnkey enterprise AI applications for oil and gas, chemicals, utilities, manufacturing, financial services, defense, intelligence, aerospace, healthcare, and telecommunications market segments. The Company also purports to have strategic partnerships with Baker Hughes related to oil and gas markets; FIS related to financial services markets; Raytheon; and AWS, Intel, and Microsoft.
The complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) C3.ai's partnership with Baker Hughes was deteriorating; (ii) C3.ai's was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (iii) C3.ai faced challenges in product adoption and significant salesforce turnover; (iv) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
On February 16, 2022, during pre-market hours, Spruce Point Capital Management ("Spruce Point") issued a report and strong sell research opinion regarding C3.ai (the "Spruce Point Report"). Specifically, Spruce Point alleged that it had uncovered, inter alia, "[e]vidence of a severely challenged partnership with Baker Hughes, a related-party and C3.ai's largest customer"; "[s]igns of problematic financial reporting and accounting regarding the Baker Hughes joint venture and a revolving door in C3.ai's Chief Financial Officer position"; that "[c]hallenges in product adoption and significant salesforce turnover make it unlikely that C3.ai will meet aggressive analyst estimates"; "[e]vidence of exaggerated or irreconcilable claims made by C3.ai[,]" including "numerous discrepancies" regarding "the value of and cumulative investment made by C3.ai in its technology, description of its customers, its total addressable market, the pace of its market growth and the scale of alliances with companies such as Microsoft, Hewlett Packard Enterprises, Google Cloud, Intel and Amazon Web Services"; and "[w]orrisome corporate governance practices and insider enrichment." As a result, Spruce Point "conservatively estimate[d] 40% - 50% downside risk to C3.ai's share price."
Following publication of the Spruce Point Report, C3.ai's stock price fell $1.01 per share, or 3.93%, to close at $24.70 per share on February 16, 2022.
As of the time this Complaint was filed, the price of C3.ai Class A common stock continues to trade below the $42.00 per share Offering price, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-c3ai-inc-class-action-lawsuit-upcoming-deadline-ai/
| 2022-04-04T07:27:54
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-c3ai-inc-class-action-lawsuit-upcoming-deadline-ai/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 24, 2019 (the "IPO" or "Offering"); and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act").
If you are a shareholder who purchased or otherwise acquired Cabaletta common stock pursuant and/or traceable to the IPO; and/or Cabaletta securities during the Class Period, you have until April 29, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Cabaletta, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Company's proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. Cabaletta's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris (the "Phase 1 Clinical Trial"), an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
On September 30, 2019, Cabaletta filed a registration statement on Form S-1 with the SEC in connection with the IPO, which, after amendment, was declared effective by the SEC on October 24, 2019 (the "Registration Statement").
On October 25, 2019, Cabaletta filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the "Prospectus" and, together with the Registration Statement, the "Offering Documents").
Pursuant to the Offering Documents, Cabaletta conducted the IPO, selling approximately 6.8 million shares of common stock priced at $11.00 per share, for approximate proceeds of $69.5 million to the Company after applicable underwriting discounts and commissions, and before expenses.
The complaint alleges that, the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On December 14, 2021, Cabaletta issued a press release "report[ing] top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV)." Among other results, Cabaletta reported that two cohort participants had "disease activity scores that worsened . . . after DSG3-CAART infusion" and thus "reduced or discontinued selected systemic therapies prior to DSG3-CAART infusion, as required by the protocol", while another participant "subsequently received systemic medication to improve disease activity after DSG3-CAART infusion."
On this news, Cabaletta's stock price fell $9.15 per share, or 73.14%, to close at $3.36 per share on December 14, 2021.
As of the time this Complaint was filed, the price of Cabaletta common stock continues to trade below the $11.00 per share Offering price, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-cabaletta-bio-inc-class-action-lawsuit-upcoming-deadline-caba/
| 2022-04-04T07:28:00
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-cabaletta-bio-inc-class-action-lawsuit-upcoming-deadline-caba/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired Homology securities during the Class Period, you have until May 24, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. The Company's lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults (the "HMI-102 Trial").
On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated HMI-102's efficacy and risk mitigation; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
On July 21, 2020, Mariner Research ("Mariner") published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company's lead product candidate for treatment of phenylketonuria. Mariner focused on Homology's HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102's lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology's Chief Communications Officer appearing to indicate the Company's awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.
On this news, Homology's stock price fell $1.71 per share, or 10.38%, over the following three trading days, closing at $14.77 per share on July 24, 2020.
Then, on February 18, 2022, Homology issued a press release disclosing that "the U.S. Food and Drug Administration has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests" and that "[t]he Company expects to receive an official clinical hold letter within 30 days."
On this news, Homology's stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-homology-medicines-inc-class-action-lawsuit-upcoming-deadline-fixx/
| 2022-04-04T07:28:07
| 1
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-homology-medicines-inc-class-action-lawsuit-upcoming-deadline-fixx/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MP Materials Corp. f/k/a Fortress Value Acquisition Corp. ("MP Materials" or the "Company") (NYSE: MP) (FVAC; FVAC WS; FVAC.U) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 22-cv-00315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired MP Materials securities between May 1, 2020 and February 2, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired MP Materials securities during the Class Period, you have until April 25, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
MP Materials engages in the ownership and operation of integrated rare earth mining and processing facilities. The Company was previously known as "Fortress Value Acquisition Corp." ("FVAC") and operated as a special purpose acquisition company ("SPAC").
In November 2020, FVAC consummated a merger with MP Mine Operations LLC ("MPMO") and Secure Natural Resources LLC ("SNR" and, collectively with MPMO, "Legacy MP Materials"), whereby, among other things, Legacy MP Materials became an indirect wholly-owned subsidiary of FVAC, and FVAC changed its name from "Fortress Value Acquisition Corp." to "MP Materials Corp." (the "Business Combination"). As a result of the Business Combination, the Company began to own and operate the Mountain Pass Rare Earth Mine and Processing Facility ("Mountain Pass") in California.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) FVAC had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the Business Combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-Business Combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China ("China") to artificially inflate the Company's profits; (v) MP Materials' ore at Mountain Pass was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
On February 3, 2022, Bonitas Research published a report (the "Bonitas Report") accusing MP Materials of executing an "abusive transfer price manipulation scheme" with a related party in China, Shenghe Resources Holding Co., Ltd. ("Shenghe"), which owned 7.7% of the Company as of March 22, 2021. Specifically, the Bonitas Report alleged that, since the second quarter of 2021, MP Materials and Shenghe "executed an abusive transfer price manipulation scheme whereby Shenghe overpaid for MP [Materials] concentrates to artificially inflate MP [Materials'] profits, [which] conveniently coincided with the SPAC insider lock-up expiration so that MP [Materials] insiders could sell MP [Materials] stock at artificially inflated prices." In addition, the Bonitas Report cited a September 2019 German academic study that concluded MP [Materials'] ore at Mountain Pass is "not economically viable to harvest for rare earth metals while 12 of the other 13 well known rare earth mines outside of China are economically feasible" at current market prices.
On this news, MP Materials' stock price fell $5.61 per share, or 14.25%, to close at $33.75 per share on February 3, 2022, on unusually heavy trading volume of 12,371,789 shares.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-mp-materials-corp-fka-fortress-value-acquisition-corp-class-action-lawsuit-upcoming-deadline-mp-fvac-fvac-ws-fvacu/
| 2022-04-04T07:28:14
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-mp-materials-corp-fka-fortress-value-acquisition-corp-class-action-lawsuit-upcoming-deadline-mp-fvac-fvac-ws-fvacu/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Telefonaktiebolaget LM Ericsson ("Ericsson" or the "Company") (NASDAQ: ERIC) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ericsson securities between April 27, 2017 and February 25, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials
If you are a shareholder who purchased or otherwise acquired Ericsson securities during the Class Period, you have until May 2, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Ericsson, together with its subsidiaries, provides communication infrastructure, services, and software solutions to the telecommunications and other sectors. The Company operates in, among other countries, the Republic of Iraq ("Iraq").
Ericsson has a well-documented history of using bribes to secure business in countries throughout the Middle East and Asia. For example, in December 2019, Ericsson was the subject of a U.S. Securities and Exchange Commission ("SEC") action alleging, among other things, that the Company used third party consultants and illicit payments from 2011 through early 2017 to access business in Djibouti, Saudi Arabia, and China. The Company also entered into a Deferred Prosecution Agreement with the U.S. Department of Justice ("DOJ") the same month for its illicit business dealings.
Following the foregoing regulatory enforcement actions—which resulted in Ericsson being fined over $520 million and nearly $540 million by the DOJ and SEC, respectively—Ericsson repeatedly assured investors that the Company had a "zero tolerance" stance for bribery and was making significant investments in related programs. For example, in a December 2019 press release, the Company asserted that it was "[e]nhancing . . . internal anti-corruption and compliance related awareness campaigns (including the Company's zero tolerance for corruption)." Likewise, in its 2019 annual report, the Company asserted that it has "zero tolerance for corruption" and "work[s] hard every day to build a culture of compliance, anchored securely within the organization, to ensure that such an event will never happen again."
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Ericsson overstated the extent to which it had reformed its business practices to eliminate the use of bribes to secure business in foreign countries; (ii) Ericsson had paid bribes to the terrorist group the Islamic State in Iraq and Syria ("ISIS" or the "Islamic State") to gain access to certain transport routes in Iraq; (iii) accordingly, the Company's revenues derived from its operations in Iraq were, in at least substantial part, derived from unlawful conduct and thus unsustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On February 15, 2022, during intraday trading hours, Ericsson issued a press release disclosing media inquiries into its business dealings in Iraq. That press release assured investors of the Company's "transparency" regarding these inquiries, while vaguely alluding to having undertaken its own investigative and compliance efforts.
Then, on February 16, 2022, Ericsson's Chief Executive Officer told a Swedish newspaper that the Company may have made payments to ISIS to gain access to certain transport routes in Iraq, noting that the Company had identified "unusual expenses dating back to 2018" but had not yet determined the final recipient of the funds for those expenses, although Defendants could "see that it disappeared[,]" and that Ericsson has spent "considerable resources trying to understand this as best we can."
Following these disclosures, Ericsson's American Depositary Share ("ADS") price fell $1.44 per ADS, or 11.57%, to close at $11.01 per ADS on February 16, 2022.
Finally, on Sunday, February 27, 2022, the International Consortium of Investigative Journalists ("ICIJ") published a report on Ericsson's alleged dealings with ISIS in Iraq, citing a leaked internal investigation that revealed that Ericsson had reportedly made "tens of millions of dollars in suspicious payments" over nearly a decade to keep its business in the country. The ICIJ report also alleged that "a spreadsheet lists company probes into possible bribery, money laundering and embezzlement by employees in Angola, Azerbaijan, Bahrain, Brazil, China, Croatia, Libya, Morocco, the United States and South Africa[,]" which "have not been previously disclosed."
On this news, Ericsson's ADS price fell $0.84 per ADS, or 8.3%, from its closing price on February 25, 2022, to close at $9.28 per ADS on February 28, 2022, the next trading day.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-telefonaktiebolaget-lm-ericsson-class-action-lawsuit-upcoming-deadline-eric/
| 2022-04-04T07:28:20
| 0
|
https://www.wflx.com/prnewswire/2022/04/03/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-telefonaktiebolaget-lm-ericsson-class-action-lawsuit-upcoming-deadline-eric/
|
Full Sail University alumni credited on projects across 10 categories
WINTER PARK, Fla., April 4, 2022 /PRNewswire/ -- Today, Full Sail University, an award-winning educational institution for those pursuing careers in entertainment media and emerging technologies, is pleased to announce that 12 alumni were credited on 10 GRAMMY®-winning projects at the 64th annual GRAMMY® Awards. This year's award ceremony was held on April 3, 2022, at the MGM Grand Garden Arena in Las Vegas, Nev., and aired on CBS.
Additionally, Full Sail University alumni have worked on projects that won across 10 different categories. Notable projects include Heaux Tales (Jazmine Sullivan), Call Me If You Get Lost (Tyler, The Creator), 662 (Christone "Kingfish" Ingram), and more.
For a look at the GRAMMY®-winning categories and projects Full Sail graduates have contributed to this year, please see below:
- Best Contemporary Blues Album, 662, Christone "Kingfish" Ingram
- Best Immersive Audio Album, Alicia, George Massenburg & Eric Schilling, immersive
- Best Latin Rock or Alternative Album, Origen, Juanes
- Best Música Urbana Album, El Último Tour Del Mundo, Bad Bunny
- Best Progressive R&B Album, Table For Two, Lucky Daye
- Best R&B Album, Heaux Tales, Jazmine Sullivan
- Best Rap Album, Call Me If You Get Lost, Tyler, The Creator
- Best Roots Gospel Album, My Savior, Carrie Underwood
- Best Traditional R&B Performance, Fight For You, H.E.R.
- Best Tropical Latin Album, Salswing!, Rubén Blades y Roberto Delgado & Orquesta
At the 64th annual GRAMMY® Awards ceremony, 46 graduates were credited on 60 GRAMMY®-nominated projects across 44 categories. To learn more about Full Sail's alumni successes and the university's Music & Recording centric degree programs, click here.
About Full Sail University
Full Sail University is an award-winning educational leader for those pursuing careers in entertainment media and emerging technologies. Founded in 1979, Full Sail has received accolades throughout its over 40-year history, including most recently being featured on the 2021 "Top 50 Film Schools and Instructors From Around the World" list by Variety Magazine and previously recognized as the "School/College of the Year" by the Florida Association of Postsecondary Schools and Colleges. Full Sail University is a graduate and undergraduate degree-granting institution offering on-campus and online degree programs in areas related to Art & Design, Business, Film & Television, Games, Media & Communications, Music & Recording, Sports, and Technology. With over 83,565+ graduates worldwide, Full Sail alumni have worked on countless award-winning projects with individual recognition including OSCAR®, Emmy®, GRAMMY®, ADDY®, MTV Video Music Award, and Video Game Award honors.
https://www.fullsail.edu/
https://twitter.com/fullsail
https://www.facebook.com/FullSailUniversity
View original content to download multimedia:
SOURCE Full Sail University
|
https://www.wflx.com/prnewswire/2022/04/04/12-full-sail-university-alumni-contribute-10-winning-projects-64th-annual-grammy-awards/
| 2022-04-04T07:28:31
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/12-full-sail-university-alumni-contribute-10-winning-projects-64th-annual-grammy-awards/
|
NEW YORK, April 4, 2022 /PRNewswire/ -- Shincheonji, Church of Jesus, the Temple of the Tabernacle of the Testimony hosted a press conference April 2nd via Zoom. In total, 1,500 pastors from various countries participated. Reporters from different media outlets also attended.
Shincheonji Church hosted the event to present results from its recent online seminars. Pastors who signed MOUs with Shincheonji shared testimonials.
"In the past, all I preached was that everyone must believe in Jesus and by sharing grace in this way would lead to salvation," said Dongsu Kim, pastor of Peace Church. "Without fulfillment, I thought heaven was somewhere one went to after death. I thought there was resurrection after death."
Pastor Kim is currently teaching Shincheonji Church's revealed word to his congregation. "The time has come for all the pastors to come and learn so that they may live a life of faith in the correct truth," he said.
To date, 2,155 pastors, 22 seminary schools and 958 churches in 67 countries have signed MOUs with Shincheonji Church. In exchange for their cooperation, Shincheonji is providing churches and seminary schools with theology materials and access to Bible instructors. In the United States, a Shincheonji instructor was invited to teach 100 members from The Early Church of the New Era. A seminary school in Pakistan is offering Shincheonji course curriculum after its dean signed an MOU with the church.
Shincheonji Church Chairman Lee Man-hee also spoke during the press conference, explaining how he has come to share the word and the role of pastors today.
"Let's fight and overcome the devil with the blood of Jesus and the word of testimony and create the people of God's kingdom so that God may finally come and reign over the world after 6000 years," Chairman Lee said. "This is what [God] has made known to us through the Bible. I hope that everyone engraves the words of all the chapters of Revelation—which is the law of heaven—in their hearts."
Shincheonji Church has taught Revelation and the secrets of the kingdom of heaven through online seminars since October 2021. The lectures have millions of YouTube views and are available in 24 different languages. The church is also broadcasting content from its intermediate-level course through June 27th. The lessons and the April 2nd press conference are available on Shincheonji Church's official YouTube channel.
Media Contact: Revelation@SCJAmericas.org
View original content to download multimedia:
SOURCE Shincheonji Church of Jesus
|
https://www.wflx.com/prnewswire/2022/04/04/1500-pastors-gather-shincheonji-church-press-conference/
| 2022-04-04T07:28:39
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/1500-pastors-gather-shincheonji-church-press-conference/
|
TIANJIN, April 3, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China ("NMPA") granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China.
Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 variants of concern ("VOC") identified by the World Health Organization ("WHO"), including the Omicron variant, a highly transmissible and the most dominant strain circulating in China and globally. Additionally, results showed that CanSinoBIO's mRNA vaccine can induce neutralizing antibodies with greater cross-reactivity against global VOCs and provide stronger protection against infections caused by the circulating variants, compared to the original strain-based COVID-19 vaccines.
The clinical trial application of CanSinoBIO's COVID-19 mRNA vaccine was filed by the Company and its subsidiary CanSino (Shanghai) Biotechnology Co., Ltd ("CanSino Shanghai"). Established in July 2021, CanSino Shanghai is focused on developing an mRNA technology platform and further strengthening the Company's research and development ("R&D") capabilities.
Compared with traditional vaccine technology platforms, the mRNA technology platform has significant advantages in the R&D process and production cycles, including fast, scalable and uniform production. CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia™. In December 2021, the NMPA granted approval for CanSinoBIO's MCV4 vaccine, Menhycia™, making it the first of its kind to be authorized in China.
About CanSinoBIO
Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses five integrated platform technologies including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology, as well as formulation and delivery technology. As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) approved in the same year. Additional information can be found online at www.cansinotech.com
View original content:
SOURCE CanSino Biologics Inc.
|
https://www.wflx.com/prnewswire/2022/04/04/cansinobios-covid-19-mrna-vaccine-receives-approval-clinical-trial-application-china/
| 2022-04-04T07:28:45
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/cansinobios-covid-19-mrna-vaccine-receives-approval-clinical-trial-application-china/
|
LONDON, April 4, 2022 /PRNewswire/ -- CentralNic Group PLC (AIM: CNIC), the online marketplace for domain names and online presence and customer acquisition tools, is pleased to announce that the Audited Annual Report for the financial year 2021 is now available on the Company's website at the following link: https://investor.centralnicgroup.com/wp-content/uploads/2022/04/Annual-Report-2021.pdf.
The Annual Report contains the company's confirmed financial results, demonstrating record revenue growth and profitability in 2021, including:
- Revenue increased by 71% to USD 410.5m (FY2020: USD 240.0m)
- Organic revenue increased by 39% (FY2020: 9%)
- Net revenue (gross profit) increased by 58% to USD 118.5m (FY2020: USD 75.1m)
As a result of CentralNic Group's outstanding financial performance, in March 2022 the company was listed among the top-250 fastest-growing companies and among the top-50 fastest-growing Technology companies in Europe in the Financial Times' sixth annual FT 1000 report.
CentralNic Group's Annual Report 2021 also includes a more comprehensive presentation of CentralNic Group's strategy on ESG and how its initiatives feed into that strategy. The company expanded the number and scope of its environmental, social and governance initiatives and practices in 2021, while maintaining its carbon neutral status since 2020.
Ben Crawford, CEO of CentralNic, said:
"We are delighted to report that CentralNic demonstrated a very strong performance in 2021, achieving record organic growth of 39%. Our significant and consistent investment in world-class talent and industry-leading products has greatly contributed to the Group's continued success.
CentralNic's results for 2021 demonstrate the potential of its strong marketplace model for Online Presence and Online Marketing services. With the completion of the acquisition of VGL in March 2022, we have recently enriched our Online Marketing marketplace with a perfectly complementary asset. Strong earnings, excellent cash conversion and a sound balance sheet will allow us to add more curated acquisitions to our two marketplaces, further supplementing our strong organic growth. Whilst it remains early into the new financial year, we remain confident in our outlook for this year and beyond."
About CentralNic Group plc
CentralNic (AIM: CNIC) is a global tech company listed on the London Stock Exchange, which drives the growth of the global digital economy by providing businesses around the world with tools to build their online presence and to win customers and earn revenues online. The Company complements its organic growth with target acquisitions of cash-generative businesses in its industry with annuity revenue streams and exposure to growth markets and migrating them onto the CentralNic software and operating platforms. CentralNic operates globally with customers in almost every country in the world. It earns recurring revenues from the worldwide sales of online presence and online marketing services on a subscription or pay per use basis. For more information please visit: www.centralnicgroup.com
For further information contact CentralNic Group media@centralnic.com
View original content to download multimedia:
SOURCE CentralNic Group
|
https://www.wflx.com/prnewswire/2022/04/04/centralnic-group-publishes-audited-annual-report-2021-reports-record-growth-expands-esg-initiatives/
| 2022-04-04T07:28:52
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/centralnic-group-publishes-audited-annual-report-2021-reports-record-growth-expands-esg-initiatives/
|
Gemini's 2022 Global State of Crypto report uncovers trends in adoption, barriers to entry, and attitudes toward crypto among nearly 30,000 respondents in 20 countries
NEW YORK, April 4, 2022 /PRNewswire/ -- Today, crypto platform Gemini released its 2022 Global State of Crypto report, finding that 2021 was a transformative year for crypto, with nearly half of all current crypto owners in the United States (44%), Latin America (46%), and Asia Pacific (45%) first buying crypto in 2021. The report also surfaced that concerns around inflation were a primary driver of adoption, the crypto gender gap may be narrowing in the coming year, and that globally education remains the greatest barrier to investing in crypto.
Additionally, developing countries Brazil and Indonesia led the way in crypto adoption with more than two in five (41%) respondents in each country reporting owning crypto, compared to just 17% across developed countries and regions including the U.S. (20%), Europe (17%), and Australia (18%). Venture capital (VC) investment also appeared to drive adoption, with high rates of adoption in Singapore (30%) and Israel (28%), which also saw the highest per capita venture capital funding globally in 2021.
Other key findings include:
- 2021 Was Crypto's Breakout Year: Forty-one percent of crypto owners surveyed globally purchased crypto for the first time in 2021. More than half of crypto owners in Brazil (51%), Hong Kong (51%), and India (54%) got started in 2021. Globally, 41% of respondents said they are crypto-curious. The crypto-curious are defined as consumers who do not currently own crypto, but are either interested in learning more or say they are likely to acquire cryptocurrency in the next year.
- The Crypto Gender Gap May Be Narrowing: Among the crypto curious who plan to purchase crypto for the first time in the next year, 47% were women globally. Among crypto owners, women in developing nations led the way with women representing at least half of crypto owners in Israel (51%), Indonesia (51%), and Nigeria (50%). Conversely, in developed countries and regions only a third (33%) of current crypto owners are women, including in the United States (32%), Europe (33%), and Australia (27%).
- Inflation a Primary Driver for Crypto Adoption: Respondents in countries that have experienced 50% or more devaluation of their currency against the USD over the last 10 years were more than 5 times as likely to say they plan to purchase crypto in the coming year**, including South Africa (32%), Mexico (32%), India (40%), and Brazil (45%). In Brazil, where the local currency has been devalued by more than 200% against the USD, 41% of respondents own crypto. In the U.S., two in five (40%) crypto owners see crypto as a hedge against inflation.
- Crypto Regulation A Top Concern Globally: Regulation is a concern globally. Among non-owners, 39% in Asia Pacific, 37% in Latin America, and 36% in Europe say there is legal uncertainty around cryptocurrency. In addition, for 30% of respondents in the Middle East, 24% in Asia Pacific, and 23% in Latin America, the tax complexities of owning cryptocurrency have kept them from investing in crypto.
- Education is the Greatest Barrier to Ownership: Globally, respondents were nearly twice as likely to say that more educational resources on cryptocurrency would help them get started with crypto (40%), compared to recommendations from friends (22%). More than half of respondents in Latin America (51%) and Africa (56%) said that educational resources would make them more comfortable purchasing cryptocurrency. Forty-four percent in Asia Pacific and 42% of those in the United States said the same.
"Crypto adoption reached a true tipping point last year, becoming an established economic driver and a valued investment across the globe," said Noah Perlman, Chief Operating Officer at Gemini. "We expect to see the influx of crypto investors continue into this year with concerns about inflation in the U.S. and globally driving interest. Education also remains a global barrier to adoption, and providing investors additional resources is key to bringing new users into the crypto ecosystem, especially women who make up a majority of the crypto-curious audience."
Methodology
The survey was conducted online between November 23, 2021 and February 4, 2022 on behalf of Gemini by Data Driven Consulting Group. The total sample has been balanced and is generally representative of the adult population in each country ages 18 to 75 with household incomes of $14,000 USD or more.
About Gemini
Gemini is a platform that allows customers to buy, sell, store, and earn cryptocurrencies like bitcoin, ether, and DeFi tokens. Gemini's simple, reliable, and secure products are built to unlock the next era of financial, creative, and personal freedom. Gemini was founded in 2014 by twin brothers Cameron and Tyler Winklevoss.
*Definitions of developed and developing nations reference United Nations data.
**Currency devaluation is defined as the percent change between the average exchange rate for a local currency to USD in 2011 and 2021 using historical exchange rate data available from the Federal Reserve.
Contact
Natalie Rix
Principal, Institutional Communications
press@gemini.com
View original content to download multimedia:
SOURCE Gemini
|
https://www.wflx.com/prnewswire/2022/04/04/crypto-ownership-nearly-doubled-united-states-latin-america-asia-pacific-2021-gemini-report-finds/
| 2022-04-04T07:28:58
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/crypto-ownership-nearly-doubled-united-states-latin-america-asia-pacific-2021-gemini-report-finds/
|
AMSTERDAM, April 4, 2022 /PRNewswire/ -- Crystal Blockchain analytics, today announced that John van Tessel has been appointed as Chief Revenue Officer (CRO). In this role, Mr. van Tessel will lead Crystal's global commercial functions and strategy as Crystal Blockchain moves into a significant period of accelerated growth. In this role, he will report to Chief Executive Officer Marina Khaustova.
John brings more than 20 years of solution-based sales skills and senior leadership to Crystal. His business intelligence and analytics experience include lead management, pipeline management, marketing, high-performance team development, sales, and executive leadership. Before joining Crystal, John was responsible for Accruent's European business, acting as Vice President, Europe. He also held senior sales management positions at Business Objects, Hewlett Packard, SAP, and SAS Institute.
"We are delighted to welcome John Van Tessel to the team as Chief Revenue Officer. At Crystal, we are committed to providing security and transparency in the cryptocurrency markets through top-class blockchain transaction analytics for AML and CFT. Considering that cryptocurrency markets and the blockchain are still emerging technologies, accountability for driving better integration and alignment between all revenue-related functions, including marketing, sales, customer support, pricing, and revenue management, is crucial for us.
We look forward to working with John in our shared mission, to parallel a strategy for profitable revenue generation alongside the organization's long-term mission to make the global financial markets safer and trusted for banks and FIs." Marina Khaustova, CEO of Crystal Blockchain.
"I am thrilled to join Crystal Blockchain Analytics which is operating in one of the most exciting tech trends at the moment with its goal to make the cryptocurrency industry safer for everyone. I look forward to joining Crystal's world-class leadership and sales team at this important moment continuing and accelerating exponential growth." - John Van Tessel, CRO.
About Crystal Blockchain (https://crystalblockchain.com/)
Crystal is the all-in-one blockchain analytics platform, providing a comprehensive view of the public blockchain ecosystem. Crystal is available as a SaaS, API, or as an on-premise installation. Crystal is engineered by the Bitfury Group, the world's leading full-service blockchain technology company.
View original content:
SOURCE Crystal Blockchain
|
https://www.wflx.com/prnewswire/2022/04/04/crystal-appoints-john-van-tessel-chief-revenue-officer/
| 2022-04-04T07:29:05
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/crystal-appoints-john-van-tessel-chief-revenue-officer/
|
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments
TARRYTOWN, N.Y. and PARIS, April 4, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow. The target action date for the FDA decision on this investigational use is August 3, 2022.
The sBLA is supported by data from two Phase 3 trials evaluating the efficacy and safety of Dupixent 300 mg weekly in patients aged 12 years and older with EoE (Part A and Part B), and data from an active long-term extension trial. Dupixent 300 mg weekly significantly improved the signs and symptoms of EoE at 24 weeks compared to placebo, including the ability to swallow and reduction in eosinophil count in the esophagus. The safety results of these trials were generally consistent with the known safety profile of Dupixent in its approved indications. The most common adverse event observed with Dupixent, in Part A and Part B, was injection site reactions.
In September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent for the treatment of patients aged 12 years and older with EoE. Dupixent was also granted Orphan Drug designation for the potential treatment of EoE in 2017. Priority review is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. Regulatory filings around the world are also planned in 2022. The potential use of Dupixent in EoE is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.
About Eosinophilic Esophagitis (EoE)
EoE is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly. For people with EoE, swallowing the smallest amount of food can be a painful and worrisome choking experience. Those with EoE live with anxiety and frustration from having a constantly evolving list of foods to avoid. This disease can also cause narrowing of the esophagus and dilation (physical expansion) of the esophagus may be needed, which is often painful. In severe cases, a feeding tube is the only option to ensure proper caloric intake and adequate nutrition. People with EoE may have poor quality of life and are more likely to experience depression than people without EoE. There are approximately 160,000 patients in the U.S. living with EoE who are currently treated, of whom approximately 48,000 have failed multiple treatments.
About Dupixent
Dupixent, which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. By demonstrating significant clinical benefit together with a decrease in type 2 inflammation following IL-4 and IL-13 blockade with Dupixent, the Dupixent Phase 3 clinical program has established that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases for which Dupixent is approved including atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), as well as investigational diseases such as EoE and prurigo nodularis, which have been studied in Phase 3 trials.
In the U.S., Dupixent is approved in patients aged 6 years and older with uncontrolled moderate-to-severe atopic dermatitis; as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Dupixent is also approved in Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma or CRSwNP in different age populations. Dupixent is approved in one or more of these indications in more than 60 countries around the world, and more than 400,000 patients have been treated globally.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create approximately a quarter of all original, FDA-approved or authorized fully human monoclonal antibodies currently available. This includes Dupixent, REGEN-COV® (casirivimab and imdevimab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn).
Dupilumab Development Program
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including eosinophilic esophagitis (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), bullous pemphigoid (Phase 3), chronic inducible urticaria-cold (Phase 3), allergic fungal rhinosinusitis (Phase 3), allergic bronchopulmonary aspergillosis (Phase 3) and peanut allergy (Phase 2). These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
U.S. Indications
DUPIXENT is a prescription medicine used:
- to treat adults and children 6 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 years of age.
- with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.
- with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyposis under 18 years of age.
IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.
Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:
- have eye problems
- have a parasitic (helminth) infection
- are scheduled to receive any vaccinations. You should not receive a "live vaccine" right before and during treatment with DUPIXENT.
- are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis or CRSwNP, and also have asthma. Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.
DUPIXENT can cause serious side effects, including:
- Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
- Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.
- Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by DUPIXENT. Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, a feeling of pins and needles or numbness of your arms or legs, or persistent fever.
- Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.
The most common side effects include:
- Atopic dermatitis: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, and cold sores in your mouth or on your lips.
- Asthma: injection site reactions, pain in the throat (oropharyngeal pain), high count of a certain white blood cell (eosinophilia), and parasitic (helminth) infections.
- Chronic rhinosinusitis with nasal polyposis: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, high count of a certain white blood cell (eosinophilia), trouble sleeping (insomnia), toothache, gastritis, and joint pain (arthralgia).
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children under 12 years of age, DUPIXENT should be given by a caregiver.
Please see accompanying full Prescribing Information including Patient Information.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of eosinophilic esophagitis; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of eosinophilic esophagitis (including potential approval by the U.S. Food and Drug Administration based on the supplemental Biologics License Application discussed in this press release), chronic obstructive pulmonary disease with evidence of type 2 inflammation, pediatric atopic dermatitis, bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, chronic inducible urticaria-cold, chronic rhinosinusitis without nasal polyposis, allergic fungal rhinosinusitis, allergic bronchopulmonary aspergillosis, peanut allergy, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates, including without limitation Dupixent; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable) to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent, Praluent® (alirocumab), and REGEN-COV® (casirivimab and imdevimab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
View original content:
SOURCE Regeneron Pharmaceuticals, Inc.
|
https://www.wflx.com/prnewswire/2022/04/04/fda-accepts-dupixent-dupilumab-priority-review-patients-aged-12-years-older-with-eosinophilic-esophagitis/
| 2022-04-04T07:29:12
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/fda-accepts-dupixent-dupilumab-priority-review-patients-aged-12-years-older-with-eosinophilic-esophagitis/
|
NACKA STRAND, Sweden, April 4, 2022 /PRNewswire/ -- Hexagon AB, a global leader in digital reality solutions combining sensor, software and autonomous technologies, today announced the acquisition of Innovatia Accelerator Inc., a developer of SaaS-based digitalisation solutions that transform operations and modernise fieldwork in the manufacturing and process industries.
For an industrial organisation to truly automate the full scope of its operations – from processes and equipment to worker performance – the operational content and procedures of its assets must be digital and connected. Innovatia Accelerator's flagship solution, AcceleratorKMS, is an AI-based infield knowledge management platform that expedites the digital transformation of paper-based, high-risk operational procedures and work processes. It enables organisations to easily manage, govern and distribute the up-to-date critical operational content field workers require to keep operations running optimally and smoothly.
"We are very excited to bring another innovative solution into our operations and maintenance portfolio and accelerate our vision of facilitating autonomy in industrial plant operation," says Hexagon President and CEO Ola Rollén. "AcceleratorKMS has a proven track record with many Fortune 500 companies to address a real business need in digitalising the paper-based ecosystem of operations and maintenance, turnaround/shutdown, and emergency procedures."
The AcceleratorKMS solution includes Procedure Lifecycle Management (PLCM), a Connected Worker Platform (CWP), a Learner Experience Platform (LXP) and a Component Content Management System (CCMS). The combined capabilities create an integrated digital content ecosystem to enhance the execution of procedures requiring collaboration and inputs from multiple users and data sources to reduce risk and increase overall worker productivity.
"Hexagon has long been a leader in delivering smart digital realities that go beyond the digital twin, offering a visual, single source of truth of location-based asset intelligence – available anywhere, anytime, on any device," continued Rollén. "This acquisition adds operational insights to support the connected worker in eliminating operational incidents caused by missing, out-of-date, or inaccessible information. The combination of AcceleratorKMS with our asset information solutions and Smart Digital Reality™ backbone will help more customers achieve efficiencies faster, improve operations and increase ROI."
Headquartered in Saint John, New Brunswick, Canada, with offices in India and the United States, Innovatia Accelerator will operate within Hexagon's PPM division. The acquisition has no significant impact on Hexagon's earnings and is expected to be completed over the coming weeks.
For further information, please contact:
Maria Luthström, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.com
Kristin Christensen, Chief Marketing Officer, Hexagon AB, +1 404 554 0972, media@hexagon.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Hexagon
|
https://www.wflx.com/prnewswire/2022/04/04/hexagon-furthers-its-commitment-innovation-operations-amp-maintenance-oampm-segment-with-acquisition-innovatia-accelerator/
| 2022-04-04T07:29:19
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/hexagon-furthers-its-commitment-innovation-operations-amp-maintenance-oampm-segment-with-acquisition-innovatia-accelerator/
|
GURUGRAM, India, April 3, 2022 /PRNewswire/ -- In a bid to enable India's decarbonization push, Indian Oil Corporation Ltd., (IndianOil), the country's top refiner and fuel retailer, Larsen & Toubro (L&T), India's premier engineering & construction conglomerate, and ReNew Power ("ReNew") (NASDAQ: RNW) (NASDAQ: RNWWW), India's leading renewable energy company, announced signing of binding term sheet for the formation of a Joint Venture (JV) company to develop the nascent green hydrogen sector in India.
The tripartite venture is a synergistic alliance that brings together the strong credentials of L&T in designing, executing, and delivering EPC projects, IndianOil's established expertise in petroleum refining along with its presence across the energy spectrum, and the expertise of ReNew in offering and developing utility-scale renewable energy solutions.
Additionally, IndianOil and L&T have signed a binding term sheet to form a JV with equity participation to manufacture and sell Electrolyzers used in the production of Green Hydrogen.
Speaking about the joint venture, Mr. SN Subrahmanyan, CEO & MD, L&T, said, "India plans to rapidly march ahead in its decarbonization efforts and production of Green Hydrogen is key in this endeavour. The IndianOil-L&T-ReNew JV will focus on developing Green Hydrogen projects in a time-bound manner to supply Green Hydrogen at an industrial scale. While L&T will bring its strong EPC credentials to the table, IOC being India's premier oil refiner with extensive capabilities in chemical processes and refining has established deep R&D capabilities in many aspects of green hydrogen value chain, and ReNew Power has in a short time established itself as a leading renewable energy supplier and has built itself a very strong reputation. We consider this partnership as a significant step in India's quest for alternative energy.
Addressing another gap in the Green Hydrogen manufacturing chain, IndianOil-L&T JV will focus on production and sale of Electrolyzer."
"Both these JVs aim to enable the nation's 'Aatmanirbhar Bharat' mission to rapidly build, expand and bring in economies of scale to make green hydrogen a cost-effective energy carrier and a chemical feedstock for many sectors."
Commenting on the occasion, Mr. Shrikant Madhav Vaidya, Chairman, IndianOil, said, "Being the Energy of India, we are committed to powering India's drive towards carbon neutrality by leveraging the power of green hydrogen. IndianOil is forging this alliance to realise India's green hydrogen aspirations, which is in sync with the Hon'ble Prime Minister's vision of making India a Green Hydrogen generation and export hub. To start with, this partnership will focus on green hydrogen projects at our Mathura and Panipat refineries. Alongside, other green hydrogen projects in India will also be evaluated. While the usage of hydrogen in the mobility sector will take its due time, however the refineries will be the pivot around which India's green hydrogen revolution will materialize in a substantial way."
"The partnership forged today will thus catalyse the greening of India's energy basket."
Mr. Sumant Sinha, Chairman and CEO of ReNew Power said, "In alignment with the government's broader strategic climate goals for 2030 and 2070 set by honourable Prime Minister Narendra Modi, ReNew looks forward to working with L&T and IndianOil to build the green hydrogen business in India. ReNew, as a leader in intelligent energy solutions and with advanced capability across renewable energy technologies, is well poised to complement the capabilities of our partners."
"The timing for these proposed JVs is excellent as they will help support Government of India's recently announced green hydrogen policy to boost India Inc.'s decarbonization journey."
The planned JVs aim to enable India's transition from a grey hydrogen economy to a greener economy that increasingly manufactures hydrogen via electrolysis powered by renewable energy.
The central government in February notified the Green Hydrogen policy aimed at boosting production of green hydrogen and green ammonia to help the nation become a global hub for the environmentally friendly version of the element.
For countries like India, with its ever-increasing oil and gas import bill, green hydrogen can also help provide crucial energy security by reducing the overall dependence on imported fossil fuels.
While nearly all hydrogen produced in India today is grey, it is estimated that demand for Hydrogen will be 12 MMT by 2030 and around 40% of the element produced in the country (around 5 MMT) will be green, as per the draft National Hydrogen Mission guidelines.
By 2050, nearly 80% of India's hydrogen is projected to be 'green' – produced by renewable electricity and electrolysis. Green hydrogen may become the most competitive route for hydrogen production by around 2030. This may be driven by potential cost declines in key production technologies and in clean energy technologies such as solar PV and wind turbines.
Today, hydrogen is mainly used in the refining, steel and fertilizer sectors, which will be the focus of the JVs' initial efforts. The country's refining sector consumes approx. 2 MMT of grey hydrogen every year, with IndianOil owning one of the largest shares of its refining output.
To help decarbonize Indian industry, the new green hydrogen policy provides for the waiver of Inter-State transmission charges for a period of 25 years and a banking provision of up to 30 days, which will help reduce the cost of green hydrogen significantly. This will, therefore, push the replacement of grey hydrogen with green. The Ministry of Power has also provided a single -window-clearance portal for all clearances and open access on priority to green hydrogen projects.
About ReNew Power
ReNew is one of the largest renewable energy Independent Power Producers (IPPs) in India and globally. ReNew develops, builds, owns, and operates utility-scale wind and solar energy projects, and hydro projects. As of February 1, 2022, ReNew had a total portfolio of 10.2 GW of renewable energy projects across India, including commissioned and committed projects. For more information, please visit: www.renewpower.in.; Follow ReNew Power on Twitter @ReNew_Power
Media Contacts:
View original content:
SOURCE ReNew Energy Global PLC
|
https://www.wflx.com/prnewswire/2022/04/04/indianoil-lampt-renew-form-jv-development-green-hydrogen-business/
| 2022-04-04T07:29:28
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/indianoil-lampt-renew-form-jv-development-green-hydrogen-business/
|
SAN FRANCISCO and SUZHOU, China, April 3, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of a phase 3 clinical trial (Study code: CREDIT-2) of recombinant full-human anti-PCSK-9 monoclonal antibody (R&D code: IBI306, independently developed by Innovent) in Chinese patients with heterozygous familial hypercholesterolemia (HeFH) have been accepted as an abstract presented (E-poster #: 1188-005) at the American College of Cardiology Annual Congress 2022 (ACC 2022).
PCSK-9 inhibitors, which can potently reduce LDL-C levels with a good safety profile, have been gradually recognized by clinicians as novel therapeutic regimens in recent years. Although there are various imported PCSK-9 inhibitors marketed in the Chinese market, there are some limitations in terms of economy and convenience. IBI306 is an innovative drug independently developed by Innovent. It is the PCSK-9 inhibitor that take the lead in carrying out long-term, large-scale, randomized and double-blind phase III clinical studies in China (CREDIT-1, CREDIT-2 and CREDIT-4), and explored and optimized the treatment regimen with long-interval dosing.
The AAC 2022 presentation is based on CREDIT-2, a randomized, double-blind, placebo-controlled phase 3 study, evaluating the efficacy and safety of IBI306 in Chinese patients with heterozygous familial hypercholesterolemia (ClinicalTrials.gov, NCT04179669). During the 12-week double-blind treatment period, patients previously received a stable lipid-lowering therapy for at least 4 weeks were randomized 2:1:2:1 to receive subcutaneous injection of IBI306 or placebo 150 mg Q2W, or IBI306 or placebo 450 mg Q4W respectively. In week 12-24, patients in control groups continued to receive IBI306 with the previous regimens; while patients in placebo groups were crossed over to receive open-label IBI306 150 mg Q2W or 450 mg Q4W, respectively. The primary endpoint was the percent change in LDL-C levels from baseline to week 12.
The results of study showed that both IBI306 150 mg Q2W or 450 mg Q4W yielded significant reduction in LDL-C levels in Chinese patients with HeFH. As for the Primary endpoint: IBI306 significantly reduced LDL-C levels (treatment difference versus placebo: −57.4% [97.5% CI, −69.2% to −45.5%] for 150 mg Q2W; −61.9% [−73.4% to −50.4%] for 450 mg Q4W; P<0·0001 for both comparisons). And for the key secondary endpoint: significantly more patients treated with IBI306 achieved ≥50% LDL-C reductions at week 12 as compared with corresponding placebo groups (58.5% [97.5% CI, 42.2% to 74.8%] for 150 mg Q2W; 73.4% [58.5% to 88.4%] for 450 mg Q4W; P<0·0001 for both comparisons). IBI306 significantly reduced Lp(a) levels (treatment difference versus placebo: -43.3% [95% CI, −58.9% to -27.6%] for 150 mg Q2W; −34.1% [−47.1% to −21.1%] for 450 mg Q4W; P<0·0001 for both comparisons). In addition, IBI306 treatment induced various improvements including LDL-C < 1.8 mmol/L response rate, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB) and other Lipid parameters after 12 weeks of treatment. At the same time, the LDL-C reduction in the IBI306 groups was well maintained at 50% and above throughout 24 weeks. The overall safety profile of IBI306 in the study was favorable and similar to the safety profile of other marketed PCSK-9 inhibitors.
Prof. Yujie Zhou, principal investigator of CREDIT-2 study and Vice President of Anzhen Hospital, from the Capital Medical University, stated, "CREDIT-2 is the first large-scale phase 3 trial in China to demonstrate the efficacy and safety of PCSK-9 inhibitors in Chinese patients with HeFH. As a domestic innovative PCSK-9 inhibitor, IBI306 can significantly reduce LDL-C levels and improve other lipid parameters to certain extent. The overall data showed that IBI306 had significant therapeutic benefits and favorable safety in Chinese patients with HeFH. I am confident that it will be an alternative and accessible treatment option for Chinese patients with HeFH."
Dr. Lei Qian, Vice President of Innovent, stated: " In CREDIT-2, IBI306 showed significant efficacy and good safety in Chinese patients with HeFH. As pioneering the development progress of PCSK-9 inhibitors in China, CREDIT-2 showed the excellent scientific research capabilities of Chinese researchers, as well as the solid and strong execution in R&D of Innovent Biologics. At the same time, the results of other registrational studies of IBI306 will also be disclosed in this year and next year, bringing more high-quality evidence-based clinical study result based in China to the global medical research community. We plan to submit a new drug application for IBI306 this year and actively communicate with regulatory authorities, hoping to benefit the majority of patients in China with more high-quality biological drugs as soon as possible."
About Hypercholesterolemia
In recent years, the blood lipid level of the Chinese population has gradually increased, and the prevalence of dyslipidemia has increased significantly with an overall prevalence of 40.4% in Chinese adults. The increase of serum cholesterol level in the population will lead to an increase of about 9.2 million cardiovascular disease events in China during 2010 ~ 2030. Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by markedly elevated serum LDL-C levels. The vast majority of FH patients are due to single allele mutations and are classified as HeFH. The incidence of HeFH is about 1 / 500 to 1 / 200.
At present, the management of hyperlipidemia in China is not optimistic. According to the 2020 China Cardiovascular Health and Disease Report, the diagnostic, treatment and control rate of dyslipidemia in Chinese adults remain low. The percentage of patients with dyslipidemia who met the LDL-C reduction goal is even more alarming. Current lipid-lowering therapies do not meet the clinical needs in patients with hyperlipidemia. Anti-PCSK-9 monoclonal antibody has a mechanism of action different from existing lipid-lowering drugs and can effectively reduce LDL-C levels, which is expected to provide a better treatment option for Chinese patients with hypercholesterolemia.
About IBI306 (PCSK-9 inhibitor)
IBI306, developed by Innovent, is an lgG2 fully human monoclonal antibody that can specifically bind to PCSK-9 and reduce LDL-C level by inhibiting PCSK-9-mediated low-density lipoprotein receptor (LDLR) endocytosis, subsequently enhancing the clearance of LDL-C, resulting in a reduction in LDL-C level.
As of now, three IBI306 registration trials have met the primary endpoint. The results from phase 1 and 2 clinical studies have been published in JACC Asia, an internationally renowned journal of cardiology. Results from the first completed CREDIT-2 phase 3 study have also been accepted and presented as a poster at the American Cardiology Association Annual Congress 2022 (ACC 2022).
About Three Registration Clinical Studies of IBI306
The CREDIT-1 study is a randomized, double-blind, placebo-controlled phase 3 clinical study to assess the efficacy and safety of IBI306 in Chinese patients with non-familial hypercholesterolemia (hypercholesterolemia with cardiovascular risk) (ClinicalTrials.gov, NCT04289285). The primary efficacy measure was the percentage reduction from baseline in LDL-C after 48 weeks of treatment.
The CREDIT-2 study is a randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of IBI306 in Chinese subjects with heterozygous familial hypercholesterolemia (ClinicalTrials.gov, NCT04179669). The primary efficacy endpoint was the percentage reduction from baseline in LDL-C after 12-week treatment.
The CREDIT-4 study was a randomized, double-blind, placebo-controlled phase 3 clinical study to assess the efficacy and safety of IBI306 in Chinese patients with hypercholesterolemia (including non-familial hypercholesterolemia and heterozygous familial hypercholesterolemia) (ClinicalTrials.gov, NCT04709536). The primary efficacy measure was the percentage reduction from baseline in LDL-C after 12 weeks of treatment.
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 29 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 7 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection), Pemazyre® (pemigatinib oral inhibitor) , NAILIKE(olverembatinib) and Cyramza® (ramucirumab), 1 asset under NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials, and an additional 19 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
Disclaimer:
- This indication is still under clinical study, which hasn't been approved in China or the U.S.
- Innovent does not recommend any off-label usage.
- For medical and healthcare professionals only.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
View original content:
SOURCE Innovent Biologics
|
https://www.wflx.com/prnewswire/2022/04/04/innovent-releases-results-phase-3-clinical-study-ibi306-pcsk-9-inhibitor-chinese-patients-with-heterozygous-familial-hypercholesterolemia-american-college-cardiology-annual-congress-2022/
| 2022-04-04T07:29:35
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/innovent-releases-results-phase-3-clinical-study-ibi306-pcsk-9-inhibitor-chinese-patients-with-heterozygous-familial-hypercholesterolemia-american-college-cardiology-annual-congress-2022/
|
TEL AVIV, Israel, April 4, 2022 /PRNewswire/ -- On April 3, 108 countries across the globe participated in International Good Deeds Day 2022, including U.S.A., Zambia, India, Portugal, Mexico, Congo, Armenia, Poland, Italy, UK, Venezuela, Haiti, Argentina, Cambodia, and more. Enthusiasm around this international event of good increases every year, with millions of people joining in to volunteer and do something positive for others on Good Deeds Day, which was launched 16 years ago in Israel and has since crossed borders to become an internationally unifying day of good.
Businesswoman and philanthropist Shari Arison, initiator of Good Deeds Day, said:
"This day, which I initiated 16 years ago, is a peak event of doing good activities that take place all year round, and I believe that if we think good, speak good, and do good, our world will look different, every day. All of us together have the power to lead the world to a better place, each in their own way and according to their heart's desire. It is heartwarming to see the outpour of responses from people across the globe who extend a helping hand at this time, in any way possible, either face-to-face or by faming on social media, and in numerous other ways that do good for the benefit of others."
Here are some of the events that took place on Good Deeds Day 2002 across the globe:
USA: Almost all 50 states participated, led by Points of Light, IAVE, Hillel, and other organizations.
Uganda: 5,000 people nationwide, in diverse projects from care for the elderly to a marching brass band.
India: Six cities participated in projects, including a three-day volunteers camp and school renovation project.
Greece: A massive beach cleanup, inviting people to take action and protect the oceans from single-use plastics.
Honduras: Opening festival in the capital Tegucigalpa, full of performances that raised funds for marginalized communities, and additional projects nationwide.
Mexico: Kite Festival, alongside sports activities and workshops that raised awareness about environmental issues.
Israel: In the country where Good Deeds Day first started 16 years ago, two million people took part in this annual celebration that crosses all cultures, religions, and ages.
Croatia: Unveiling of 'The School of Good Deeds project', with 500 projects made by students from 100 primary schools across the country about nature, animals, and marginalized populations.
Cambodia: More than 1000 participants in 21 cities, all united around releasing 16 million fish, one for each citizen in a country with a population of 16 million, symbolizing happiness, wealth, luck, and positive long-term impact.
Tanzania: Over 5,000 people and 80+ organizations came together in a Good Deeds Day fair involving 1,000 people sharing information and ways to get involved with nonprofits, alongside activities that raised donations to charity.
Democratic Republic of Congo: 10,000 people took part in a series of week-long projects in Kinshasa, mobilizing volunteers and organizations, including the United Nations Volunteers Program, with radio appearances, tree planting to fight against climate change, sanitation of universities, photo exhibition, and more.
Contact information:
Hannah Wojno, Director, Good Deeds Day
Good-deeds-day.org | Facebook | Twitter | Instagram | info@good-deeds-day.org
Hashtag: #GoodDeedsDay
Tag us: @GoodDeedsDay
Photo - https://mma.prnewswire.com/media/1779389/International_Good_Deeds_Day.jpg
View original content to download multimedia:
SOURCE International Good Deeds Day
|
https://www.wflx.com/prnewswire/2022/04/04/international-good-deeds-day-2022-108-countries-took-part-thousands-projects-dedicated-bettering-society/
| 2022-04-04T07:29:42
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/international-good-deeds-day-2022-108-countries-took-part-thousands-projects-dedicated-bettering-society/
|
- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated
- ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen
- Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk
CARLSBAD, Calif., April 4, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). These data were presented at the American College of Cardiology's 71st Annual Scientific Session & Expo.
The ETESIAN Phase 2b study's objective was to assess the efficacy, safety and tolerability of ION449 in patients with high-risk hypercholesterolemia. The study met its primary endpoint in reducing serum LDL-C levels by up to 79%. Both the 50mg and 90mg doses reached statistically significant and clinically meaningful reductions in LDL-C levels from baseline of 73% (95% confidence interval [CI]: 77%, 68%) and 79% (95% CI: 83%, 76%), respectively, versus 2% (95% CI: 17%, -15%) for placebo. The reductions in LDL-C were maintained until week 14 (6 weeks after the last dose).
The trial also met the secondary endpoints, including significantly reducing PCSK9 levels by up to 94%. The 50mg and 90mg doses achieved reductions in PCSK9 levels of 89% (95% CI: 91%, 86%) and 94% (95% CI: 95%, 92%), respectively, versus 5% (95% CI: 23%, -18%) for placebo. The sustained reductions in PCSK9 levels were maintained until week 14 (6 weeks after last dose). Reducing PCSK9 levels leads to lower LDL-C levels in the bloodstream, which is known to reduce the risk of developing coronary heart disease.
ION449 was generally well tolerated during the 12-week treatment period and the 12-week follow up period in the study.
"The positive results of the ETESIAN study, along with the clinical studies to date, reinforces our confidence that ION449 (AZD8233) is a potential new treatment option that may be able to change the current standard of care for patients affected by hypercholesterolemia who have cardiovascular disease," said Brett P. Monia, Ph.D., Ionis' chief executive officer.
"Today, we are pleased to announce that ETESIAN Phase 2b for ION449 (AZD8233) demonstrated a clear dose-response for both PCSK9 and LDL-C levels. The results underscore ION449's (AZD8233) potential best-in-class efficacy profile and support further development of ION449 (AZD8233) as a next-generation PCSK9 inhibitor that is self-administered monthly," said Mene Pangalos, executive vice president and president, BioPharmaceuticals R&D at AstraZeneca.
ION449 is being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.
About ION449
ION449 (AZD8233) dosed once monthly via subcutaneous administration, is an investigational medicine that uses Ionis' advanced LIgand-Conjugated Antisense (LICA) technology platform. It is designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.
Elevated levels of LDL-C are a key risk factor in the development of cardiovascular disease, including heart attack, stroke and peripheral arterial disease. Higher levels of LDL-C in the blood are directly related to greater risk of vascular disease, while reduction of LDL-C leads to a significant decrease in risk. Despite the presence of several lipid-lowering agents, many patients are unable to achieve recommended LDL-C levels and remain at increased risk for cardiovascular disease. The development of additional, highly potent LDL-C lowering drugs can address this persistent unmet need.
About ETESIAN
ETESIAN is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b study in patients with hypercholesterolemia. The primary objective was to assess the effect of different doses of ION449 (AZD8233) on LDL-C compared to placebo at Week 12 in patients on statin therapy. Secondary endpoints included change in PCSK9 levels and the assessment of safety and tolerability of ION449.
The study had 119 participants, aged 18-75, who had LDL-C levels between 70 and 190mg/dL and were receiving moderate or high-intensity statin therapy.
Three dose levels of ION449 were evaluated (15mg, 50mg, 90mg), given monthly by sub-cutaneous injection over the 12-week dosing period. All active arms demonstrated reductions in LDL-C and PCSK9 levels at week 12 compared to placebo.
The percent changes from baseline to week 12 in LDL-C at the 15mg, 50mg and 90mg monthly dose were –39% (95% confidence interval [CI] –48%, –29%), –73% (95% CI: –77%, –68%), –79% (95% CI: –83%, –76%), respectively. The percent changes from baseline to week 12 in PCSK9 levels at the 15mg, 50mg and 90mg monthly dose were –58% (95% CI, –66%, –48%), –89% (95% CI: –91%, –86%), –94% (95% CI: –95%, –92%), respectively. ION449 was generally well-tolerated. The adverse events (AEs) were similar between the 15mg, 50mg and placebo groups. Most AEs were mild to moderate including transient, moderate treatment-emergent elevations in liver enzyme levels in the 90mg group.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, ION449 and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021, which is on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc.
|
https://www.wflx.com/prnewswire/2022/04/04/ionis-announces-positive-data-etesian-phase-2b-study-antisense-medicine-targeting-pcsk9-2022-american-college-cardiology-scientific-session/
| 2022-04-04T07:29:49
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/ionis-announces-positive-data-etesian-phase-2b-study-antisense-medicine-targeting-pcsk9-2022-american-college-cardiology-scientific-session/
|
SUZHOU, China, April 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
- E-Poster
Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients
Abstract#: 5274
Session Title: COVID-19 and Cancer
Session Time: April 8, 2022, 12:00 PM - 1:00 PM
Abstract Link: https://www.abstractsonline.com/pp8/#!/10517/presentation/18533
Discovery and evaluation of GT19630, a c-Myc/GSPT1 cereblon E3 ligase modulator(CELMoD) , for targeting Myc-driven blood cancers and small cell lung cancers(SCLC)
Abstract#: 5479
Session Title: Small Molecule Therapeutic Agents
Session Time: April 8, 2022, 12:00 PM - 1:00 PM
Abstract Link: https://www.abstractsonline.com/pp8/#!/10517/presentation/18624
Please refer to the website of AACR for more details.
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecules and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.
View original content:
SOURCE Kintor Pharma
|
https://www.wflx.com/prnewswire/2022/04/04/kintor-pharma-announces-two-upcoming-poster-presentations-aacr-2022/
| 2022-04-04T07:29:57
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/kintor-pharma-announces-two-upcoming-poster-presentations-aacr-2022/
|
PriceRunner will bring new features to the Klarna app globally to help consumers save time and money, and make informed decisions to take control of their finances
STOCKHOLM, April 4, 2022 /PRNewswire/ -- Klarna, a leading global retail bank, payments, and shopping service today announced the completion of its acquisition of PriceRunner, the leading comparison shopping service in the Nordic region with operations in Sweden, Denmark, Norway and the United Kingdom.
PriceRunner will bring new features to the Klarna app globally in the form of rich product discovery, price comparisons and product reviews to help consumers save time and money, and make informed decisions so they can take control of their finances. Klarna's 400k+ global retail partners as well as PriceRunner's retail partners will benefit from increased website traffic from high intent consumers and optimized marketing opportunities to further drive their growth.
All 200+ PriceRunner employees in Sweden, Denmark and Norway are now officially part of the Klarna family.
David Fock, Klarna's Chief Product Officer commented: "Together with PriceRunner we already have some exciting plans on how we can swiftly integrate our teams and technology stacks to launch products that enhance the shopping experience for Klarna's 147m global consumers. We look forward to welcoming our new colleagues to Klarna.
"The acquisition will serve to strengthen our consumer offering and that Klarna will not be a marketplace but a viable and competitive alternative for retail partners vs Amazon, Google and Facebook. Klarna and PriceRunner are united in our fundamental belief that tech companies, no matter where they operate, compete on the basis of their own merit with the best products and services to gain consumers' trust."
Mikael Lindahl, CEO of PriceRunner, said: "We are really excited about this next chapter in PriceRunner's journey, continuing it with a strong, global player like Klarna. I know that we can create the very best shopping experience for consumers together and am really excited for how our company will grow in the future together with Klarna."
Klarna will assume complete ownership from previous main owners Karl-Johan Persson, chairman of the board at H&M, Eequity, former PriceRunner CEO Nicklas Storåkers and current CEO Mikael Lindahl.
For media enquiries, please contact:
Klarna
Candice Macdonald
E: press@klarna.com
T: +44 (0) 7971 797208
Mikael Lindahl
CEO PriceRunner
E: mikael.lindahl@pricerunner.com
T: +46 (0) 70 744 74 43
About Klarna
Since 2005 Klarna has been on a mission to revolutionize the retail banking industry. With over 147 million global active users and 2 million transactions per day, Klarna is meeting the changing demands of consumers by saving them time and money while helping them be informed and in control of their personal finances. Over 400,000 global retail partners, including H&M, Saks, Sephora, Macys, IKEA, Expedia Group, and Nike have integrated Klarna's innovative technology to deliver a seamless shopping experience online and in-store. With over 5,000 employees, Klarna is active in 45 markets and is one of the most highly-valued private fintechs globally, with a valuation of $45.6 billion. For more information, visit Klarna.com
About PriceRunner
PriceRunner is the largest independent comparison shopping service in the Nordics. The company operates in four countries and compares 3.7 million products from 22,500 stores in 25 different countries. At PriceRunner, consumers can compare products, prices, specifications, read professional product tests and find out how other customers reviewed products and stores. We have roughly 200 employees in Denmark, Norway and Sweden. PriceRunner is a completely independent company. We are not owned by any merchants and are not dependent on them, retailers or other organizations with an interest to spread biased information. Our goal is to help consumers find the right products at a better price. We help millions of consumers every month to find better and cheaper products while they at the same time save money by using PriceRunner's services.
This information was brought to you by Cision http://news.cision.com
View original content:
SOURCE Klarna Bank AB (publ)
|
https://www.wflx.com/prnewswire/2022/04/04/klarna-completes-acquisition-pricerunner/
| 2022-04-04T07:30:04
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/klarna-completes-acquisition-pricerunner/
|
DANVERS, Mass., April 4, 2022 /PRNewswire/ -- The Plexus team at ITW Performance Polymers is introducing Plexus MA8105 as its newest adhesive, continuing to push the limits of what is possible with MMA (methyl methacrylate) adhesives and addressing the challenges of earlier generations.
MMA structural adhesives offer distinct advantages over other adhesives: Fast room temperature curing, excellent mechanical properties, and a broad range of adhesion. Older MMA adhesives bond a wide range of materials but struggle with "difficult to bond" metals like hot dipped galvanized steel, or tough semi-crystalline plastics like polyamides (nylons).
Challenges and Requirements
Broad Adhesion – Customers need to bond a full range of materials. Older generations of adhesives had difficulty bonding galvanized steel, nylons to composites, other metals and plastics.
High Temperature Resistance – Certain applications require high strength even at 180°F (82°C) or higher.
Fast Throughput – The adhesive strength development must match expectations. Making more parts per hour improves efficiency and lowers cost.
Toughness Requirement – Users need high strength adhesives with good elongation handling impact and fatigue.
Cure Tack-Free, Sandable & Paintable – Adhesive squeeze out happens. It's beneficial to have an adhesive that cures tack-free and accepts most paints.
Non-Sag on Vertical Surfaces – It stays where you put it.
Handle Off-Ratio Mixing – Older adhesives require exact mix ratios.
Expanding the Plexus MA8100 Brand
Enter MA8105, a 5-minute working time product with fixture times between 12-15 minutes. MA8105 takes the robust adhesion of other MA8100 series products and adds quicker product throughput.
The Results
MA8105 has excellent primerless adhesion to a wide range of substrates. Composites, painted metals, and amorphous thermoplastics are often bonded with little to no surface preparation. MA8105 adhesive even bonds oily metals. MA8105 withstands long-term environmental exposure. Parts can be bonded and survive in typical outdoor environments with significantly higher heat resistance than competitive structural adhesives. MA8105 cures quickly in a range of temperatures, enabling fast throughput. Quick dispensing and part joining mean manufacturing and assembly are optimized, producing more parts per hour. Labor shortages mean manufacturers can turn to the creative solutions of adhering their parts in a fast, efficient manner.
About Plexus:
A brand of ITW Performance Polymers. Plexus industrial adhesives create durable bonds in a variety of applications providing dependable solutions across multiple markets. Used to improve processes and techniques in manufacturing and assembly, these products are available around the world.
About ITW Performance Polymers:
A world leader in the research, development and manufacturing of grouting and chocking compounds, structural and semi-structural adhesives, sprayable syntactic materials, and wear-resistant coatings and repair compounds. These value-added solutions are widely used in several markets including wind, transportation, marine, electronics, and other industrial OEM & MRO applications.
Media Contact:
Max VanRaaphorst
(978) 412-2773
mvanraaphorst@itwpp.com
View original content:
SOURCE ITW Performance Polymers
|
https://www.wflx.com/prnewswire/2022/04/04/next-generation-mma-adhesives-plexus-ma8105/
| 2022-04-04T07:30:11
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/next-generation-mma-adhesives-plexus-ma8105/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Apyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 14, 2022, Apyx issued a press release "announc[ing] it has been notified by the U.S. Food and Drug Administration ('FDA'; 'Agency') that the Agency intends to post a Medical Device Safety Communication related to the Company's Advanced Energy products." In the press release, Apxy's President and Chief Executive Officer stated that "[b]ased on our initial interactions with the FDA, we believe the Agency's MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures[.]"
On this news, Apyx's stock price fell $4.02 per share, or 40.61%, to close at $5.88 per share on March 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-apyx-medical-corporation-apyx/
| 2022-04-04T07:30:17
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-apyx-medical-corporation-apyx/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. ("Beigene" or the "Company") (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Beigene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 9, 2022, the U.S. Securities and Exchange Commission ("SEC") published a notification identifying Beigene, among other companies, as in potential violation of the Holding Foreign Companies Accountable Act, which allows the SEC to delist companies and ban a company's shares from being traded if the company fails to allow U.S. regulators to review their company audits for three straight years. Beigene and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.
On this news, Beigene's stock price fell $11.47 per share, or 5.87%, to close at $184.00 per share on March 10, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-beigene-ltd-bgne/
| 2022-04-04T07:30:26
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-beigene-ltd-bgne/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 11, 2022, post-market, the Center for Medicare and Medicaid Services ("CMMS") announced its draft decision on reimbursement for Aduhelm, Biogen's proposed treatment for Alzheimer's disease. CMMS proposed to cover reimbursement under "Coverage with Evidence Development," limiting reimbursement only to patients enrolled in a clinical trial. Additionally, it limited those patients eligible as those with mild forms of cognitive impairment or mild dementia and those patients who already have amyloid plaques. Further, CMMS proposed limiting reimbursement to clinical trials in a hospital-based outpatient setting. CMMS's reimbursement decision functionally amounted to agreeing to reimburse Biogen for running a new clinical trial, all but destroying the value of Aduhelm as an approved drug.
On this news, Biogen's stock price fell $16.18 per share, or 6.7%, to close at $225.34 per share on January 11, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-biogen-inc-biib/
| 2022-04-04T07:30:33
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-biogen-inc-biib/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Core Scientific, Inc. f/k/a Power & Digital Infrastructure Acquisition Corp. ("Core Scientific" or the "Company") (NASDAQ: CORZ; CORZW; XPDI; XPDIU; XPDIW). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Core Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Core Scientific began as a special purpose acquisition company ("SPAC"), also called a blank-check company, which is a development stage company that has no specific business plan or purpose, or has indicated its business plan is to engage in a merger or acquisition with an unidentified company or companies, other entity, or person. On January 20, 2022, Core Scientific completed a business combination with a target company and began offering blockchain and artificial intelligence infrastructure services. Then, on March 3, 2022, Culper Research ("Culper") issued a short report alleging that Core Scientific "has wildly oversold both its mining and hosting businesses, which it cobbled together in a series of questionable transactions before dumping onto the market via SPAC." The Culper report also stated that, "[o]n Monday, Core [Scientific] disclosed that its board waived the 180-day lockup on over 282 million shares, making them free to be dumped just 5 trading days from today[,]" which "shows insiders have abandoned any pretense of care for minority shareholders."
On this news, Core Scientific's stock price fell $0.72 per share, or 9.35%, to close at $6.98 per share on March 3, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-core-scientific-inc-fka-power-amp-digital-infrastructure-acquisition-corp-corz-corzw-xpdi-xpdiu-xpdiw/
| 2022-04-04T07:30:46
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-core-scientific-inc-fka-power-amp-digital-infrastructure-acquisition-corp-corz-corzw-xpdi-xpdiu-xpdiw/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DiDi Global Inc. ("DiDi" or the "Company") (NYSE: DIDI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether DiDi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 11, 2022, media outlets reported that DiDi suspended preparation for its planned Hong Kong listing, following notice from the Cyberspace Administration of China that DiDi's proposals to prevent security and data leaks had fallen short of requirements.
On this news, DiDi's American Depositary Receipt ("ADR") price fell $1.49 per ADR, or more than 44%, to close at $1.89 per share on March 11, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-didi-global-inc-didi/
| 2022-04-04T07:30:53
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-didi-global-inc-didi/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corporation ("ELMS" or the "Company") (NASDAQ: ELMS; ELMSW; FIII; FIIIW; FIIIU). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether ELMS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 1, 2022, during after-market hours, ELMS announced that certain of the Company's previously issued consolidated financial statements should be restated and no longer be relied upon. ELMS also disclosed that a member of the Company's Board of Directors (the "Board"), Shauna McIntyre, was named interim Chief Executive Officer ("CEO") and President following the resignation of former CEO, James Taylor ("Taylor"). According to the Company, Taylor resigned after an investigation by a Special Committee of the Board found that, in November and December of 2020, certain Company executives, including Taylor, purchased equity in the firm at substantial discounts to the current market value without any independent valuation.
On this news, ELMS's stock price fell $2.88 per share, or 51.52%, to close at $2.71 per share on February 2, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-electric-last-mile-solutions-inc-fka-forum-merger-iii-corporation-elms-elmsw-fiii-fiiiw-fiiiu/
| 2022-04-04T07:30:59
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-electric-last-mile-solutions-inc-fka-forum-merger-iii-corporation-elms-elmsw-fiii-fiiiw-fiiiu/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FAT Brands Inc. ("FAT" or the "Company") (NASDAQ: FAT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether FAT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 22, 2022, FAT disclosed in a filing with the U.S. Securities and Exchange Commission that its Chief Executive Officer Andy Wiederhorn has been under federal investigation for several months "concerning, among other things, the Company's December 2020 merger with Fog Cutter Capital Group Inc., transactions between these entities and Mr. Wiederhorn, and compensation, extensions of credit and other benefits or payments received by Mr. Wiederhorn or his family."
On this news, FAT's stock price fell $2.42 per share, or 22.92%, to close at $8.14 per share on February 22, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-fat-brands-inc-fat/
| 2022-04-04T07:31:06
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-fat-brands-inc-fat/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gatos Silver, Inc. ("Gatos" or the "Company") (NYSE: GATO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Gatos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 25, 2022, post-market, Gatos issued a press release disclosing that "[d]uring the Company's resource and reserve update process for the Los Gatos Joint Venture ("LGJV") . . . the Company concluded that there were errors in the technical report entitled 'Los Gatos Project, Chihuahua, Mexico' with an effective date of July 1, 2020 (the '2020 Technical Report'), as well as indications that there is an overestimation in the existing resource model." Accordingly, "[o]n a preliminary basis, the Company estimates a potential reduction of the metal content of CLG's mineral reserve ranging from 30% to 50% of the metal content remaining after depletion" and advised that "the mineral resource and reserve estimates in the 2020 Technical Report should not be relied upon."
On this news, Gatos' stock price fell $7.02 per share, or 68.89% percent to close at $3.17 per share on January 26, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-gatos-silver-inc-gato/
| 2022-04-04T07:31:13
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-gatos-silver-inc-gato/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Graphite Bio, Inc. ("Graphite" or the "Company") (NASDAQ: GRPH). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Graphite and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On or around June 25, 2021, Graphite conducted its initial public offering ("IPO"), issuing 14 million shares of common stock priced at $17.00 per share. Then, on March 21, 2022, Graphite issued a press release providing business updates and announcing is fourth quarter and fiscal year 2021 financial results. Among other items, Graphite disclosed that the early proof-of-concept data from the Phase 1/2 CEDAR clinical trial for GPH101 in sickle cell disease are now expected in 2023, attributing the delay "to impacts of the recent COVID-19 Omicron variant surge on patients and site resources and operations[.]"
On this news, Graphite's stock price fell $1.23 per share, or 15.15%, to close at $6.89 per share on March 21, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-graphite-bio-inc-grph/
| 2022-04-04T07:31:20
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-graphite-bio-inc-grph/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kingsoft Cloud Holdings Limited ("Kingsoft" or the "Company") (NASDAQ: KC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Kingsoft and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On or around May 8, 2020, Kingsoft conducted its initial public offering ("IPO"), selling 30 million American Depositary Shares ("ADSs") priced at $17.00 per ADS. Then, on March 14, 2022, a J.P. Morgan analyst downgraded Kingsoft stock from neutral to underweight, cutting its price target from $8.00 per ADS to $3.50 per ADS.
On this news, Kingsoft's stock price fell $2.35 per share, or 47.86%, to close at $2.56 per share on March 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-kingsoft-cloud-holdings-limited-kc/
| 2022-04-04T07:31:26
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-kingsoft-cloud-holdings-limited-kc/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On or around October 16, 2020, Kiromic conducted its initial public offering, selling 1.25 million shares of common stock priced at $12.00 per share. Then, on July 16, 2021, Kiromic issued a press release disclosing that, following the May 2021 submission of two Investigational New Drug Applications ("INDs") to the U.S. Food and Drug Administration ("FDA") "for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors", the "FDA returned with comments on the Company's allogeneic CAR-T products with respect to . . . Tracing of all reagents used in manufacturing . . . Flow chart of manufacturing processes . . . [and] Certificate of Analysis (COA) for the Company's CAR-T products (allogeneic CAR-T)."
On this news, Kiromic's stock price fell $0.63 per share, or 16.76%, to close at $3.13 per share on July 16, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-kiromic-biopharma-inc-krbp/
| 2022-04-04T07:31:35
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-kiromic-biopharma-inc-krbp/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Li-Cycle Holdings Corp. ("Li-Cycle" or the "Company") (NYSE: LICY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Li-Cycle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 24, 2022, Blue Orca Capital published a report (the "Report") characterizing the Company as "a near fatal combination of stock promotion, laughable governance, a broken business hemorrhaging cash, and highly questionable Enron-like accounting." According to the Report, "Li-Cycle recognizes revenues using an Enron-like mark-to-model accounting gimmick.
Li-Cycle recognizes revenues months prior to the actual sales of its recycled black mass, based on its own provisional estimate of the future value of the product. This accounting treatment is plainly vulnerable to abuse, giving Li-Cycle discretion over its reported revenues. We suspect that under this framework, LiCycle marks up the value of its receivables on unsold products and runs the gains through its revenue line."
On this news, Li-Cycle's stock price fell $0.47 cents per share, or 5.60% to close at $7.93 per share on March 24, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-li-cycle-holdings-corp-licy/
| 2022-04-04T07:31:41
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-li-cycle-holdings-corp-licy/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lilium N.V. ("Lilium" or the "Company") (NASDAQ: LILM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Lilium and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 14, 2022, Iceberg Research published a short report entitled "Lilium NV – The Losing Horse in the eVTOL [electric vertical take-off and landing aircraft] Race" (the "Iceberg Report"). The Iceberg Report asserted, among other issues, that "[m]any experts have raised serious doubts about" the viability of the Company's Lilium Jet reaching its objective of "fly[ing] up to 155 miles[,]" citing "its configuration of 36 ducted fans (recently reduced to 30) that devour power during takeoff and landing (hovering), and leaves little power for actual flight." The Iceberg Report also noted that while "Lilium promises its Jet has ready access to battery cells with energy density of 320-330 Wh/kg[,]" "[o]ne of the sources it relies on to show these batteries are within reach is . . . a 34.8% Lilium-owned associated company whose CEO Sujeet Kumar was accused by General Motors of misrepresenting battery performance, while at his previous company Envia Systems." The Iceberg Report further noted that Lilium's Chief Executive Officer "had no meaningful professional aerospace experience before starting Lilium in 2015" and "estimate[d] that Lilium has about 18 months before its cash runs dry."
On this news, Lilium's stock price fell $1.25 per share, or 33.88%, to close at $2.44 per share on March 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-lilium-nv-lilm/
| 2022-04-04T07:31:48
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-lilium-nv-lilm/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lockheed Martin Corporation ("Lockheed" or the "Company") (NYSE: LMT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Lockheed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 16, 2022, Bloomberg reported that the U.S. Department of Defense will request 61 Lockheed F-35 fighter jets in its next budget, 33 fewer than previously planned. Bloomberg reported that the proposed reduction follows the "flawed execution of a crucial upgrade of [the F-35's] software and hardware capabilities that's estimated to cost $14 billion."
On this news, Lockheed's stock price fell sharply during intraday trading on March 16, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-lockheed-martin-corporation-lmt/
| 2022-04-04T07:31:55
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-lockheed-martin-corporation-lmt/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MoneyLion Inc. ("MoneyLion" or the "Company") (NYSE: ML). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether MoneyLion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 10, 2022, MoneyLion disclosed in a filing with the U.S. Securities and Exchange Commission that "the Company's management has noted errors related to operating expenses, net loss and basic and diluted earnings (loss) per share in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and additional paid-in capital and retained earnings in the condensed consolidated balance sheet as of September 30, 2021, along with related impacts to the condensed consolidated statement of cash flows for the nine months ended September 30, 2021 and the condensed consolidated statements of redeemable convertible preferred stock, redeemable noncontrolling interests and stockholders' deficit for the three and nine months ended September 30, 2021." MoneyLion further disclosed that "the Company's management identified a second error . . . as the denominator of the diluted net income per share calculation for the three months ended September 30, 2021 did not include the impact of dilutive securities" and that "[t]he Company's management, in consultation with its advisors, has determined that the calculation of diluted net income per share included within the condensed consolidated statement of operations for the three months ended September 30, 2021 should have included the impact of dilutive securities." Accordingly, the Audit Committee of MoneyLion's Board of Directors determined that the financial statements in question "should no longer be relied upon and should be restated in order to correct the errors described above."
On this news, MoneyLion's stock price fell $0.18 per share, or 7.11%, to close at $2.29 per share on March 10, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-moneylion-inc-ml/
| 2022-04-04T07:32:02
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-moneylion-inc-ml/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Natera and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 9, 2022, Hindenburg Research published a short report addressing Natera, entitled "Natera: Pioneers In Deceptive Medical Billing." Among other allegations, Natera stated that "[b]ased on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online complaints, FOIA requests to state Medicaid offices and state Attorneys General, and the company's financial filings, we show how Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
Following publication of the Hindenburg Research report, Natera's stock price fell $17.95 per share, or 32.79%, to close at $36.80 per share on March 9, 2022.
Then, on March 15, 2022, CareDx, Inc. ("CareDx") announced that it had won a $44.9 million false advertising lawsuit against Natera after a federal jury found that Natera and its senior executives falsely advertised its Prospera kidney transplant rejection assessment test and made false comparisons to CareDx's competing product, AlloSure.
On this news, Natera's stock price fell $5.57 per share, or 15.52%, to close at $30.32 per share on March 15, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-natera-inc-ntra/
| 2022-04-04T07:32:08
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-natera-inc-ntra/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Okta, Inc. ("Okta or the "Company") (NASDAQ: OKTA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Okta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 22, 2022, Okta confirmed that in January 2022 the Company had experienced a data breach caused by a hacking group known as Lapsus$, which potentially affected as many as 366 Okta customers. Separately, Okta was downgraded by Raymond James from "strong buy" to "market perform," citing a "continually disconnected CIAM go-to-market strategy (i.e. still separate reps for Auth0/Okta, no communication to incent channel cross-sell, no evidence of improved technology/integration [...]) While partners were willing to trust Okta's track record, the handling of its latest security incident adds to our mounting concerns."
On this news, Okta's stock price fell $17.88 per share, or 10.74%, to close at $148.55 per share on March 23, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-okta-inc-okta/
| 2022-04-04T07:32:17
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-okta-inc-okta/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Pulse and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 8, 2022, Pulse issued a press release "announc[ing] an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System's current labeling." Specifically, Pulse advised that following its submission of " a 510(k) in December 2021 to add the treatment of sebaceous hyperplasia to the CellFX System's indications for use in the United States", " [o]n February 5, 2022, the Company received an Additional Information ("AI") letter from the FDA", in which "the FDA stated it did not believe the Company provided sufficient clinical evidence at this time to support the expanded indication for use, and that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study."
On this news, Pulse's stock price fell $3.74 per share, or 34.44%, to close at $7.12 per share on February 8, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-pulse-biosciences-inc-plse/
| 2022-04-04T07:32:24
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-pulse-biosciences-inc-plse/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SunPower Corporation ("SunPower" or the "Company") (NASDAQ: SPWR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether SunPower and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 20, 2022, SunPower announced that it had "identified a cracking issue that developed over time in certain factory-installed connectors" and that the Company "expects approximately $27 million of supplier-quality related charges in fourth quarter 2021 and approximately $4 million in the first quarter of 2022" to replace the faulty connectors.
On this news, SunPower's stock price fell $3.22 per share, or 16.9%, to close at $15.80 per share on January 21, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-sunpower-corporation-spwr/
| 2022-04-04T07:32:30
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-sunpower-corporation-spwr/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TAL Education Group ("TAL" or the "Company") (NYSE: TAL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether TAL and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 25, 2021, media reports revealed that the City of Beijing had fined four online education agencies, including TAL, the maximum fine of 500,000 yuan (approximately $80,000) each for misleading customers with false advertising regarding course pricing. On May 12, 2021, news reports revealed that an impending crackdown by the Chinese government on the private tutoring sector would be further reaching and more drastic than previously publicly known, including that regulators had already taken adverse actions against TAL and other for-profit tutoring companies.
On this news, TAL's American Depository Share ("ADS") price fell $6.89 per ADS, or 13%, over the following two trading sessions to close at $46.25 per ADS on May 13, 2021.
On June 1, 2021, Chinese regulators announced that they had fined 15 off-campus training institutions, including TAL, for illegal activities such as false advertising and fraud. On this news, TAL's ADS price fell $7.24 per ADS, or nearly 18%, over the following two trading sessions to close at $33.27 per ADS on June 3, 2021. Finally, on July 23, 2021, China unveiled a sweeping overhaul of its education sector, banning companies that teach the school curriculum from making profits, raising capital or going public, effectively ending any potential growth in the for-profit tutoring sector in China.
On this news, TAL's ADS price fell $16.12 per ADS, or 78.56%, over the following two trading sessions to close at $4.40 per ADS on July 26, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-tal-education-group-tal/
| 2022-04-04T07:32:37
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-tal-education-group-tal/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TaskUs, Inc. ("TaskUs" or the "Company") (NASDAQ: TASK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether TaskUs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 20, 2022, Spruce Point Capital Management ("Spruce Point") published a report on TaskUs. Citing "a forensic financial and accounting review," the Spruce Point report described TaskUs as having "a pattern of exaggerated and inflated business claims, including revenue, and . . . covering-up financial strain with reduced disclosures, cherry-picked market data, and non-standard key performance metrics."
On this news, TaskUs's stock fell $5.46 per share, or nearly 15.34%, to close at $30.13 per share on January 20, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-taskus-inc-task/
| 2022-04-04T07:32:45
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-taskus-inc-task/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tattooed Chef, Inc. ("Tattooed Chef" or the "Company") (NASDAQ: TTCF). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Tattooed Chef and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 12, 2021, Tattooed Chef issued a press release announcing its financial results for the second quarter of 2021. Among other results, the Company disclosed revenue of $50.7 million, missing consensus estimates by $3.35 million.
On this news, Tattooed Chef's stock price fell $3.30 per share, or 16.25%, to close at $17.01 per share on August 13, 2021.
Then, on March 11, 2022, Tattooed Chef issued a press release stating that on March 7, 2022, the Company's Board of Directors "concluded that the Company's unaudited interim condensed consolidated financial statements for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021, each as previously filed with the Securities and Exchange Commission ('SEC'), should no longer be relied upon because the Company did not properly record the tax effects associated with the Company's issuance of 825,000 shares of its common stock to Harrison Co. in June 2021 as partial consideration for services rendered in connection with the Company's de-SPAC transaction that occurred in October 2020." Accordingly, Tattooed Chef advised that "[t]he Company will restate the unaudited consolidated financial statements" at issue.
On this news, Tattooed Chef's stock price fell $1.03 per share, or 9.07%, to close at $10.33 per share on March 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-tattooed-chef-inc-ttcf/
| 2022-04-04T07:32:52
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-tattooed-chef-inc-ttcf/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telos Corporation ("Telos" or the "Company") (NASDAQ: TLS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Telos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On November 15, 2021, Telos held an earnings call to discuss the Company's financial results for the third quarter of 2021. During the call, Telos's Chief Financial Officer, Mark Bendza, disclosed that the Company's contracts with the Centers for Medicare and Medicaid Services ("CMS") and U.S. Transportation Security Administration ("TSA") would be delayed, with only the TSA contract commencing in 2022, while the CMS contract was pushed back until after 2022. During the call, Bendza acknowledged deficiencies in Telos's past guidance process, stating that "going forward . . . I will guide based on what [we] have a high degree of visibility into at a point in time. And so, you're going to see that in how we guide going forward."
On this news, Telos's stock price fell $6.84 per share, or more than 28%, to close at $17.54 per share on November 15, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-telos-corporation-tls/
| 2022-04-04T07:32:59
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-telos-corporation-tls/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vertiv Holdings Co ("Vertiv" or the "Company") (NYSE: VRT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Vertiv and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 23, 2022, at 6:00 a.m. Eastern, Vertiv reported disappointing financial results, including $0.06 earnings per share for fourth quarter 2021, missing analyst estimates of $0.28 per share. Vertiv's Chief Executive Officer attributed the poor results to management "consistently underestimat[ing] inflation and supply chain constraints for both timing and degree, which dictated a tepid 2021 pricing response."
On this news, the Company's stock price fell $7.19 per share, or 37%, to close at $12.38 per share on February 23, 2022, on unusually heavy trading volume.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-vertiv-holdings-co-vrt/
| 2022-04-04T07:33:06
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-vertiv-holdings-co-vrt/
|
NEW YORK , April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Yext, Inc. ("Yext" or the "Company") (NYSE: YEXT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Yext and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 8, 2022, Yext issued a press release announcing its fourth quarter and full year fiscal 2022 results. Among other items, Yext reported revenue of $100.9 million for the quarter, falling well short of consensus estimates, as well as revenue outlooks for the first quarter and full year fiscal 2023 that likewise missed consensus estimates. Yext further announced the departure of the Company's Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer.
On this news, Yext's stock price fell $0.55 per share, or 9.29%, to close at $5.37 per share on March 9, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-yext-inc-yext/
| 2022-04-04T07:33:13
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-yext-inc-yext/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Zai Lab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 9, 2022, the U.S. Securities and Exchange Commission ("SEC") published a notification identifying Zai Lab, among other companies, as in potential violation of the Holding Foreign Companies Accountable Act, which allows the SEC to delist companies and ban a company's shares from being traded if the company fails to allow U.S. regulators to review their company audits for three straight years. Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.
On this news, Zai Lab's stock price fell $6.74 per share, or 18.34%, to close at $30.02 per share on March 10, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-zai-lab-limited-zlab/
| 2022-04-04T07:33:19
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-zai-lab-limited-zlab/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cano Health, Inc. ("Cano" or the "Company") f/k/a Jaws Acquisition Corp. ("Jaws") (NYSE: CANO; CANO/WS; JWS; JWS.U; JWS WS) and certain of its officers. The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 22-cv- 20827, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cano securities between May 18, 2020 and February 25, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired Cano securities during the Class Period, you have until May 17, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Cano provides primary care medical services to its members in the United States and Puerto Rico. The Company owns and operates medical centers, as well as operates pharmacies.
Cano used to be a special purpose acquisition company ("SPAC") and operated under the name "Jaws Acquisition Corp." A SPAC, also called a blank-check company, is a development stage company that has no specific business plan or purpose or has indicated its business plan is to engage in a merger or acquisition with an unidentified company or companies, other entity, or person. On June 3, 2021, Jaws consummated a merger with Primary Care (ITC) Intermediate Holdings, LLC, whereby, among other things, Jaws changed its name to "Cano Health, Inc." and began to provide primary care medical services (the "Business Combination").
As a publicly traded company, Cano must adhere to strict financial reporting requirements by, among other things, timely filing periodic financial reports with the U.S. Securities and Exchange Commission and complying with Financial Accounting Standards Board guidelines, including Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Particularly, under ASC 606, Cano must analyze its revenue recognition with respect to, inter alia, certain Medicare risk adjustments.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Cano overstated its due diligence efforts and expertise with respect to acquiring target businesses; (ii) accordingly, Cano performed inadequate due diligence into whether the Company, post-Business Combination, could properly account for the timing of revenue recognition as prescribed by ASC 606, particularly with respect to Medicare risk adjustments; (iii) as a result, the Company misstated its capitated revenue, direct patient expense, accounts receivable, net of unpaid service provider costs, and accounts payable and accrued expenses; (iv) accordingly, the Company was at an increased risk of failing to timely file one or more of its periodic financial reports; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
On February 28, 2022, Cano issued a press release "announc[ing] it will delay its fourth quarter and full year 2021 earnings release, conference call and 2022 guidance updates, previously scheduled for Monday, February 28, 2022." In explaining the delay, Cano advised that "in the course of finalizing its audit of the financial statements for the year ended December 31, 2021, the Company and its independent auditor . . . identified certain potential non-cash adjustments to account for revenue recognition under accounting standard ASC 606." Specifically, Cano advised that "[t]he adjustments relate to how and when the Company accrues revenue related to Medicare Risk Adjustments" and that "[t]he adjustments are expected to impact the timing of revenue recognition, by delaying recognition of certain amounts related to the Medicare Risk Adjustment to subsequent periods[.]"
On this news, Cano's Class A common stock price fell $0.32 per share, or 6.17%, to close at $4.87 per share on February 28, 2022.
On March 14, 2022, Cano filed its annual report for the quarter and year ended December 31, 2021 (the "2021 10-K"). That filing stated, inter alia, that "[t]he correction in the timing of revenue recognition under ASC 606 resulted in adjustments to capitated revenue, direct patient expense, accounts receivable, net of unpaid service provider costs, and accounts payable and accrued expenses[,]" and that the Company therefore "restated its financial statements for each of the quarterly periods ended March 31, 2021, June 30, 2021 and September 30, 2021 in the [2021 10-K.]" For example, the 2021 10-K reported that, as restated, capitated revenue decreased 2.13% for the three months ended March 31, 2021; 13.11% for the three months ended June 30, 2021; and 5.58% for the three months ended September 30, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
Media Contact:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-cano-health-inc-fka-jaws-acquisition-corp-class-action-lawsuit-upcoming-deadline-cano-canows-jws-jwsu-jws-ws/
| 2022-04-04T07:33:26
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-cano-health-inc-fka-jaws-acquisition-corp-class-action-lawsuit-upcoming-deadline-cano-canows-jws-jwsu-jws-ws/
|
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 22-cv-00115, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fennec securities between May 28, 2021 and November 26, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired Fennec securities during the Class Period, you have until April 11, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Fennec is a biopharmaceutical company that develops product candidates for use in the treatment of cancer in the United States. The Company's lead product candidate is PEDMARK, a formulation of sodium thiosulfate, which has completed a Phase III clinical trial for the prevention of cisplatin induced hearing loss, or ototoxicity, in children.
In December 2018, Fennec initiated a rolling New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for PEDMARK for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors, which was completed in February 2020 (the "Initial Pedmark NDA").
In August 2020, Fennec announced that it had received a Complete Response Letter ("CRL") from the FDA for the Initial Pedmark NDA because of deficiencies identified at the manufacturing facility of the Company's drug product manufacturer.
Then, in May 2021, the Company announced that it had resubmitted the NDA for PEDMARK with the FDA following receipt of final minutes from a Type A meeting with the FDA (the "Resubmitted Pedmark NDA").
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK; (ii) as a result, the FDA was unlikely to approve the Resubmitted Pedmark NDA; (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On November 29, 2021, during pre-market hours, Fennec issued a press release "announc[ing] that it expects to receive a [CRL] after the PDUFA [Prescription Drug User Fee Act] target action date of November 27, 2021 from the [FDA] regarding its [Resubmitted Pedmark NDA]." Specifically, Fennec advised investors that "[t]he FDA has indicated that, following a recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, deficiencies have been identified[,]" and that "[o]nce the official CRL is received, the Company plans to request a Type A meeting to discuss the deficiencies and steps required for the resubmission of the NDA for PEDMARKTM."
On this news, Fennec's common share price fell $4.86 per share, or 50.41%, to close at $4.78 per share on November 29, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-fennec-pharmaceuticals-inc-class-action-lawsuit-upcoming-deadline-fenc/
| 2022-04-04T07:33:33
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-their-investment-fennec-pharmaceuticals-inc-class-action-lawsuit-upcoming-deadline-fenc/
|
ÖSTERSUND, Sweden, April 4, 2022 /PRNewswire/ -- Skanska has signed a contract with Bon Secours - St. Francis Medical Center, Inc. to renovate and expand an acute care services facility in Midlothian, Virginia, USA. The contract is worth USD 78M, about SEK 720M, which will be included in the US order bookings for the first quarter 2022.
The expansion aspect of the project includes a vertical two-floor addition above the existing surgical department on the second floor. The new third floor will house a med-surg nursing unit with observation rooms and the new the fourth floor will be used for critical care ICU beds and NICU rooms.
As part of the renovation of the existing building, a former ICU unit will be renovated to accommodate an observation unit. The fourth floor of the adjacent building will be reconfigured to accommodate a new Mother-Infant Unit. Additional renovations will include a new retail pharmacy, MRI suite, physicians dining and central plant upgrades.
Construction began December 2021, and completion is scheduled for April 2024.
CONTACT:
For further information please contact:
Maritza E. Ferreira, Communications Director, Skanska USA, tel +1 (678) 4922003
Andreas Joons, Press Officer, Skanska AB, tel +46 (0)10 449 04 94
Direct line for media, tel +46 (0)10 448 88 99
This and previous releases can also be found at www.skanska.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Skanska
|
https://www.wflx.com/prnewswire/2022/04/04/skanska-renovates-expands-acute-care-services-facility-hospital-virginia-usa-usd-78m-about-sek-720m/
| 2022-04-04T07:33:39
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/skanska-renovates-expands-acute-care-services-facility-hospital-virginia-usa-usd-78m-about-sek-720m/
|
John Eland Appointed Chief Executive Officer, STACK EMEA
Adam Tamburini Appointed Chief Hyperscale Officer, STACK EMEA
DENVER, April 4, 2022 /PRNewswire/ -- STACK Infrastructure ("STACK"), the digital infrastructure partner to the world's most innovative companies, today announced that it has appointed two experienced data center industry professionals to its EMEA leadership team. John Eland has joined as Chief Executive Officer, STACK EMEA and Adam Tamburini has joined as Chief Hyperscale Officer, STACK EMEA.
"We're thrilled to welcome John to the STACK team to drive our strategy and operations in the EMEA region," said Phil Koen, Chairman of the Board of STACK. "John is a proven leader who brings over two decades of strategy, development and management experience in the data center industry, including extensive regional expertise that we believe will be highly valuable as we continue to expand STACK's already successful European business."
John joins STACK with over 22 years of experience across the data center, telecom and investment sectors. Most recently, he served as Chief Strategy Officer of the Global Data Centers division at NTT Ltd., a London-based global technology services company. In this role, John led strategy and corporate development in existing and new markets. He also oversaw NTT's ongoing expansion efforts through M&A, joint ventures, strategic partnerships and development.
John commented, "I have been impressed by STACK's accelerating momentum both globally and in Europe, where we have created a strong operating platform and team now operating under the STACK brand. I look forward to driving continued growth across the EMEA region and further strengthening STACK's market position as a trusted global digital infrastructure partner with significant resources, capacity and development expertise."
Mr. Koen added, "We are also excited to welcome Adam, another proven leader in the data center industry. We are confident he will be successful in supporting John and the EMEA leadership team on growing and enhancing relationships with key hyperscalers."
Adam has decades of experience in the data center industry in sales and development and construction. Most recently, he served as SVP Hyperscale Sales at NTT where he was responsible for sales and customer relationships globally with the hyperscale accounts. While at NTT, Adam held various other positions in construction and development in EMEA.
Contacts
STACK Infrastructure
Alyssa Lorenzo / Hayley Cook / Michelle Van Wyk
Sard Verbinnen & Co.
STACK-SVC@sardverb.com
STACK EMEA
Elisabeth Lennhede
Head of Communications
+46703322705
press-nordics@stackinfra.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE STACK Infrastructure
|
https://www.wflx.com/prnewswire/2022/04/04/stack-infrastructure-announces-new-senior-leadership-appointments-emea-region/
| 2022-04-04T07:33:46
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/stack-infrastructure-announces-new-senior-leadership-appointments-emea-region/
|
DUBAI, UAE, April 4, 2022 /PRNewswire/ -- The second edition of the global FoodTech Challenge, that seeks to find the next wave of technology innovations on the cusp of transforming traditional agriculture practices, efficiently and sustainably, was launched at the EXPO2020 Dubai, and today unveils the competition's pooled prize amount of US $2 million.
Targeted at early-stage start-ups, ranging from international university-based research teams to individual entrepreneurs and small firms, the competition invites innovations related to two critical tracks: 'food production' to address the availability and abundance of food and explore 'next gen', nutrient rich alternatives, and 'food loss and waste' to ensure sustainability across the food supply chain and the planet more broadly.
With a pooled prize of up to US $2 million, the winners will be offered an opportunity to scale-up their business model within the UAE, supported with R&D, start-up acceleration, commercial incentives and mentorship to take winning concepts from lab-to-market. Applications are being encouraged from around the world, with a priority on agri-tech concentrated nations.
The FoodTech Challenge is organised by the UAE Ministry of Climate Change and Environment and Tamkeen, an Abu Dhabi entity that partners with leading local and international institutions to deliver projects that enrich the UAE's social, cultural and educational landscape. For this edition of the competition, they are joined by ASPIRE, the programme management pillar of the Advanced Technology Research Council (ATRC), which oversees technology related R&D funding for Abu Dhabi and the wider UAE. Each track is also being supported by a local champion, with ADQ and Silal being the track partners for increasing food production, and Emirates Foundation the track partner for reducing food loss and waste.
Commenting on the launch, Her Excellency Mariam Almheiri, Minister of Climate Change and Environment, said: "The importance of food security has never been more pertinent, with supply chain challenges and climate change disrupting the world as we know it. The pressure is on for us to rethink food for the future, to rethink resilient agricultural practices, and to leverage the best of technological advancements in doing so. The FoodTech Challenge brings us closer to finding some of those solutions, acknowledging the critical role that innovation has to play in addressing our shared challenges".
Rima Al Mokarrab, Chair of Tamkeen, added: "Responding to the UAE's long-term and far-reaching food security ambitions requires bold approaches that foster creative ideas, newfound models and extensive coordination with the global agri-tech ecosystem. The FoodTech Challenge brings together a powerful consortium of multi-sector partners who drive progress – supporting sustainable, technology-driven, commercially viable solutions to thrive here in the UAE".
With a focus on breakthrough technologies, His Excellency Faisal Al Bannai, Secretary General of ATRC, said: "The UAE is one of the most exciting places in the world right now when it comes to innovation and harnessing the power of cutting-edge technology to help find the answers to some of society's most pressing issues. The FoodTech Challenge is yet another fantastic example of this with the UAE hosting the brightest minds on the planet as they come together to collaborate, explore, and push the boundaries in agri-tech."
The competition is additionally supported by Abu Dhabi Global Market, Abu Dhabi Residents Office, The Catalyst Accelerator, and Khalifa Fund for Enterprise Development.
Applications for the Challenge will remain open until June, when submissions will be shortlisted and the top 10 teams given an opportunity to present their business cases at the Awarding Ceremony in November. Entrants can submit their applications via www.foodtechchallenge.com.
The first edition of the FoodTech Challenge saw 437 applications from across 68 countries, with winners announced from Australia, Saudi Arabia, the UAE and the UK.
Logo - https://mma.prnewswire.com/media/1777878/FoodTech_Challenge_Logo.jpg
View original content to download multimedia:
SOURCE FoodTech Challenge
|
https://www.wflx.com/prnewswire/2022/04/04/uae-announces-us-2-million-global-foodtech-challenge-prize-attract-cutting-edge-agri-tech-solutions/
| 2022-04-04T07:33:52
| 0
|
https://www.wflx.com/prnewswire/2022/04/04/uae-announces-us-2-million-global-foodtech-challenge-prize-attract-cutting-edge-agri-tech-solutions/
|
KINGSTON, Jamaica, April 4, 2022 /PRNewswire/ -- On March 29, 2022 the Parliament of Papua New Guinea approved an amendment to the Income Tax Act which introduces a new Additional Company Tax ("ACT") on the telecommunications and banking sector. The ACT imposes a one-time PGK 350 million (approximately US$100 million) tax liability on Digicel (PNG) Limited with a further penalty of a further PGK 50 million (approximately US$14 million) for non-payment.
Introduction of the new arbitrary, company-specific tax Act on March 25, 2022 without any consultation is perplexing not just for Digicel, but also for the Papua New Guinea economy given the reputational and credit rating implications of this sudden, bizarre and unprecedented tax. Under the ACT the disputed tax was payable on March 30, 2022
At a meeting last week between Denis O'Brien and Prime Minister Marape and two of his regional Governors, the Prime Minister assured Digicel that the new tax would not proceed and Digicel is now engaged in discussions with the Papua New Guinea Government and other relevant stakeholders to ensure this commitment is honoured.
This matter requires urgent resolution given its implications for the sale of Digicel's Pacific operations to Telstra but also given the knock-on consequences for all foreign direct investment exiting Papua New Guinea and the wider reputational and credit rating implications for Papua New Guinea internationally. In parallel with these discussions Digicel is also considering its legal options in the event that this discriminatory tax is not removed.
These matters will affect the timing of the previously announced sale of Digicel Group Holdings Limited's wholly owned subsidiary Digicel Pacific Limited ("DPL") to a wholly owned subsidiary of Telstra Corporation Limited. Prior to the introduction of the ACT, all but one of the required regulatory approvals to complete the transaction had been obtained.
Digicel will provide a further update in due course.
For Reference:
About Digicel
As a Digital Operator, Digicel is in the business of delivering powerful digital experiences 1440 minutes of each day to customers – that's every minute, all day, every day.
Through its world-class LTE and fibre networks, together with its suite of 8 apps spanning sports (SportsMax), music (D'Music), news (Loop), local radio and podcasts (GoLoud), TV streaming (PlayGo), enhanced messaging and marketplaces (BiP), cloud storage (Billo) and self-care (MyDigicel app), Digicel is the only operator in its markets that can deliver that.
Serving consumer and business customers in 32 markets in the Caribbean, Central America and Pacific, its investments of over US$7 billion and a commitment to its communities through its Digicel Foundations in Haiti, Jamaica, Papua New Guinea and Trinidad & Tobago have contributed to positive outcomes for over 3 million people to date.
With its Better Together brand, Digicel is making a promise of simply more to customers and communities and its 7,000 employees worldwide work together to make that a powerful reality day in, day out. Visit www.digicelgroup.com for more.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws of the United States. Certain other jurisdictions may have analogous concepts. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict.
Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. We do not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
Other disclosure
Our debt securities are not registered with the SEC or any other securities regulator and are not listed with any exchange. We have no intention of registering the securities in the United States or listing them with any exchange.
Certain figures in this release, including financial data, are rounded. Accordingly, corresponding calculated figures, including totals and percentage changes, may not be an exact arithmetic presentation of the corresponding figures.
Regulation G
This release contains non-GAAP financial measures as defined by Regulation G of the rules of the Securities and Exchange Commission.
Logo - https://mma.prnewswire.com/media/737804/Digicel_Logo.jpg
View original content:
SOURCE Digicel Group Limited
|
https://www.wflx.com/prnewswire/2022/04/04/update-digicel-pacific/
| 2022-04-04T07:34:00
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/update-digicel-pacific/
|
HANGZHOU, China, April 4, 2022 /PRNewswire/ -- Weidai Ltd. (the "Company" or "Weidai") (NYSE: WEI), a leading auto-backed financing solution provider in China, is issuing this press release in light of the unusual trading activity related to the American depositary shares (the "ADSs") of the Company on the New York Stock Exchange (the "NYSE") on April 1, 2022.
Normally, Weidai does not comment on market activity or rumors. However, Weidai confirms that it is not aware of any undisclosed material change or development in its business and operations or rumors in the market that would account for the recent increase in trading activity, and related increase in trading price, of its ADSs on the NYSE.
About Weidai Ltd.
Weidai Ltd. is a pioneer and leading auto-backed financing solution provider in China supported by sophisticated and effective risk management system and technology. The Company transforms used automobiles, a type of "non-standard" collateral, into investable assets, to provide accessible credit for China's small and micro enterprises, and connects the borrowers with institutional funding partners through its platform.
For more information, please visit http://weidai.investorroom.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Weidai may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Weidai's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited the following: Weidai's goal and strategies; Weidai's expansion plans; Weidai's future business development, financial condition and results of operations; Weidai's expectations regarding demand for, and market acceptance of, its solutions and services; Weidai's expectations regarding keeping and strengthening its relationships with borrowers, investors and financial institutions and other platform participants; general economic and business conditions; Weidai's assumptions underlying or related to any of the foregoing regulations and governmental policies relating to the online consumer finance industry in China; its ability to comply with existing or future laws and regulations related to data protection or data security; and Weidai's ability to meet the standards necessary to maintain listing of its ADSs on the NYSE, including its ability to cure any non-compliance with the NYSE's continued listing criteria; litigation and negative publicity surroundings China -based companies listed in the U.S.; and the duration of the COVID-19 outbreak, including the emergence of COVID variants, and its potential impact on the Company's business and financial performance. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Weidai does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Christensen
Mr. Rene Vanguestaine
Tel: +86-10-5900-1548
E-mail: rvanguestaine@christensenir.com
In US:
Christensen
Ms. Linda Bergkamp
Tel: +1-480-614-3004
E-mail: lbergkamp@christensenir.com
View original content:
SOURCE Weidai Ltd.
|
https://www.wflx.com/prnewswire/2022/04/04/weidai-comments-unusual-market-activity/
| 2022-04-04T07:34:06
| 1
|
https://www.wflx.com/prnewswire/2022/04/04/weidai-comments-unusual-market-activity/
|
Officers reunite 75-year-old homeless woman with family
HENDERSON, Nev. (CNN) - Two Nevada police officers went beyond the call of duty to save an elderly homeless woman and reunite her with her family.
Henderson Police Officers Carlos Chorens and Sterling Candland felt they were up against the clock when they first encountered 75-year-old Rose Brazdovic hidden behind a cement barrier.
“She’s not going to make it much longer, we didn’t think,” Candland said.
Brazdovic didn’t ask for the officers’ help, but they spent two days with her and a man she considered her caretaker, just asking questions.
“She ended up selling her place, and she was going to do some traveling in a motorhome. Apparently, that didn’t work out,” Chorens said.
Chorens and Candland also reached out to Rochelle Fletcher in Henderson’s Community Resource and Resiliency Center to find a safe place for Brazdovic. Though the 75-year-old was a retiree from Walmart and had some finances, Fletcher says she trusted the wrong people and didn’t have enough control over that money.
“I like to help people, and sometimes by helping people, they take advantage of it,” Brazdovic said.
Soon, those helping Brazdovic learned she had a son that she lost touch with nearly 30 years ago. Fletcher says she became determined to reunite the family.
Through some social media sleuthing, Fletcher found Jennifer Michrina, the daughter-in-law Brazdovic didn’t even know she had, living in Louisiana with Mike Michrina, Brazdovic’s son and their two boys.
Fletcher set up a Zoom call for the family, a surprise for Brazdovic.
Mike Michrina says he and his mom decided to focus on a fresh start, rather than dwelling on the past, and his heart opened back up to her immediately.
“It was kind of interesting not knowing what had happened to my mom for 29 years, but it was good,” he said. “Now that she’s back, I can see what I was missing.”
Soon, Brazdovic was ready to move to be with her family, and they were ready to welcome her. Leaving Nevada, she got a special airport escort: Candland and Chorens walked her right to her gate.
“She thanked us, and she was very excited to see her family,” Chorens said. “It’s incredible. It makes you feel like you accomplished something and you helped somebody out.”
In Louisiana, all four of the Michrinas were at the airport waiting for Brazdovic.
Now, more than a year after Brazdovic was found, she’s safe and surrounded by love, a fresh start thanks to two community relations police officers who never stopped caring.
“God put them in her life just to take care of her,” said Mike Michrina, as he teared up.
Brazdovic says she spends her time playing basketball and going on bike rides with her two grandsons.
“I got to have a family. That is the best part,” she said.
Copyright 2022 CNN Newsource. All rights reserved.
|
https://www.wflx.com/2022/04/04/officers-reunite-75-year-old-homeless-woman-with-family/
| 2022-04-04T07:45:58
| 0
|
https://www.wflx.com/2022/04/04/officers-reunite-75-year-old-homeless-woman-with-family/
|
This content is only available to subscribers.
Support Local Journalism
$1 for 6 Months.
Your subscription supports:
Are you a subscriber with digital access?
Sign in to your accountAre you a subscriber without digital access?
Activate your digital accountAre you a subscriber without digital access?
Activate your digital accountThis content is only available to subscribers.
Support Local Journalism
$1 for 6 Months.
Your subscription supports:
Are you a subscriber with digital access?
Sign in to your accountAre you a subscriber without digital access?
Activate your digital account
|
https://www.enterprisenews.com/restricted/?return=https%3A%2F%2Fwww.enterprisenews.com%2Fstory%2Fbusiness%2Freal-estate%2F2022%2F04%2F04%2Freal-estate-sales-transactions-brockton-area-feb-28-to-march-4-2022%2F7076480001%2F
| 2022-04-04T08:22:31
| 1
|
https://www.enterprisenews.com/restricted/?return=https%3A%2F%2Fwww.enterprisenews.com%2Fstory%2Fbusiness%2Freal-estate%2F2022%2F04%2F04%2Freal-estate-sales-transactions-brockton-area-feb-28-to-march-4-2022%2F7076480001%2F
|
(NEXSTAR) – Universal Champion Roman Reigns defeated WWE Champion Brock Lesnar in a “Winner Take All” main event at WrestleMania in AT&T Stadium to become the sole heavyweight champion in WWE. The pair headlined two days of matches that saw more than 150,000 fans at the home of the Dallas Cowboys in Arlington, Texas.
The two titans battled back and forth crashing through ringside barricades and kicking out of each other’s signature moves. In the end, Reigns hit one last spear to take down “The Beast” and earn a pinfall victory.
Reigns and Lesnar had been on a collision course over the last year emerging as sports entertainment’s two top modern-day stars. Lesnar won the 2022 Royal Rumble and immediately selected Reigns at his WrestleMania opponent.
The duo previously met in main event matches at WrestleMania 31 and WrestleMania 34.
For the majority of Lesnar’s time in WWE, longtime advocate Paul Heyman had been in his corner. Heyman recently turned on his friend and client instead siding with the younger Reigns. Since that time, the former UFC champion became a fan favorite speaking for himself for the first time in his career.
On the other side of things, Reigns has been dominant since returning to the ring following a hiatus over health. The 36-year-old came back with a new attitude and look finally embracing a bad-guy persona as “The Tribal Chief.”
Going into WrestleMania, Reigns held the Universal Championship for more than 580 days. This was Reigns’ 6th WrestleMania main event.
Reigns’ rocky road to the top
Reigns debuted as part of a three-man group called The Shield in 2012. He set out on his own two years later and was quickly promoted as fan favorite and top act. In the years that followed, fans pushed back on Reigns often booing him when the WWE hoped fans would be in his corner.
Nevertheless, he found success in the ring winning five world championships and regularly having some of the company’s top matches. The last time WrestleMania was at AT&T Stadium in 2016, the event ended with Reigns defeating legendary champion Triple H.
Towards the end of 2018, Reigns revealed he was battling leukemia and would be leaving wrestling to concentrate on his health. This was the second time he battled blood cancer first beating it in 2007. He had been in remission ever since.
Reigns took the time off to get in the best shape of his career eventually returning in 2020 following an additional leave of absence during the pandemic due to his compromised health.
Lesnar’s success across sports
When Lesnar made his WWE debut in 2002, he was immediately labeled “The Next Big Thing” – which absolutely proved to be true. In the months that followed, the former NCAA wrestling champion became a top star winning the company’s biggest championships. It appeared he’d be a main event act for decades to come, but Lesnar had other plans. Citing the demands of the schedule, Lesnar left WWE in 2004 to try his hand in other sports.
Having not played organized football since high school, Lesnar tried out for the Minnesota Vikings and played a few preseason games before getting released.
He eventually tried his hand at mixed martial arts competing for UFC. After a handful of fights, he captured the UFC Heavyweight Championship showing he could be dominate across sports.
In 2012, he’d return to WWE and immediately spark a feud with John Cena. This time, Lesnar would stick around. Working a reduced schedule, “The Beast” would pop in and out of the title picture for the next decade – regularly appearing at WrestleMania and other big events.
Gallery: History of Reigns vs. Lesnar
WrestleMania Sunday notes
- Vince McMahon, 76, defeated Pat McAfee in an impromptu match following McAfee’s victory over Austin Theory.
- Edge defeated AJ Styles with a massive spear after Damian Priest provided a distraction at ringside.
- Randy Orton and Matt Riddle successfully defended their RAW tag team titles over Alpha Academy and the Street Profits. After the match, NCAA champion wrestler Gable Steveson confronted Chad Gable tossing him with an overhead belly-to-belly suplex.
- Former champion Bobby Lashley defeated the 7’3″ giant Omos after two spears.
- Sasha Banks and Naomi captured the Women’s Tag Team Championships in a fatal 4-way match.
WrestleMania Saturday notes
- Steve Austin made his long-awaited return to the ring defeating Kevin Owens in a no-holds barred match.
- Charlotte Flair defeated “The Baddest Woman on the Planet” Ronda Rousey by pinfall to retain her Smackdown Women’s Championship.
- YouTube superstar Logan Paul earned a WrestleMania win after his tag team partner The Miz pinned Rey Mysterio to defeat Rey and his son Dominik. After the victory, The Miz turned on Paul hitting the Skull-Crushing Finale and leaving him laying.
- Bianca Belair captured the RAW Women’s Championship defeating champ Becky Lynch.
- Rick Boogs suffered a serious leg injury in his WrestleMania debut. Boogs was unable to finish the match. The show’s announcers confirmed he’d need surgery.
- On Friday night, wrestling legend The Undertaker was inducted into WWE’s Hall of Fame as part of WrestleMania weekend. He appeared in front of the crowd on Saturday and received a standing ovation.
|
https://fox59.com/news/entertainment/roman-reigns-defeats-brock-lesnar-in-wrestlemanias-main-event/
| 2022-04-04T09:10:23
| 1
|
https://fox59.com/news/entertainment/roman-reigns-defeats-brock-lesnar-in-wrestlemanias-main-event/
|
COLUMBUS, Ohio (WCMH) – Americans are divided on whether the country’s most popular sport is appropriate for kids to play, according to a study by researchers at The Ohio State University.
The survey of nearly 4,000 adults found about 45% of Americans agreed that tackle football is appropriate for kids, while 50% disagreed. The respondents were asked to rate on a scale of 1 (strongly disagree) to 4 (strongly agree) the statement: “Tackle football is an appropriate sport for kids to play.” The remaining 5% said they didn’t know.
Researchers said they did not define “kid” for participants intentionally.
“We purposefully left that open,” said study co-author Chris Knoester, professor of sociology at Ohio State.
“People might have different perceptions of what counts as a kid,” Knoester added. “And some of the previous research that tracks participation actually finds that we’ve seen a particularly marked decrease in kids ages 6 to 12 playing tackle football, and also a previous public opinion results have been more in agreement that football is risky for kids under the age of 13.”
A news release on the study by the university noted a 20% decline in tackle football participation among children ages 6 to 12 from 2008 to 2018.
Mariah Warner, the lead author of the study and a doctoral student in sociology at Ohio State, said when broken down further, results showed the question also divided Americans by race and class.
Black Americans, men, heterosexuals, conservatives, and those with only a high school education were not as negative about tackle football for kids as were white Americans, the college-educated, and those who live in suburbs.
“There is a noticeable difference,” Warner stated. “Wealthier folks of higher socioeconomic status, are less likely to think that tackle football is appropriate for kids. Whereas lower-class folks are more likely to think that it’s okay. Part of the theorizing behind that – football is a fairly inexpensive sport, especially in comparison to what we might call like ‘country club sports,’ like tennis or swimming, so it’s more accessible.”
|
https://fox59.com/news/national-world/study-50-of-americans-say-tackle-football-is-inappropriate-for-kids/
| 2022-04-04T09:10:29
| 0
|
https://fox59.com/news/national-world/study-50-of-americans-say-tackle-football-is-inappropriate-for-kids/
|
Leaders condemn Russia’s alleged atrocities in Ukraine
BUCHA, Ukraine (AP) - As foreign outrage mounts over evidence of possible executions and other atrocities by Russian forces in Ukraine, Germany’s defense minister says Europe must consider stepping up penalties for Moscow by boycotting its gas exports, an economically painful step European leaders previously avoided.
Japanese Prime Minister Fumio Kishida said Monday that “we strongly condemn attacks on civilians” following reports of bodies found with signs of torture in areas abandoned by Russian forces. New Zealand Prime Minister Jacinda Ardern called reports of rape and other atrocities by Russian soldiers “beyond reprehensible.”
Meanwhile, President Volodymyr Zelenskyy appealed in a video shown during the Grammy Awards in Las Vegas for musicians and other artists to help tell the story of Russia’s invasion. “Support us in any way you can,” Zelenskyy said.
Also Sunday, at least seven people were killed and 34 wounded, including three children, by Russian shelling of Kharkiv in the northeast, Ukraine’s second-biggest city, according to the regional prosecutor’s office. In the Black Sea port of Mykolaiv, regional Gov. Vitaliy Kim said at least one person died in shelling and 14 were wounded.
Ukrainian officials said bodies of 410 civilians were found in towns around the capital, Kyiv, that were recaptured from Russian forces.
In Bucha, northwest of the capital, Associated Press journalists saw 21 bodies. One group of nine, all in civilian clothes, were scattered around a site that residents said Russian troops used as a base. They appeared to have been shot at close range. At least two had their hands tied behind their backs.
GRAPHIC WARNING: Videos in this story may contain disturbing content.
Zelenskyy called the killings evidence of genocide, but Russia’s Defense Ministry rejected the accusation. It said photos and videos of dead bodies “have been stage managed by the Kyiv regime for the Western media.”
The ministry said “not a single civilian” in Bucha faced any violent military action and the mayor did not mention any abuses a day after Russian troops left.
Russian President Vladimir Putin’s Feb. 24 invasion has killed thousands of people and forced more than 4 million Ukrainians to flee their country. Putin has said the attack is aimed at eliminating a security threat after Ukraine’s government pursued membership in the U.S.-European NATO military alliance.
The head of Ukraine’s delegation in talks with Russia said Moscow’s negotiators informally agreed to most of a draft proposal discussed during talks in Istanbul, but no written confirmation has been provided. Russian demands include Ukraine declaring itself neutral and renouncing membership in military alliances.
Russian forces retreated from some areas around Kyiv after Moscow said it was focusing its offensive on the country’s east, where two regions are controlled by Russian-backed separatists. Russian troops had rolled into Bucha in the early days of the invasion and stayed up until March 30.
The reports of atrocities are severe enough that European officials “would have to talk about halting gas supplies from Russia,” German Defense Minister Christine Lambrecht said on public broadcaster ARD. “Such crimes must not go unanswered.”
Europe gets 40% of its gas and 25% of its oil from Russia, while such sales are the Kremlin’s main source of export revenue.
Governments have been scrambling to find ways to reduce that reliance. Estimates of the impact of a gas boycott on European countries vary but most involve a substantial loss of economic output.
For its part, Russia is temporarily enjoying a windfall as global prices surge due to anxiety over possible supply disruptions.
Kyiv Mayor Vitali Klitschko called on nations to end Russian gas imports. He said they were funding the killings.
On Saturday, Lithuania announced it had stopped imports of Russian gas and urged other European governments to do the same.
“If we can do it, the rest of Europe can do it too!” President Gitana Nauseda said on Twitter, referring to Russia as “the aggressor.”
Some European leaders said the killings in the Kyiv area amounted to war crimes.
U.S. Secretary of State Antony Blinken called images of what happened near Kyiv “a punch to the gut” on CNN’s “State of the Union.” The United States has previously said that it believes Russia committed war crimes.
“It is a brutality against civilians we haven’t seen in Europe for decades,” NATO Secretary-General Jens Stoltenberg said on the same broadcast.
Russia asked for a meeting Monday of the U.N. Security Council to discuss events in the city. The United States and Britain have recently accused Russia of using Security Council meetings to spread disinformation.
One resident of Bucha, who refused to give his name out of fear for his safety, said Russian troops went building to building and took people out of the basements where they were hiding. The resident said soldiers checked their phones for evidence of anti-Russian activity and took them away or shot them.
The AP also saw two bodies, that of a man and a woman, wrapped in plastic that residents said they had covered and placed in a shaft until a proper funeral could be arranged.
“He put his hands up, and they shot him,” said the resident who refused to be identified.
Oleksiy Arestovych, an adviser to Zelenskyy, claimed some of the women had been raped before being killed and the Russians then burned the bodies.
On Monday, the Ukrainian military said its forces had retaken some towns in the Chernihiv region and humanitarian aid was being delivered. The road between Chernihiv and Kyiv was to reopen to some traffic later in the morning, according to the news agency RBK Ukraina.
The mayor of Chernihiv, which has been cut off from food and other supplies for weeks, said Russian shelling has destroyed 70% of the northern city.
In a video address posted online Sunday, Zelenskyy said Russian soldiers who killed and tortured civilians were responsible for “concentrated evil.”
“It is time to do everything possible to make the war crimes of the Russian military the last manifestation of such evil on earth,” he said in remarks translated by his office.
The president directed some of his remarks at the mothers of Russian soldiers.
“Even if you raised looters, how did they also become butchers?” he said. “You couldn’t overlook that they are deprived of everything human. No soul. No heart. They killed deliberately and with pleasure.”
In Motyzhyn, some 50 kilometers (30 miles) west of Kyiv, residents told AP that Russian troops killed the town’s mayor, her husband and her son and threw their bodies into a pit in a pine forest behind houses where Russian forces had slept.
Inside the pit, AP journalists saw four bodies of people who appeared to have been shot at close range. The mayor’s husband had his hands behind his back, with a piece of rope nearby, and a piece of plastic wrapped around his eyes like a blindfold.
Ukrainian Deputy Prime Minister Iryna Vereshchuk confirmed the mayor was killed while being held by Russian forces.
___
Qena reported from Motyzhyn, Ukraine. Yuras Karmanau in Lviv, Ukraine, and Associated Press journalists around the world contributed.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wflx.com/2022/04/04/leaders-condemn-russias-alleged-atrocities-ukraine/
| 2022-04-04T09:19:53
| 1
|
https://www.wflx.com/2022/04/04/leaders-condemn-russias-alleged-atrocities-ukraine/
|
NJ man picking up furniture drove into a man and left him for dead
MANCHESTER — A 63-year-old township resident has been sentenced to six years in state prison after being found guilty of knowingly leaving the scene of a fatal motor vehicle accident.
On April 13, township police responded to a residence on Yorktowne Parkway in the Whiting section about 3:45 p.m., according to the Ocean County Prosecutor's Office.
Officers found that a pedestrian, 69-year-old Jack Gotfried, had been struck by a car. He was lying in the roadway with traumatic injuries to his lower body.
Gotfried was flown to Jersey Shore University Medical Center in Neptune, where he was pronounced dead.
An investigation found that 63-year-old Kevin Noonan, of Manchester, had stopped at Gotfried's home to pick up furniture that Gotfried was giving away.
While loading the furniture into Noonan's vehicle, Noonan backed his car up at a high rate of speed and struck Gotfried, pinning him between the rear of the vehicle and a truck parked in front of the residence.
Noonan then fled the scene, leaving Gotfried injured in the roadway. A short time later, Noonan was found walking in the area of Western Boulevard in Lacey, where he was taken into custody by a detective from the prosecutor's office.
Noonan has been held at the Ocean County Jail since his arrest.
Aside from his six-year prison sentence for knowingly leaving the scene of a motor vehicle accident, a judge also suspended Noonan's driving privileges for two years. The judge also suspended Noonan's driving privileges for one year and fined him $2,500 as a result of his previously entered guilty plea to the motor vehicle offense of leaving the scene of a motor vehicle accident resulting in injury or death.
Noonan pleaded guilty to both charges on Feb. 14.
Jen Ursillo is a reporter and anchor for New Jersey 101.5. You can reach her at jennifer.ursillo@townsquaremedia.com
Click here to contact an editor about feedback or a correction for this story.
7 New Jersey candle scents we need
|
https://nj1015.com/nj-man-picking-up-furniture-drove-into-a-man-and-left-him-for-dead/
| 2022-04-04T09:40:29
| 1
|
https://nj1015.com/nj-man-picking-up-furniture-drove-into-a-man-and-left-him-for-dead/
|
Rutgers extends mask mandate for campus classes
Rutgers University is relaxing their mask policy for students and staff, but face coverings are still be required in most teaching spaces.
As of Monday, April 4, university officials say students and faculty may go unmasked in offices, conference rooms, research labs, housing facilities, and public spaces inside campus buildings.
However, everyone will still need to mask-up inside all teaching spaces. This includes classrooms, lecture halls, teaching and computer labs, libraries and clinical facilities.
Masks are also still required on all campus busses.
Everyone on campus is encouraged to carry a mask with them at all times.
Since the earliest stages of the pandemic, Rutgers has had some of the strictest COVID-19 protocols in New Jersey and the nation.
In March, 2021, the university became the first in the nation to require proof of COVID vaccination for all students attending on-campus classes.
A large number of students protested the requirement, and a small group of students sued Rutgers claiming the policy was "both illegal and unconstitutional."
The suit was rejected by a federal judge, and the vaccine mandate remains in place. The majority of colleges and universities in New Jersey and around the U.S. have adopted similar policies.
COVID cases have been steadily rising in recent weeks. New Jersey's rate of transmission is 1.03, meaning an active spread of the virus. Despite the increase, there have not been any reports of a sharp increase in serious illness and hospitalizations have remained at about 300 statewide.
Last week, Gov. Phil Murphy tested positive for COVID-19 and was isolating for five days. Asked the likelihood of imposing new mandates to deal with a new wave of infections, Murphy said he did not anticipate that would be the case.
"We are not going to manage this to zero," Murphy said, echoing previous statements he has made while relaxing COVID restrictions he had previously put in place.
Murphy lifted his controversial mask mandate for schools on March 7.
Eric Scott is the senior political director and anchor for New Jersey 101.5. You can reach him at eric.scott@townsquaremedia.com
Click here to contact an editor about feedback or a correction for this story.
|
https://nj1015.com/rutgers-extends-mask-mandate-for-campus-classes/
| 2022-04-04T09:40:35
| 0
|
https://nj1015.com/rutgers-extends-mask-mandate-for-campus-classes/
|
FIRST ALERT- Tracking strong storms for Tuesday afternoon
COLUMBIA, S.C. (WIS) - Heads up! We’ve got a First Alert Day for Tuesday as we see the chance of some strong storms capable of producing tornadoes.
First Alert Headlines
- Gorgeous weather today with highs in the mid 70s and partly cloudy skies.
- FIRST ALERT for Tuesday as some slow-moving thunderstorms move in by the afternoon.
- There’s an enhanced risk (level 3) for areas around Orangeburg and Clarendon Counties, high winds and even a tornado or two cannot be ruled out.
- Heavy rain is possible as well with around a half inch to 1.25″ possible. We could see higher totals within the storms.
- We warm up Wednesday with highs in the low 80s.
- There’s another chance of some showers and storms Thursday, right now it’s a 40% shot.
First Alert Summary
Today is beautiful with highs in the mid 70s and partly cloudy skies. High pressure holds on to our forecast today and tonight.
Lows tonight are in the mid 50s with mostly clear skies.
Tuesday a low pressure system approaches from the west and brings a 60% chance of rain and storms for the afternoon. Some of these storms could become severe. There’s a slight risk (level 2) for the Columbia area and an enhanced risk (level 3) for areas to the south of Columbia. High winds and a few tornadoes cannot be ruled out with this system. Right now it looks to occur by mid afternoon into the evening hours. We stay dry in the morning and then see the rain push in by early afternoon, with the heaviest during the early evening hours. Highs are in the mid 70s.
Wednesday morning we are down to 63 in the morning and highs reach the low 80s. Partly cloudy skies are expected and we have a 20% chance of showers.
Another system moves in form the west and brings a 40% chance of showers and storms Thursday. Morning lows are in the mid 60s and highs reach the mid 70s by the afternoon.
Friday we cool off with lows in the upper 40s in the morning and highs reach the mid 60s. Saturday is even cooler with low in the low 40s and highs reach the upper 50s.
Forecast Update
Today: Partly cloudy and warm with highs in the mid 70s.
FIRST ALERT Tuesday: Showers and storms, some storms may become severe (60%) with highs in the mid 70s.
Wednesday: Mostly cloudy with a few scattered showers (20%). Highs around 82.
Thursday: A few isolated storms (40%) with highs in the mid 70s.
Friday: Sunshine and clouds with highs in the mid 60s.
Saturday: Partly cloudy with highs in the mid 60s.
Copyright 2022 WIS. All rights reserved.
Notice a spelling or grammar error in this article? Click or tap here to report it. Please include the article’s headline.
|
https://www.wistv.com/2022/04/03/first-alert-tracking-rain-slow-moving-storms-tuesday-warmup-wednesday/
| 2022-04-04T09:58:32
| 1
|
https://www.wistv.com/2022/04/03/first-alert-tracking-rain-slow-moving-storms-tuesday-warmup-wednesday/
|
Russia faces growing outrage amid new evidence of atrocities
BUCHA, Ukraine (AP) - Russia faced a fresh wave of condemnation on Monday after evidence emerged of what appeared to be deliberate killings of civilians in Ukraine. Some Western leaders called for further sanctions in response to the alleged atrocities, even as Moscow continued to press its offensive in the country’s east.
Germany’s defense minister suggested the European Union discuss a ban on Russian gas imports, but more senior officials indicated an immediate boycott was not possible — a sign that leaders could struggle in the short-term to ramp up already severe sanctions on Russia.
Ukrainian officials said bodies of 410 civilians were found in towns around the capital, Kyiv, that were recaptured from Russian forces in recent days. In Bucha, northwest of the capital, Associated Press journalists saw 21 bodies. One group of nine, all in civilian clothes, were scattered around a site that residents said Russian troops used as a base. They appeared to have been shot at close range. At least two had their hands tied behind their backs.
The images of battered bodies lying in the streets or hastily dug graves unleashed a wave of outrage that could signal a turning point in the nearly 6-week-old war. But sanctions have thus far failed to halt the offensive, and rising energy prices along with the tight controls on Russian currency market have blunted their impact, with the ruble rebounding strongly after initially crashing.
Western and Ukrainian leaders have accused Russia of war crimes before, and the International Criminal Court’s prosecutor has opened a probe to investigate the conflict. But the latest reports ratcheted up the condemnation even further, with Ukraine’s President Volodymyr Zelenskyy and some Western leaders going so far as to accuse Russia of genocide.
Russia’s Defense Ministry rejected the accusations. It said photos and videos of dead bodies “have been stage managed by the Kyiv regime for the Western media.” The ministry said “not a single civilian” in Bucha faced any violent military action.
GRAPHIC WARNING: Videos in this story may contain disturbing content.
In a video shown during the Grammy Awards in Las Vegas for musicians and other artists, Zelenskyy implored them to support his nation and “fill the silence with your music.”
French President Emmanuel Macron said Monday that there is “clear evidence of war crimes” in Bucha.
“What just happened in Bucha calls for a new round of sanctions and very clear measures,” he said on France-Inter radio. “I’m in favor of a new round of sanctions and in particular on coal and petrol. We need to act.”
European Council President Charles Michel earlier tweeted that the EU is assisting Ukrainians and rights groups in gathering evidence to be used in international courts, adding that “further EU sanctions & support are on their way.”
Spanish Prime Minister Pedro Sánchez also called for those responsible for the slayings in Bucha to be punished, saying they should “answer these alleged cases of crimes against humanity, war crimes and, why not say it, of genocide, too.”
Poland’s Prime Minister Mateusz Morawiecki described Russia as a “totalitarian-fascist state,” saying “the bloody massacres perpetrated by Russian soldiers deserve to be called by name: This is genocide.”
The crime of genocide is difficult to prove, as prosecutors would have to show that the killers or their commanders had a “specific intent” to partially or wholly destroy a group of people.
In the meantime, the U.S. and its allies have sought to punish Russia for the war by imposing sweeping sanctions on Russia. But they may be reluctant to impose measures that cause further harm to a global economy still recovering from the coronavirus pandemic. As a major oil and gas exporter, Russia stands to benefit from any rise in already high global energy prices.
Europe is in a particular bind, since it gets 40% of its gas and 25% of its oil from Russia. Governments have been scrambling to find ways to reduce that reliance. Estimates of the impact of a gas boycott on European countries vary but most involve a substantial loss of economic output.
German Vice Chancellor Robert Habeck, who is also the economy minister and responsible for energy, said Europe can go “significantly further” in imposing sanctions against Russia. But he said Germany is right to take a longer-term approach to abandoning Russian energy imports.
Germany has faced criticism for opposing an immediate halt to Russian energy deliveries. The country says it hopes to end Russian coal imports this summer and oil imports by the end of the year, but halting gas will take longer.
“We are working every day on creating the conditions for and steps toward an embargo,” Habeck said. “We are on the right track.”
German Defense Minister Christine Lambrecht had earlier said on public broadcaster ARD that the reports of atrocities were severe enough that European officials “would have to talk about halting gas supplies from Russia.”
Russian President Vladimir Putin’s Feb. 24 invasion has killed thousands of people and forced more than 4 million Ukrainians to flee their country. Putin has said the attack is aimed at eliminating a security threat and demanded that Ukraine drop its bid to join the NATO military alliance of Western countries. Ukraine insists it never posed any threat but has offered to officially declare itself neutral.
The head of Ukraine’s delegation in talks with Russia has said Moscow’s negotiators informally agreed to most of a draft proposal discussed during talks in Istanbul, but no written confirmation has been provided.
While Western officials initially said they believed Putin’s goal was to take Kyiv and potentially install a Kremlin-friendly government, Russian forces faced stiff resistance on their road to the capital and have now retreated from some areas around it. Now, Moscow says it is focusing its offensive on the Donbas in the country’s east, where Russian-backed separatists have been fighting Ukrainian forces for years.
Britain’s Defense Ministry said Monday that Russia is continuing to flood soldiers and mercenaries from the Wagner private military group into the Donbas. It said Russian troops are also still trying to take strategic port city of Mariupol, which lies in the region and has seen weeks of heavy fighting and some of the worst suffering of the war.
“The city continues to be subject to intense, indiscriminate strikes, but Ukrainian Forces maintain a staunch resistance, retaining control in central areas,” the ministry said. “Mariupol is almost certainly a key objective of the Russian invasion as it will secure a land corridor from Russia to the occupied territory of Crimea,” in the south, which Moscow annexed in 2014.
On Monday, the Ukrainian military said its forces had retaken some towns in the northern Chernihiv region and humanitarian aid was being delivered. The road between Chernihiv and Kyiv was to reopen to some traffic, according to the news agency RBK Ukraina.
The mayor of Chernihiv, which has been cut off from food and other supplies for weeks, said Russian shelling has destroyed 70% of the northern city.
___
Qena reported from Motyzhyn, Ukraine. Yuras Karmanau in Lviv, Ukraine, and Associated Press journalists around the world contributed.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wistv.com/2022/04/04/leaders-condemn-russias-alleged-atrocities-ukraine/
| 2022-04-04T09:58:38
| 0
|
https://www.wistv.com/2022/04/04/leaders-condemn-russias-alleged-atrocities-ukraine/
|
Officers reunite 75-year-old homeless woman with family
HENDERSON, Nev. (CNN) - Two Nevada police officers went beyond the call of duty to save an elderly homeless woman and reunite her with her family.
Henderson Police Officers Carlos Chorens and Sterling Candland felt they were up against the clock when they first encountered 75-year-old Rose Brazdovic hidden behind a cement barrier.
“She’s not going to make it much longer, we didn’t think,” Candland said.
Brazdovic didn’t ask for the officers’ help, but they spent two days with her and a man she considered her caretaker, just asking questions.
“She ended up selling her place, and she was going to do some traveling in a motorhome. Apparently, that didn’t work out,” Chorens said.
Chorens and Candland also reached out to Rochelle Fletcher in Henderson’s Community Resource and Resiliency Center to find a safe place for Brazdovic. Though the 75-year-old was a retiree from Walmart and had some finances, Fletcher says she trusted the wrong people and didn’t have enough control over that money.
“I like to help people, and sometimes by helping people, they take advantage of it,” Brazdovic said.
Soon, those helping Brazdovic learned she had a son that she lost touch with nearly 30 years ago. Fletcher says she became determined to reunite the family.
Through some social media sleuthing, Fletcher found Jennifer Michrina, the daughter-in-law Brazdovic didn’t even know she had, living in Louisiana with Mike Michrina, Brazdovic’s son and their two boys.
Fletcher set up a Zoom call for the family, a surprise for Brazdovic.
Mike Michrina says he and his mom decided to focus on a fresh start, rather than dwelling on the past, and his heart opened back up to her immediately.
“It was kind of interesting not knowing what had happened to my mom for 29 years, but it was good,” he said. “Now that she’s back, I can see what I was missing.”
Soon, Brazdovic was ready to move to be with her family, and they were ready to welcome her. Leaving Nevada, she got a special airport escort: Candland and Chorens walked her right to her gate.
“She thanked us, and she was very excited to see her family,” Chorens said. “It’s incredible. It makes you feel like you accomplished something and you helped somebody out.”
In Louisiana, all four of the Michrinas were at the airport waiting for Brazdovic.
Now, more than a year after Brazdovic was found, she’s safe and surrounded by love, a fresh start thanks to two community relations police officers who never stopped caring.
“God put them in her life just to take care of her,” said Mike Michrina, as he teared up.
Brazdovic says she spends her time playing basketball and going on bike rides with her two grandsons.
“I got to have a family. That is the best part,” she said.
Copyright 2022 CNN Newsource. All rights reserved.
|
https://www.wistv.com/2022/04/04/officers-reunite-75-year-old-homeless-woman-with-family/
| 2022-04-04T09:58:46
| 0
|
https://www.wistv.com/2022/04/04/officers-reunite-75-year-old-homeless-woman-with-family/
|
Staley leads South Carolina over UConn for second NCAA title
MINNEAPOLIS (AP) — Dawn Staley hoisted the championship trophy high, strutted around the court and stopped for a brief victory dance. She handed over the hardware to South Carolina’s student band, then headed back to midcourt for more merriment.
The Gamecocks hit all the right notes this season, and they finished with a masterpiece.
Staley’s team buttoned up on defense and dominated on the glass, beating UConn 64-49 on Sunday night to end the Huskies’ undefeated streak in title games. Destanni Henderson scored a career-high 26 points, Aliyah Boston added 11 points and 16 rebounds, and the Gamecocks handed Geno Auriemma’s Huskies their first loss in 12 NCAA title games.
“We played every possession like it was our last possession,” said Staley, the first Black men’s or women’s coach with two Division I titles. “They were determined to be champions today.”
A year ago, South Carolina lost in the Final Four when Boston missed a layup before the buzzer.
“Honestly, I’ve been thinking about this since last season. Everyone had a picture of me crying,” said Boston, who was the Most Outstanding Player of the Final Four. “Today, we’re national champions and I’m in tears.”
With Staley calling the shots in a Louis Vuitton letterman jacket, South Carolina took UConn to school on the boards and capped a wire-to-wire run as the No. 1 team in the country in The Associated Press poll. The Gamecocks also won the championship in 2017 with A’ja Wilson leading the way.
This time it was Boston — the AP Player of the Year — and her fellow South Carolina post players who dominated on the game’s biggest stage. The Gamecocks outrebounded UConn 49-24, including a 21-6 advantage on offensive boards.
“We knew tonight that if we didn’t hold our own on the boards, that it was going to be a really bad night for us,,” Auriemma said. “And that’s exactly what happened.”
They also clamped down on star Paige Bueckers and the Huskies on defense, just like they did all season long.
“They deserved it 100%,” Auriemma said. “They were the best team all year.”
It was South Carolina’s night from the start. The Gamecocks (35-2) jumped to an 11-2 lead, grabbing nearly every rebound on both ends of the floor. They led to 22-8 after one quarter much to the delight of their fans, who made the trip to Minneapolis to be part of the sellout crowd.
UConn (30-6) trailed by 16 in the second quarter before Bueckers, a Minnesota native, got going. After having just one shot in the first quarter, she scored nine points in the second to get the Huskies within 35-27 at the half. She finished with 14.
An 8-2 run to start the third quarter put South Carolina up 43-29 before the Huskies finally started connecting from behind the arc. UConn missed its first eight 3-point attempts until Caroline Ducharme made one from the wing and Evina Westbrook followed with another to get the Huskies within 43-37.
That’s as close as they could get because of Henderson.
The senior guard had a three-point play to close the third quarter and then had the team’s first four points in the fourth to restore the double-digit lead. The Huskies couldn’t recover.
“My teammates believed in me once again. We’ve been working so hard since Day 1, and it finally paid off, all my hard work, all my focus,” Henderson said. “Me trusting the process. Me trusting God. She just put me in a position just to be great, and today, we national champions.”
This was UConn’s first trip to the championship game since 2016, when the Huskies won the last of four straight titles. Since then, the team has suffered heartbreaking defeats in the national semifinals, losing twice in overtime, before holding off Stanford on Friday night. The Huskies were trying to win their 12th title in the same city they won their first one in 1995.
Auriemma said Saturday that when his team had won each of its 11 titles, the Huskies entered the game as the better team. They certainly weren’t on Sunday.
“We just didn’t have enough,” he said. “They were just too good for us.”
It had been one of the most challenging seasons of Auriemma’s Hall of Fame career. UConn overcame losing eight players for at least two games with injury or illness, including Bueckers, who missed nearly three months with a left knee injury suffered in early December. She came back in late February but wasn’t at the same level that earned her AP Player of the Year as a freshman last season.
DEFENSE WINS CHAMPIONSHIPS
The Gamecocks have been stalwarts on defense all season long, ranking third nationally with 50.5 points allowed per game. They were even sharper in the NCAA Tournament, holding opponents to 44.8 points entering Sunday’s finale.
Henderson had three steals, Boston blocked two shots and South Carolina forced 15 turnovers. The Gamecocks’ plus-25 rebounding margin was the second biggest ever in a title game.
BIG PICTURE
UConn: The Huskies lose three seniors in Christyn Williams, Westbrook and Olivia Nelson-Ododa but still have a solid group back led by Bueckers and freshman Azzi Fudd. If the Huskies stay healthy, they’ll have a good shot to contend for next year’s title.
South Carolina: The Gamecocks lose Henderson and Victaria Saxton but have all the talent to repeat as champions.
___
More AP coverage of March Madness: https://apnews.com/hub/march-madness and https://apnews.com/hub/womens-college-basketball and https://twitter.com/AP_Top25
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wistv.com/2022/04/04/staley-leads-south-carolina-over-uconn-second-ncaa-title/
| 2022-04-04T09:58:53
| 1
|
https://www.wistv.com/2022/04/04/staley-leads-south-carolina-over-uconn-second-ncaa-title/
|
Woman robbed after thief intentionally rear-ended her on highway
SACRAMENTO, Calif. (KCRA) - Police in California’s capital are investigating recent fender bender robberies where thieves purposefully rear-end victims with the intent to rob them.
Rindy Merrifield, a victim of one of these crimes, is sharing her story in hopes it helps others avoid being a target of the thieves. She was headed home on the highway March 10 after running some errands in Sacramento when a driver bumped her car from behind.
She didn’t think much of it, not worried the bump did any damage to her SUV. She says the same car bumped her again about a mile later, but still not too concerned, Merrifield kept driving.
“He pulled beside me, told me to pull over,” Merrifield said. “So, I thought, ‘OK, maybe he did do some damage, and that’s why he wants me to pull over.’”
She found a place to stop off the exit near Cal Expo and got out of her car to speak with the other driver.
“I just came around, looked and said, ‘You know what? No damage. Just go on your way,’” Merrifield said. “That’s when he said, ‘Well, I really think we should exchange insurances because that’s the right thing to do.’”
Merrifield went to the passenger side door and opened it. She says the other driver then pushed her away, grabbed her purse and swatted away her arm, preventing her from retrieving it.
“It was just, ‘How dare you… take my purse.’ And I was bound and determined to get it back or hurt him enough that I could get it,” Merrifield said.
She followed after the other driver as he returned to his own car. She says she slammed his own car door on his legs five times as he was getting away. Merrifield’s efforts didn’t stop the thief, who escaped with her purse and its contents, including her credit cards, cash, car keys and cell phone.
Police say a similar fender bender-type robbery happened the next day, involving a different victim. Detectives arrested Phung Nguyen and Hau Nguyen and charged them for that crime.
Police received an arrest warrant April 1 for Phung Nguyen for charges related to Merrifield’s case. His whereabouts are not currently known, and he is considered wanted by law enforcement.
California law indicates drivers are required to stop and exchange information after a crash.
Merrifield is determined to warn others, using her own experience as an example. She organized a personal safety seminar with law enforcement and safety experts about how to handle situations just like the fender bender robbery she endured.
“Knowing that I was so naïve and trustworthy and not watching my surroundings, I didn’t want anybody else to go through that,” Merrifield said. “It may never happen again… but I’ll be ready.”
She also plans to organize other safety sessions in the near future.
Copyright 2022 KCRA via CNN Newsource. All rights reserved.
|
https://www.wistv.com/2022/04/04/woman-robbed-after-thief-intentionally-rear-ended-her-highway/
| 2022-04-04T09:59:00
| 1
|
https://www.wistv.com/2022/04/04/woman-robbed-after-thief-intentionally-rear-ended-her-highway/
|
Full Sail University alumni credited on projects across 10 categories
WINTER PARK, Fla., April 4, 2022 /PRNewswire/ -- Today, Full Sail University, an award-winning educational institution for those pursuing careers in entertainment media and emerging technologies, is pleased to announce that 12 alumni were credited on 10 GRAMMY®-winning projects at the 64th annual GRAMMY® Awards. This year's award ceremony was held on April 3, 2022, at the MGM Grand Garden Arena in Las Vegas, Nev., and aired on CBS.
Additionally, Full Sail University alumni have worked on projects that won across 10 different categories. Notable projects include Heaux Tales (Jazmine Sullivan), Call Me If You Get Lost (Tyler, The Creator), 662 (Christone "Kingfish" Ingram), and more.
For a look at the GRAMMY®-winning categories and projects Full Sail graduates have contributed to this year, please see below:
- Best Contemporary Blues Album, 662, Christone "Kingfish" Ingram
- Best Immersive Audio Album, Alicia, George Massenburg & Eric Schilling, immersive
- Best Latin Rock or Alternative Album, Origen, Juanes
- Best Música Urbana Album, El Último Tour Del Mundo, Bad Bunny
- Best Progressive R&B Album, Table For Two, Lucky Daye
- Best R&B Album, Heaux Tales, Jazmine Sullivan
- Best Rap Album, Call Me If You Get Lost, Tyler, The Creator
- Best Roots Gospel Album, My Savior, Carrie Underwood
- Best Traditional R&B Performance, Fight For You, H.E.R.
- Best Tropical Latin Album, Salswing!, Rubén Blades y Roberto Delgado & Orquesta
At the 64th annual GRAMMY® Awards ceremony, 46 graduates were credited on 60 GRAMMY®-nominated projects across 44 categories. To learn more about Full Sail's alumni successes and the university's Music & Recording centric degree programs, click here.
About Full Sail University
Full Sail University is an award-winning educational leader for those pursuing careers in entertainment media and emerging technologies. Founded in 1979, Full Sail has received accolades throughout its over 40-year history, including most recently being featured on the 2021 "Top 50 Film Schools and Instructors From Around the World" list by Variety Magazine and previously recognized as the "School/College of the Year" by the Florida Association of Postsecondary Schools and Colleges. Full Sail University is a graduate and undergraduate degree-granting institution offering on-campus and online degree programs in areas related to Art & Design, Business, Film & Television, Games, Media & Communications, Music & Recording, Sports, and Technology. With over 83,565+ graduates worldwide, Full Sail alumni have worked on countless award-winning projects with individual recognition including OSCAR®, Emmy®, GRAMMY®, ADDY®, MTV Video Music Award, and Video Game Award honors.
https://www.fullsail.edu/
https://twitter.com/fullsail
https://www.facebook.com/FullSailUniversity
View original content to download multimedia:
SOURCE Full Sail University
|
https://www.wistv.com/prnewswire/2022/04/04/12-full-sail-university-alumni-contribute-10-winning-projects-64th-annual-grammy-awards/
| 2022-04-04T09:59:06
| 0
|
https://www.wistv.com/prnewswire/2022/04/04/12-full-sail-university-alumni-contribute-10-winning-projects-64th-annual-grammy-awards/
|